US Pat. No. 11,028,236

METHOD FOR PROCESSING DANDELION PLANT COMPONENTS

GEA Mechanical Equipment ...

1. A method for processing dandelion plant components (10), wherein obtaining of rubber as a first valuable product is achieved in the method and is characterized by the following steps:A) comminution and/or squeezing of the dandelion plant components (10), wherein the dandelion plant components (10) are dried dandelion roots from the species Taraxacum kok-saghyz, preferably with addition of water (30), to form a slurry (60), in which slurry the dandelion plant components (10) are suspended in water with a mean diameter of between 2 to 10 mm;
wherein the comminution of the dandelion plant components (10) encompasses at least one precomminution (20) and a grinding and/or squashing (50),
wherein the water (30) is added to an extent of from 5 to 20 parts, based on the weight of the plant components, and wherein the water has a neutral pH or an acidic pH, and
wherein water is added before or after the precomminution (20) of the dandelion plant components (10), and the water is pressed out before the grinding and/or squashing to obtain an inulin syrup and/or inulin press water (340),
wherein the inulin syrup and/or inulin press water is removed, and
wherein the remaining solids after the press-out are re-suspended with addition of fresh water to form a slurry,
B) first separation (70) of the slurry (60) into at least one high-inulin low-rubber phase (80, 80?) and at least one high-rubber low-inulin phase (90, 90?),
wherein the first separation (70) is done by a two-phase decanter or separator,
wherein the high-rubber low-inulin phase (90, 90?) forms the first valuable product or the first valuable product is obtained from the high-rubber low-inulin phase (90, 90?),
wherein at least step A) is done at a temperature of less than 40° C., and
wherein steps A) and B) are done without enzyme addition.

US Pat. No. 11,028,235

POLYCARBOXYLATED COMPOUNDS AND COMPOSITIONS CONTAINING SAME

WISCONSIN ALUMNI RESEARCH...

1. A polycarboxylated compound comprising phenylpropanoid units, wherein:each of the phenylpropanoid units comprises an ?-carbon and a ?-carbon;
the phenylpropanoid units are linked to each other via linkages comprising one or more of a ?-O-4 linkage, a ?-1 linkage, a ?-5 linkage, a 4-O-5 linkage, a 5-5 linkage, and a ?-?linkage;
the phenylpropanoid units comprise ?-O-4 phenylpropanoid units;
each of the ?-O-4 phenylpropanoid units is a single one of the phenylpropanoid units and is linked via its ?-carbon with a ?-O-4 linkage;
each ?-O-4 phenylpropanoid unit in at least a portion of the ?-O-4 phenylpropanoid units comprises a secondary hydroxyl moiety on the ?-carbon of the ?-O-4 phenylpropanoid unit and a carboxylic acid or carboxylate moiety on the ?-carbon of the ?-O-4 phenylpropanoid unit; and
the polycarboxylated compound comprises from 0.05 to 0.8 carboxylic acid or carboxylate functional groups per phenylpropanoid unit.

US Pat. No. 11,028,232

PROCESS FOR PREPARING SILOXANES CONTAINING OXAMIDO ESTER GROUPS

WACKER CHEMIE AG, Munich...

1. A method for preparing siloxanes having oxamidoester groups, comprising:reacting
(A) silanes of the formula

optionally (B) silanes of the formula
R4t(R5O)4-tSi  (III)
and (W) water,
where
R1 each independently are monovalent, optionally substituted, SiC-bonded hydrocarbon radicals that may be interrupted by heteroatoms,
R2 each independently are hydrogen or monovalent, optionally substituted hydrocarbon radicals optionally interrupted by heteroatoms,
R3 each independently are monovalent, optionally substituted hydrocarbon radicals optionally interrupted by oxygen atoms,
Rx each independently are hydrogen or optionally substituted hydrocarbon radicals,
Y each independently are divalent, optionally substituted hydrocarbon radicals optionally interrupted by oxygen atoms or nitrogen atoms,
R4 each independently are monovalent, optionally substituted, SiC-bonded hydrocarbon radicals optionally interrupted by heteroatoms,
R5 each independently are hydrogen or monovalent, optionally substituted hydrocarbon radicals optionally interrupted by heteroatoms,
s is 0, 1 or 2 and
t is 0, 1, 2 or 3.

US Pat. No. 11,028,227

POLY(AMIDE-IMIDE) COPOLYMER, COMPOSITION FOR PREPARING POLY(AMIDE-IMIDE) COPOLYMER, ARTICLE INCLUDING POLY(AMIDE-IMIDE) COPOLYMER, AND DISPLAY DEVICE INCLUDING THE ARTICLE

SAMSUNG ELECTRONICS CO., ...

1. A poly(amide-imide) copolymer that is a reaction product of a substituted or unsubstituted linear aliphatic diamine comprising two terminals, a diamine represented by Chemical Formula 1, a dicarbonyl compound represented by Chemical Formula 2, and a tetracarboxylic acid dianhydride mixture comprising a tetracarboxylic acid dianhydride represented by Chemical Formula 3-1 and a tetracarboxylic acid dianhydride represented by Chemical Formula 3-2:NH2-A-NH2  Chemical Formula 1
wherein in Chemical Formula 1,
A is a ring system comprising two or more C6 to C30 aromatic rings linked by a single bond, wherein each of the two or more aromatic rings is independently unsubstituted or substituted by an electron-withdrawing group;

wherein, in Chemical Formula 2,
R3 is a substituted or unsubstituted phenylene or a substituted or unsubstituted biphenylene group, and
each X is an identical or different halogen atom;
wherein the linear aliphatic diamine is present in an amount of greater than 20 mol % and less than 90 mol %, and the diamine represented by Chemical Formula 1 is present in an amount of less than or equal to 80 mol % and greater than or equal to 10 mol %, based on the amount of total diamine.

US Pat. No. 11,028,226

HEAT RESISTANT POLYIMIDE FILM AND PREPARATION METHOD THEREOF

1. A method of preparing heat resistant polyimide film, characterized in that: the method of preparing heat resistant polyimide film comprises the steps of:(a) weighing to obtain 100 parts by weight of polyimide solution, 10 parts to 40 parts by weight of inorganic filler modifier and 0.1 parts to 5 parts by weight of interface coupling agent; adding the 10 to 40 parts of inorganic filler modifier and the 0.1 parts to 5 parts of interface coupling agent to the 100 parts of polyimide solution under a temperature of 90° C. to 120° C. while stirring; and stirring for 10 minutes to 30 minutes to obtain an adhesive agent;
wherein the polyimide solution is manufactured by a process comprising the steps of:
adding N,N-dimethylacetamide; adding aromatic diamine to the N,N-dimethylacetamide under a nitrogen atmosphere and stirring for 1 hour to 5 hours; then adding aromatic dianhydride and stirring for 1 hour to 5 hours to obtain a mixed solution; adding 4-phenylethynylphthalic anhydride to the mixed solution, stirring and allowing reaction for 1 hour to 5 hours; then adding toluene, heating to a temperature of 120° C. to 130° C. and carrying out reflux reaction for 5 hours to 20 hours under a temperature condition of 120° C.˜130° C. to obtain the polyimide solution;
wherein a molar ratio of the aromatic dianhydride to the aromatic diamine is (0.50˜0.95):1; a mass ratio of the N,N-dimethylacetamide to the toluene is 1:(0.2˜0.5); a molar ratio of the aromatic diamine to 4-phenylethynylphthalic anhydride is 1:(0.01˜1); and a total number of moles of anhydride functional group in the aromatic dianhydride and the 4-phenylethynyl phthalic anhydride is equal to the number of moles of amino functional group of the aromatic diamine;
a ratio of a total mass of the N,N-dimethylacetamide and the toluene to a total mass of the 4-phenylethynylphthalic anhydride, the aromatic dianhydride and the aromatic diamine is (2.5˜4):1;

the aromatic diamine has a structural formula of:

where R1 is O or NH,
(b) filtering and degassing the adhesive agent, casting to a drum made of stainless steel and loaded with carrier cloth and release paper to obtain a self-supporting film; then under a temperature of 60° C. to 150° C., heating for 1 min to 60 min, then under a temperature of 150° C. to 300° C., heating for 1 min to 60 min, and finally under a temperature of 50° C. to 140° C., annealing for 1 min to 20 min to obtain the heat resistant polyimide film;
wherein the heat resistant polyimide film has a thickness of 0.30 mm˜0.60 mm;
in the step (a), the inorganic filler modifier consists of silicon dioxide (silica)-based substance and substance for increasing interface bonding, and the mass ratio of the silica-based substance and the substance for increasing interface bonding is 1:(0.1˜0.5),
the silica-based substance is hollow ceramic microspheres, fumed silica (silicon dioxide in gaseous state), fused silica (melted silicon dioxide) or amorphous silica,
the substance for increasing interface bonding is one or a mixture of two or more selected from the group consisting of: aluminum hydroxide, magnesium hydroxide, molybdenum oxide, aluminum nitride, aluminum oxide, boron nitride and silicon carbide,
in the step (a), the polyimide solution comprises polyimide which has a structural formula of:

where n is 1˜19;
where Ar1 has a structural formula of:

where Ar2 has a structural formula of:

where R1 is O or NH.

US Pat. No. 11,028,225

MONOMER MIXTURE AND CURABLE COMPOSITION CONTAINING SAME

DAICEL CORPORATION, Osak...

1. A monomer mixture containing at least:a compound represented by Formulas (a-1) and/or (a-2):

a compound (2B?), represented by Formula (2b-1):

where X represents a single bond or a linking group;
a compound (3B?) represented by Formula (3b-1):

where each R? represents an aliphatic hydrocarbon group, and s represents an integer of 3 to 6, and
a compound represented by Formula (c-1):

wherein a total content of the compound represented by Formula (a-1) and the compound represented by Formula (a-2) is from 1 to 20 wt. % of a total amount of the monomer mixture;
a content of the compound represented by Formula (c-1) is from 5 to 95 wt. % of the total amount of the monomer mixture, and
the monomer mixture meets one of conditions [1] and [2] as follows:
[1] a weight ratio of contents of the compound (2B?)/the compound (3B?) is from 0.1 to 0.8; and
[2] a weight ratio of contents of the compound (2B?)/the compound (3B?) is from greater than 0.8 to 1.8, and a content of a compound or compounds containing two or more oxetanyl groups per molecule, including the compound represented by Formula (c-1), is from 45 to 95 wt. % of the total amount of the monomer mixture.

US Pat. No. 11,028,224

MONOMER MIXTURE AND CURABLE COMPOSITION CONTAINING SAME

DAICEL CORPORATION, Osak...

1. A monomer mixture comprising two or more types of cationically polymerizable monomers, the monomer mixture comprising, as the cationically polymerizable monomers: a compound (A) having one vinyl ether group and one hydroxyl group; a compound (B) having one oxetanyl group and one hydroxyl group; a compound (C) represented by Formula (c):
where X denotes a single bond or a linking group; and a compound (E) having two or more oxetanyl groups, excluding a compound having a hydroxyl group;
wherein a total content of the compound (A), the compound (B), and the compound (C) is 50 wt. % or greater of the total amount of the monomer mixture, and a content [A] of the compound (A) and a content [B] of the compound (B) satisfy Relationship (1);
A/(A+B)?0.3  (1)and the content of the compound (E) being from 15 to 40 wt. % of the total amount of the monomer mixtureand the content [B] of the compound (B) being from 1 to 15 wt. % of the total amount of the monomer mixture.

US Pat. No. 11,028,223

CEILING TILE WITH BUILT-IN AIR FLOW MECHANISM AND UV AIR PURIFYING DEVICE

WLC Enterprises, Inc., S...

1. An air purifying device, comprising:a ceiling tile having at least one vent and one fan portion;
an upper cover attached to the ceiling tile defining at least an airway between the fan portion and the vent;
a fan positioned in the fan portion adapted to guide air to the airway;
a UV light source mounted in the airway, wherein the UV light source is a UV-C light source emitting light having a wavelength between 200 and 280 nanometers;
a first baffle positioned in the airway and a second baffle positioned in the airway, wherein the first baffle and second baffle are configured to direct air guided by the fan to the airway along the UV light source; and
wherein the first baffle and the second baffle are positioned in the first airway to act as a barrier preventing light emitted from the UV light source from exiting the air purifying device.

US Pat. No. 11,028,222

ADVANCED PROCESSING OF ABSORBABLE POLY(P-DIOXANONE) CONTAINING HIGH LEVEL OF P-DIOXANONE MONOMER

Ethicon, Inc., Somervill...

1. A method of making absorbable poly(p-dioxanone) pellets by melt polymerization of p-dioxanone conducted in a single reactor with a temperature regulator, and comprising the steps of:i. charging a melt reactor with a mixture of p-dioxanone (PDO) monomer, initiator, catalyst, and optionally a dye;
ii. melt polymerizing the mixture at a reaction temperature of between 95° C. and 145° C. in the melt reactor with sufficient agitation of the mixture to allow complete mixing of the monomer and for sufficient time to form a PDO polymer product having an unreacted PDO monomer content;
iii. placing the PDO polymer product under a vacuum for about 60 to 180 minutes to remove at least portion of unreacted PDO, as measured by monomer content, wherein the unreacted PDO monomer content after step (iii) is between about 15 mole percent to about 35 mole percent;
iv. discharging the PDO polymer product from the melt reactor directly into an in-line, underwater pelletizer to produce undried PDO pellets,
v. collecting the undried PDO pellets, and
vi. storing the collected PDO pellets in the freezer or a vacuum chamber.

US Pat. No. 11,028,220

RELATING TO STRUCTURAL ADHESIVES

ZEPHYROS, INC., Romeo, M...

1. An adhesive for providing corrosion resistance to a substrate to which the adhesive is adhered, the adhesive comprising:a) from about 25% to about 50%, by weight of the adhesive, epoxy resin with about 25% to about 75%, by weight of the epoxy resin, being high molecular weight resin, the high molecular weight resin including a phenoxy resin;
b) from about 10% to about 25%, by weight of the adhesive, core/shell impact modifier; and
c) from about 0.5% to about 10%, by weight of the adhesive, curing agent;
wherein the adhesive is reformable from about 60° C. to about 120° C., and wherein the adhesive is curable from about 125° C. to about 230° C.;
wherein a temperature range in which GI>GII is from about 10° C. to about 50° C.;
wherein a temperature range in which GII>GI is from about 80° C. to about 120° C.;
wherein the adhesive is free from crosslinking below 125° C.;
wherein the epoxy resin comprises a solid epoxy resin and a liquid epoxy resin; and
wherein a ratio of the solid epoxy resin to the epoxy resin is from about 1:9 to about 1:16, by weight.

US Pat. No. 11,028,217

THERMOPLASTIC POLYURETHANE COMPOSITIONS COMPRISING NITRO-SUBSTITUTED POLYESTER DIOLS

BioCellection Inc., Menl...

1. A thermoplastic polyurethane elastomer composition comprising the reaction product of(a) a composition comprising at least one nitro-substituted polyester diol (NO2-PED), and at least one polyester diol that is not substituted by a nitro group, wherein the NO2-PED has the formula:

wherein n is 0-14, y is 1-100, X?H or NO2, and R is alkylenyl, alkylenyl with one or more CH2 groups substituted by —O—, cycloalkylenyl, or arylenenyl, wherein at least one X is NO2,
(b) at least one polyisocyanate, and
(c) at least one chain extender.

US Pat. No. 11,028,211

BIOCOMPATIBLE AND CONDUCTIVE HYDROGELS WITH TUNABLE PHYSICAL AND ELECTRICAL PROPERTIES

Northeastern University, ...

1. A biocompatible conductive hydrogel comprising a biocompatible polymer conjugated to a first ionic constituent of a bio-ionic liquid;wherein the bio-ionic liquid has a melting temperature less than 35° C.; and
wherein the biocompatible polymer and the first ionic constituent are conjugated via a diacrylate linker.

US Pat. No. 11,028,210

CORE-SHELL FLOW IMPROVER

LIQUIDPOWER SPECIALTY PRO...

1. A flow improver comprising:solid particles each having a polymeric core and a polymeric shell at least partly surrounding said polymeric core,
wherein said polymeric core comprises a drag reducing polymer, wherein said polymeric shell comprises a shell copolymer having repeat units of a hydrophobic compound and repeat units of a first amphiphilic compound,
wherein an amount of said repeat units of the hydrophobic compound ranges from about 25 to about 98 weight percent of said shell copolymer, and
wherein said polymeric core and said polymeric shell are formed by emulsion polymerization, and said solid particles have a mean particle size of less than 1000 nm.

US Pat. No. 11,028,209

CONDUCTIVE RESIN COMPOSITION FOR ELECTRODES, ELECTRODE COMPOSITION, ELECTRODE USING SAME AND LITHIUM ION BATTERY

Denka Company Limited, T...

1. A conductive resin composition for electrodes, comprising a dispersant, a conductive agent, and a binding material, wherein:the dispersant comprises a graft copolymer in which a monomer containing acrylonitrile as a main component is grafted onto polyvinyl alcohol;
the average degree of polymerization of the polyvinyl alcohol is 300 to 3,000, and the degree of saponification of the same is 90 mol % to 100 mol %; and
the polyvinyl alcohol content and the polyacrylonitrile content in the graft copolymer are, respectively, 10 mass % to 40 mass % and 90 mass % to 60 mass %,
wherein the conductive resin composition has a viscosity, measured at a shear velocity of 0.1 s?1, of 11 Pa·s or less.

US Pat. No. 11,028,205

WATER-BREAKABLE FORMULATIONS AND ADDITIVE MANUFACTURING PROCESSES EMPLOYING SAME

Stratasys Ltd., Rehovot ...

1. A curable formulation comprising at least one mono-functional curable material and at least one multi-functional curable material, said mono-functional and multi-functional curable materials and a concentration ratio thereof being selected such that a cured material formed upon exposing the formulation to a curing energy breaks into particles upon immersion in an aqueous solution,wherein:
said cured material breaks upon said immersion into particles having a size ranging from 1 micron to 100 mm; and/or
said cured material features a degree of cross linking that ranges from 10 to 80%; and/or
said cured material has a swelling capacity of from 10 to 300% by weight; and/or
a 3-gram cube made of said cured material breaks upon static immersion in water in less than 10 hours.

US Pat. No. 11,028,202

RESIN COMPOSITION WITH A (METH)ACRYLIC COPOLYMER, ANTIFOULING PAINT COMPOSITION, AND METHOD FOR PRODUCING SAME

Mitsubishi Chemical Corpo...

1. A resin composition, comprising:a (meth)acrylic copolymer:
an organic solvent,
wherein the (meth)acrylic copolymer is present in the resin composition in an amount of at least 45 mass %, relative to a total resin composition mass,
wherein the organic solvent is present in the resin composition in an amount of at least 15 mass %, relative to the total resin composition mass,
wherein the (meth)acrylic copolymer comprises
a constituent unit (A) comprising a constituent unit (A1) comprising a structure (I) of formula (1), formula (2), or formula (3), a constituent unit (A2) comprising a triorganosilyloxycarbonyl group, and/or a constituent unit (A3) comprising a structure (III) of formula (4) or formula (5),
a constituent unit (B) derived from at least one polysiloxane block-containing polymerizable monomer (b) comprising a polymerizable monomer of formula (b1), a polymerizable monomer of formula (b2), a polymerizable monomer of formula (b3), and/or a polymerizable monomer of formula (b4), and
a constituent unit (C) derived from a macromonomer (c) comprising two or more constituent units of formula (c?)—COO-M-OCO—  (4)
—COO-M-R22  (5)
CH2?CR3a—CO—O—(CuH2u—O)v—CwH2w—(SiR3bR3c—O)x—SiR3dR3eR3f  (b1)
CH2?CR4a—CO—O—(Cu?H2u?—O)v?—Cw?H2w?—Si(OSiR4bR4cR4d)  (b2)
CH2?CR2a—CO—O—(Ck?H2k?—O)l?—Cm?H2m?—Si((OSiR2bR2c)r—OSiR2dR2eR2f)2—OSi((OSiR2gR2h)s—OsiR2iR2jR2k)2—Co?H2o?—(O—Cp?H2p?)q?—O—CO—CR21?CH2  (b3)
CH2?CR1a—CO—O—(CkH2k—O)1—CmH2m—(SiR1bR1c—O)n—SiR1dR1e—CoH2o—(O—CHpH2p)q—O—CO—CR1f?CH2  (b4)

wherein, in formula (1) to (5), (1) to (b4), and (c?),
X is —O—, —S—, or —NR14—, —R14 being H or an alkyl group,
R1 and R2 are independently or an alkyl group comprising 1 to 10 carbon atoms,
R3 and R5 are independently an alkyl group comprising 1 to 20 carbon atoms, a cycloalkyl group, or an aryl group,
R4 and R6 are independently an alkylene group comprising 1 to 10 carbon atoms,
M is Zn, Cu, Mg, or Ca,
R22 is a monovalent organic acid residue,
R1a, R1f, R2a, R3a, R4a, R21, are independently H or a methyl group,
R1b to R1e and R3b to R3f are independently an alkyl group, an alkoxy group, a phenyl group, a substituted phenyl group, a phenoxy group, or a substituted phenoxy group,
R4b to R4d are independently an alkyl group, —(OSiR51R52)y—OSiR53R54R55with y being an integer in a range of from 0 to 20, and R51 to R55 represent being an alkyl group), —R56-(OC2H4)y?—OR57 with y? being an integer in a range of 1 to 20, R56 being an alkylene group, and R57 being an alkyl group,
R2b to R2k are independently an alkyl group,
r and s are independently a number in a range of from 0 to 20,
l, l?, q, q?, v, and v? are independently a number in a range of from 0 to 50,
k, k?, in, m?, o, o?, p, p?, u, u?, w, and w? are independently an integer in a range of from 2 to 5,
n and x are independently a number in a range of from 3 to 80,
R41 is H, a methyl group, or CH2OH
R42 is OR43, a halogen atom, COR44, COOR45, CN, CONR46R47, or R48,
R43 to R47 are independently H or an optionally substituted alkyl, alicyclic, aryl, heteroaryl, non-aromatic heterocyclic, aralkyl, alkaryl, or organosilyl group, and
R48 is an optionally substituted aryl or heteroaryl group.

US Pat. No. 11,028,200

SIDE-CHAIN-OLEFIN-CONTAINING VINYL ALCOHOL POLYMER AND METHOD OF PRODUCING SAME

KURARAY CO., LTD., Kuras...

1. A vinyl alcohol-based polymer comprising an olefin in a side chain, the vinyl alcohol-based polymer comprising:a vinyl alcohol unit and
a structural unit represented by the following formula (I):

wherein X represents at least one alkylene group selected from the group consisting of a methylene group, an ethylene group, a propylene group and a butylene group, having an alkyl group as a branched structure; Y represents a hydrogen atom; and Z represents a hydrogen atom.

US Pat. No. 11,028,198

TETRAFLUOROETHYLENE AND PERFLUORINATED ALLYL ETHER COPOLYMERS

3M INNOVATIVE PROPERTIES ...

1. A copolymer comprisingat least 66% by weight based on the total weight of the copolymer of tetrafluoroethylene units;
units independently represented by formula
in a range from 0.2 to 12% by weight, based on the total weight of the copolymer, wherein n is independently from 1 to 6, z is 0, 1, or 2, and Rf is a linear or branched perfluoroalkyl group having from 1 to 8 carbon atoms and optionally interrupted by one or more —O— groups;from 5 to 22% by weight based on the total weight of the copolymer of units derived from hexafluoropropylene; and
units represented by formula

wherein a is 0 or 1, each b is independently from 1 to 4, c is 0 to 4, d is 0 or 1, e is 1 to 6, and X is independently —F, —NH2, —OH, or —OZ, and wherein Z is independently a metallic cation or a quaternary ammonium cation,
wherein the copolymer has a melt flow index in a range from 1 to 19 grams per 10 minutes; and
wherein the copolymer has up to 200 —SO2X groups per 106 carbon atoms and up to 100 unstable end groups per 106 carbon atoms, wherein X is independently —F, —NH2, —OH, or —OZ, wherein Z is independently a metallic cation or a quaternary ammonium cation, wherein the unstable end groups are selected from —COOM, —CH2OH, —COF, and —CONH2, and wherein M is independently an alkyl group, a hydrogen atom, a metallic cation or a quaternary ammonium cation.

US Pat. No. 11,028,196

POLYOLEFIN COMPOSITIONS

ExxonMobil Chemical Paten...

1. A composition comprising:(i) from about 5 to about 50 wt % of a vinyl-terminated polyethylene having an Mn from about 200 g/mol to about 10,000 g/mol; and
(ii) from about 50 to about 95 wt % of a comb polyolefin having polyethylene arms attached to a random copolymer backbone, said backbone including a majority of units derived from propylene, as determined by molar percentage of units,
wherein the polyethylene arms have an Mn from about 200 g/mol to about 10,000 g/mol, and
wherein the comb polyolefin has an Mp from about 7,500 to about 400,000 g/mol.

US Pat. No. 11,028,194

BIS-SCHIFF BASE COMPOSITIONS AND FORMULATIONS

Jalapeno Holdings, LLC, ...

1. A chemical composition comprising a chemical having the structure of Formula (I):wherein:R is selected from at least one of Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), Formula (XIV), Formula (XV), Formula (XVI), Formula (XVII), Formula (XVIII), Formula (XIX), Formula (XX), Formula (XXII), Formula (XXIII), Formula (XXIV), Formula (XXV), Formula (XXVI), Formula (XXVII), Formula (XXVIII), Formula (XXIX), Formula (XXX), or Formula (XXXI);
X comprises an aromatic moiety, an aliphatic moiety, or a hydrogen when R is selected from Formula (VI), Formula (VII), Formula (VIII), Formula (XII), Formula (XIII), Formula (XIV), Formula (XV), Formula (XVI), Formula (XIX), Formula (XX), Formula (XXII), Formula (XXIII), Formula (XXIV), Formula (XXV), Formula (XXVI), Formula (XXVII), Formula (XXVIII), Formula (XXIX), Formula (XXX), or Formula (XXXI);
X consists of a hydrogen when R is selected from Formula (IV), Formula (V), Formula (IX), Formula (X), Formula (XI), or Formula (XVII);
X? comprises an aromatic moiety, an aliphatic moiety, or a hydrogen when R is selected from Formula (VI), Formula (VII), Formula (VIII), Formula (XII), Formula (XIII), Formula (XIV), Formula (XV), Formula (XVI), Formula (XIX), Formula (XX), Formula (XXII), Formula (XXIII), Formula (XXIV), Formula (XXV), Formula (XXVI), Formula (XXVII), Formula (XXVIII), Formula (XXIX), Formula (XXX), or Formula (XXXI); and
X? consists of a hydrogen when R is selected from Formula (IV), Formula (V), Formula (IX), Formula (X), Formula (XI), or Formula (XVII):
wherein for Formula (XXV), Formula (XXVI), Formula (XXVII), Formula (XXVIII), Formula (XXIX), Formula (XXX), or Formula (XXXI):R1, R2, R3, R4, R5, R6, R7, and R8 are each independently selected from Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), Formula (XIV), Formula (XV), Formula (XVI), Formula (XVII), Formula (XVIII), Formula (XIX), Formula (XX), Formula (XXI), Formula (XXII), Formula (XXIII), and Formula (XXIV),
the aromatic moieties Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, and Ar7 are meta-substituted or para-substituted; and
Formula (XXVIII), Formula (XXIX), Formula (XXX), and Formula (XXXI) are each illustrated broken across multiple lines but represent a single continuous structure.

US Pat. No. 11,028,193

AZIDE-MODIFIED OLEFIN AS POLYMERIC COUPLING AGENT

BRASKEM AMERICA, INC., P...

1. A polymeric coupling agent comprising:a polymer comprising at least one of the following repeating units:

wherein:
R? is vinyl, —C(O)H, or —CN; and
one or more reactive coupling groups covalently bonded to one or more repeating units of the polymer as pendent groups, optionally via one or more linking moieties,
wherein the reactive coupling group is selected from the group consisting of sulfonyl azide, aryl azide, phosphoryl azide, acyl azide, formyl azides, and combinations thereof,
wherein the polymer further comprises one or more reactive coupling groups covalently bonded to one or more terminal ends of the polymer chain.

US Pat. No. 11,028,192

SOLUTION PROCESS TO MAKE ETHYLENE COPOLYMERS

ExxonMobil Chemical Paten...

1. A process to polymerize olefins comprising contacting, in solution phase at a temperature of 85° C. to 200° C., ethylene, at least one olefin comonomer, and optional diene, with a catalyst system comprising a non-coordinating anion activator and a metallocene catalyst compound represented by the formula:wherein:M is Hf;
each R3 is independently an anionic group;
each R2 is independently H or a C1 to C20 hydrocarbyl or C1 to C20 substituted hydrocarbyl;
R4 is a hydrocarbyl radical having from 1 to 20 carbon atoms, hydrides, amides, alkoxides, sulfides, phosphides, halides, dienes, amines, phosphines, ethers, and a combination thereof;
R* is phenyl or a substituted phenyl;
each R5 is independently H or a C1 to C20 hydrocarbyl or C1 to C20 substituted hydrocarbyl;
each R6 is independently H or a C1 to C20 hydrocarbyl or C1 to C20 substituted hydrocarbyl;
each R7 is independently H or a C1 to C20 hydrocarbyl or C1 to C20 substituted hydrocarbyl;
each R8 is independently H or a C1 to C20 hydrocarbyl or C1 to C20 substituted hydrocarbyl;
where at least one of each adjacent pair of R7 and R8 is not H; and
2) obtaining ethylene copolymer comprising ethylene, from 0.5 to 25 mol % C3 to C20 olefin comonomer, and optionally from 0.5 to 20 mol % diene, said ethylene copolymer having a Mw greater than 100,000 g/mol where the % olefin comonomer incorporated is X % or more, where X=(Z?858,441)/(?26,760), where Z is the Mn in g/mol of the ethylene copolymer.

US Pat. No. 11,028,191

POLYMERIZATION CATALYSTS WITH IMPROVED ETHYLENE ENCHAINMENT

Univation Technologies, L...

8. A method of producing a bimodal polyethylene having improved ethylene enchainment, the method comprising:polymerizing ethylene in a reactor in presence of a bimodal polymerization catalyst system to form the bimodal polyethylene, wherein the bimodal polymerization catalyst comprises:
a non-metallocene catalyst; and
a zirconocene catalyst of Formula I:

wherein R1 is a C1 to C20 alkyl, aryl or aralkyl group, wherein R2 is an C1 to C20 alkyl, aryl or aralkyl group, and wherein R3 is a C1 to C20 alkyl or a hydrogen, wherein each X is independently a halide, C1 to C20 alkyl, aralkyl or hydrogen, and wherein R3 is a C1 alkyl or a linear C3 alkyl.

US Pat. No. 11,028,190

BIS-PHOSPHAGUANIDINE AND POLY-PHOSPHAGUANIDINE LIGANDS WITH GROUP IV METAL CATALYSTS PRODUCED THEREFROM

Dow Global Technologies L...

1. A phosphaguanidine compound comprising the structure of formula I:whereinR2, R5, R7, and R9 are independently selected from hydrides, aliphatic moieties, heteroaliphatic moieties, aromatic moieties, heteroaromatic moieties, and a lone pair of electrons;
R6 is an aliphatic, heteroaliphatic, aromatic, or heteroaromatic moiety;
R1 and R8 are independently selected from the same or different moieties selected from aliphatic moieties, heteroaliphatic moieties, aromatic moieties, heteroaromatic moieties and a lone pair of electrons;
Ra1, Ra2, Rb1, and Rb2 are independently selected from aliphatic moieties, heteroaliphatic moieties, aromatic moieties, and heteroaromatic moieties.

US Pat. No. 11,028,189

PREPARATION METHOD OF ANIONIC POLYMERIZATION INITIATOR, DEVICE FOR MANUFACTURING ANIONIC POLYMERIZATION INITIATOR AND ANIONIC POLYMERIZATION INITIATOR PREPARED THEREFROM

LG Chem, Ltd.

1. A method for preparing an anionic polymerization initiator comprising:introducing an amine compound of Formula 2 below and an organometallic compound into a continuous reactor to react them:

wherein,
R23, R24 and R25 independently represent hydrogen, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 1 to 6 carbon atoms or an alkynyl group having 1 to 6 carbon atoms,
Y represents nitrogen, oxygen or sulfur,
R26 is absent when Y is oxygen or sulfur, and represents an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 1 to 6 carbon atoms, an alkynyl group having 1 to 6 carbon atoms or a hetero atom when Y is nitrogen, and
b is an integer of 1 to 20.

US Pat. No. 11,028,158

ANTI-TRANSTHYRETIN ANTIBODIES

Prothena Biosciences Limi...

1. A vector comprising a nucleic acid encoding a mature heavy chain variable region and a mature light chain variable region operably linked to one or more regulatory sequences to effect expression in a mammalian cell of an antibody comprising the mature heavy chain variable region and mature light chain variable region that binds to human transthyretin, wherein the mature heavy chain variable region comprises three heavy chain CDRs having sequences comprising SEQ ID NOS:67-69, respectively, and the mature light chain variable region comprises three light chain CDRs having sequences comprising SEQ ID NOS:77-79, respectively, except that positions H52 and L26 by Kabat numbering are independently each N or S.

US Pat. No. 11,028,139

RECOMBINANT PROTEIN FOR PREVENTING OR TREATING TISSUE FIBROSIS AND COMPOSITION FOR PREVENTING OR TREATING TISSUE FIBROSIS COMPRISING THE SAME

NEXEL CO., LTD., Seoul (...

1. An isolated recombinant protein for preventing or treating tissue fibrosis, the recombinant protein consists of the amino acid sequence of SEQ ID NO: 1, which is a fragment of human milk fat globule-EGF factor 8 (MFG-E8) protein.

US Pat. No. 11,028,131

MUTANT OF ADENO-ASSOCIATED VIRUS (AAV) CAPSID PROTEIN

NIPPON MEDICAL SCHOOL FOU...

1. A mutant of an adeno-associated virus (AAV) capsid protein, comprising one or more amino acid replacements in a PLA2 domain as compared with the amino acid sequence of a wild-type AAV capsid protein,wherein the one or more amino acid replacements comprise an amino acid replacement of alanine at position 68 in the amino acid sequence of AAV2 VP1 capsid protein, and said position is based on the amino acid sequence of wild-type AAV2 VP1 capsid protein shown by SEQ ID NO: 2, and
wherein the mutant is a mutant of AAV2 capsid protein.

US Pat. No. 11,028,125

METHODS FOR EXTRACTING PROTEINS FROM A BLOOD-BASED MATERIAL

Plasma Technologies, LLC,...

1. A method of producing an immunoglobulin G product from a blood-based material, the method comprising:applying the blood-based material to a first fractionation module, wherein a first salt is added to the blood-based material to produce a first intermediate, wherein the salt comprises between 11-20 wt % of the first intermediate; and wherein the first intermediate is separated to produce a first supernatant and a first paste;
transferring the first supernatant to a second fractionation module, wherein a second salt is added to the first supernatant to produce a second intermediate, wherein the second salt comprises between 15-30 wt % of the second intermediate; and wherein the second intermediate is separated to produce a second supernatant and a second paste;
dissolving the second paste to generate a dissolved second paste;
transferring the dissolved second paste to a viral inactivation module and applying a virus inactivating agent to the dissolved second paste to generate a treated dissolved second paste; and
transferring the treated dissolved second paste to a first chromatography module wherein the treated dissolved second paste is separated by a first chromatography process comprising an anion exchange resin to produce a first flow-through and a first eluate,
wherein the first flowthrough comprises immunoglobulin G.

US Pat. No. 11,028,124

METHODS, DEVICES AND SYSTEMS FOR 3-STAGE FILTRATION

Repligen Corporation, Wa...

1. A filtration method comprising:passing a first fluid that comprises cells, cell debris and a targeted product produced by the cells through a first filter such that the first fluid is separated by the first filter into a first retentate comprising the cells and a first permeate comprising the targeted product and a first portion of the cell debris that passes through the first filter;
combining resin beads having affinity for the targeted product with the first permeate such that a second fluid is formed that comprises the resin beads with bound target product and the first portion of the cell debris;
passing the second fluid through a second filter such that the second fluid is separated by the second filter into a second retentate comprising the resin beads with the bound target product and second permeate comprising a second portion of the cell debris that passes through the second filter;
unbinding the targeted product from the resin beads with the bound targeted product such that a third fluid is formed that comprises a mixture of the resin beads and the targeted product; and
passing the third fluid through a third filter such that the third fluid is separated by the third filter into a third retentate comprising the resin beads and a third permeate comprising the targeted product.

US Pat. No. 11,028,122

ANTISENSE NUCLEIC ACIDS

NIPPON SHINYAKU CO., LTD....

1. A composition comprising a cationic polymer with a phosphorodiamidate morpholino oligomer (PMO) antisense oligomer that is 100% complementary to a target sequence of 5?-GAACACCUUCAGAACCGGAGGCAAC-3? (SEQ ID NO: 124),wherein said PMO antisense oligomer causes skipping of the 53rd exon in a human dystrophin pre-mRNA,
wherein said PMO antisense oligomer hybridizes to said target sequence with Watson-Crick base pairing under physiological conditions,
wherein said PMO antisense oligomer has exactly 25 phosphorodiamidate morpholino monomers, each of which has the formula:

wherein each of R2 and R3 represents a methyl, wherein Base is a nucleobase selected from the group consisting of uracil, cytosine, thymine, adenine, and guanine, and
wherein the 5? end of said PMO antisense oligomer has a formula selected from the group consisting of:

US Pat. No. 11,028,120

CD73 INHIBITORS

ORIC PHARMACEUTICALS, INC...

1. A compound selected from:or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,119

SYNTHETIC ROUTE TO 2?-DEOXY-2?,2?-DIFLUOROTETRAHYDROURIDINES

OTSUKA PHARMACEUTICAL CO....

1. A method of producing compound 1:or a salt thereof;comprising the steps of:(a) hydrogenating the starting compound of Formula IV:wherein R is a hydroxyl protecting group,to produce the compound of Formula IIa:(b) reducing the compound of Formula IIa to produce the compound of Formula IIIa:(c) deprotecting the compound of Formula IIIa to produce compound 2:and(d) precipitating or crystallizing compound 2 in the presence of a catalyst to produce compound 1:or a salt thereof;wherein the catalyst is 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), acetic acid, trifluoroacetic acid, diisopropylethylamine, or ammonium hydroxide; andwherein the hydrogenating in step (a) is carried out in the presence of a palladium catalyst.

US Pat. No. 11,028,118

EFFICIENT SYNTHESIS OF NICOTINAMIDE MONONUCLEOTIDE

Cornell University, Itha...

1. A process for the preparation of nicotinamide mononucleotide having formula (I):
or a salt thereof, wherein the process comprises the step of reacting a compound of formula (IV):

wherein R1 and R2 are independently C1-C6 alkyl or, taken together along with the carbon atom to which they are attached, form a 5-7 membered carbocyclic ring,
with an acid catalyst in a mixture of solvents to provide nicotinamide mononucleotide,
wherein the acid catalyst is trifluoroacetic acid, and
wherein the mixture of solvents is a mixture of dichloromethane and water.

US Pat. No. 11,028,117

BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM

1. A compound of formula (I):
wherein T1 and T2 are each independently selected from the group consisting of OR1 and OR2;
and; wherein
R1 is H or a hydroxyl protecting group, and
R2 is a phosphorus moiety; and wherein
Bx is a nucleobase.

US Pat. No. 11,028,116

LABELLED NUCLEOTIDES

Illumina Cambridge Limite...

1. A method for determining the sequence of a single-stranded target polynucleotide, comprising:(a) contacting a primer polynucleotide/target polynucleotide complex with one or more of nucleoside triphosphates A, G, C and T, wherein at least one of said nucleoside triphosphate has the structure:

wherein
B is a nucleobase selected from the group consisting of a purine, a pyrimidine and a deazapurine;
Z is —CH2N3;
X is a triphosphate group;
Linker-Label comprises

 wherein R is an optionally present electron-withdrawing group; Fluor is a fluorophore; and the dotted line connecting the Fluor and the benzene ring indicates that substitution may be at any free position on the benzene ring and further atoms not shown maybe present;
(b) incorporating one nucleoside triphosphate into the primer polynucleotide;
(c) performing one or more fluorescent measurements to determine the identity of the incorporated nucleoside triphosphate; and
(d) cleaving the Linker after performing the one or more fluorescent measurements.

US Pat. No. 11,028,115

LABELLED NUCLEOTIDES

Illumina Cambridge Limite...

1. An oligonucleotide comprising a nucleotide residue, wherein said nucleotide residue comprises the structure:
wherein Z is —CH2N3;
B is a nucleobase selected from the group consisting of a purine, a pyrimidine and a deazapurine; and
Linker-Label comprises
wherein R is an optionally present electron-withdrawing group; Fluor is a fluorophore; and the dotted line connecting the Fluor and the benzene ring indicates that substitution may be at any free position on the benzene ring and further atoms not shown may be present.

US Pat. No. 11,028,114

AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX

The Board of Trustees of ...

1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

US Pat. No. 11,028,113

CYPHOMYCIN, COMPOSITIONS AND USES THEREOF

Wisconsin Alumni Research...


US Pat. No. 11,028,112

INOSITOL DERIVATIVES FOR USE IN PATHOLOGICAL CRYSTALLIZATION

ETH ZURICH, Zurich (CH) ...

1. A method for treatment of a condition associated with cardiovascular calcification, comprising administering to a subject in need thereof a compound described by a general formula (II)whereinone or two or three X are R1 and the remaining X independently from each other are selected from OPO32?, OPSO22?, and OSO3?; and
each R1 independently of any other R1 is a polyethylene glycol or a polyglycerol,
and wherein the condition is selected from the group consisting of coronary artery disease, vascular stiffening, valvular calcification, myocardial infarction, cardiovascular mortality, progression of chronic kidney disease, peripheral arterial disease, critical limb ischemia, calciphylaxis, general arterial calcification of infancy, aortic stenosis, atherosclerosis, pseudoxanthoma elasticum, cardiac hypertrophy, heart failure, arrhythmia, aneurysm, valvular stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, stroke, and cognitive function.

US Pat. No. 11,028,111

COMPOUND FOR TREATING METABOLIC DISEASES AND PREPARATION METHOD AND USE THEREOF

1. A compound as shown in Formula (I), ora racemate, a stereoisomer, a geometric isomer, a tautomer, or a pharmaceutically acceptable salt thereof:

wherein,
R1 is hydrogen, substituted or unsubstituted alkyl or halogen;
each of the R2 is independently selected from the group consisting of substituted or unsubstituted alkyl, halogen, hydroxyl, nitro, cyano, sulphonic acid group and carboxyl;
m is 0, 1, 2, 3 or 4;
each of the R3 is independently selected from the group consisting of substituted or unsubstituted alkyl, halogen, hydroxyl and aryl; and
n is 0, 1, 2, 3 or 4.

US Pat. No. 11,028,110

PROCESS FOR THE ALKOXYCARBONYLATION OF ALCOHOLS

EVONIK OPERATIONS GMBH, ...

1. A process for forming an ester mixture product having n- and iso-ester components from a corresponding first alcohol substrate and CO and a second alcohol comprising the following process steps:a) introducing the first alcohol selected from a secondary or tertiary alcohol, having 2 to 30 carbon atoms, to form a reaction mixture;
b) adding a phosphine ligand and a compound which comprises Pd, or adding a complex comprising Pd and the phosphine ligand;
c) adding the second alcohol;
d) supplying CO;
e) heating the reaction mixture, the first alcohol reacting with CO and then the second alcohol to form the ester mixture with the iso- and n-products;
where the phosphine ligand is a compound of formula (I)
where m and n are each independently 0 or 1;R1, R2, R3, R4 are each independently selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl or —(C3-C20)-heteroaryl, where each is substituted or unsubstituted; and
at least one of the R1, R2, R3, R4 radicals is a —(C3-C20)-heteroaryl radical; wherein
the substituents are selected from
—(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —O—(C1-C12)-alkyl, —O—(C1-C12)-alkyl-(C6-C20)-aryl, —O—(C3-C12)-cycloalkyl, —S—(C1-C12)-alkyl, —S—(C3-C12)-cycloalkyl, —COO—(C1-C12)-alkyl, —COO—(C3-C12)-cycloalkyl, —CONH—(C1-C12)-alkyl, —CONH—(C3-C12)-cycloalkyl, —CO—(C1-C12)-alkyl, —CO—(C3-C12)-cycloalkyl, —N—[(C1-C12)-alkyl]2, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C3-C20)-heteroaryl, —(C3-C20)-heteroaryl-(C1-C12)-alkyl, —(C3-C20)-heteroaryl-O—(C1-C12)-alkyl, —COOH, —OH, —SO3H, —NH2 or halogen.

US Pat. No. 11,028,109

PHOSPHORUS-CONTAINING COMPOUND, MANUFACTURING METHOD THEREOF AND FLAME-RETARDANT THERMOSET

National Chunghsing Unive...

1. A phosphorus-containing compound, comprising a structure represented by formula (I):
wherein R1 and R2 are each independently a hydrogen atom, an alkyl group of 1 to 6 carbon atoms, a trifluoromethyl group, an unsubstituted phenyl group, a substituted phenyl group, an unsubstituted naphthyl group or a substituted naphthyl group, wherein R1 and R2 are not the hydrogen at the same time, and the hydrogen on the phenyl group of the substituted phenyl group is substituted by a monovalent organic group, the hydrogen on the naphthyl group of the substituted naphthyl group is substituted by a monovalent organic group, and the monovalent organic group is the alkyl group of 1 to 6 carbon atoms, X and Y are each independently —OH or a group represented by formula (MA):

wherein R3 is the hydrogen atom or the alkyl group of 1 to 6 carbon atoms.

US Pat. No. 11,028,108

METHOD FOR PRODUCING DIALKYLAMINOSILANE

JNC Corporation, Tokyo (...

1. A method for producing dialkylaminosilane, wherein dialkylamine is fed simultaneously during feeding chlorosilane in the presence of metal to cause reaction in a batch reactor wherein the metal to be added is magnesium.

US Pat. No. 11,028,105

DIFLUOROMETHYL AND DIFLUOROMETHYLENE TRANSFER REAGENTS

THE REGENTS OF THE UNIVER...

1. A compound of Formula (I):having a structure of:

wherein:
the dashed lines indicate optional double bonds;
R1 is C6-20 aryl or C1-15 heteroaryl, and the heteroaryl comprises 1-5 ring heteroatoms selected from N, O, and S;
each R2 and R3 is independently OH, N(R4)2, C1-6 alkyl, C3-8cycloalkyl, OC1-6 alkyl, or OC3-8 cycloalkyl; or adjacent R2 and R3, taken together with the atoms to which they are attached, form an optionally substituted 5-7 membered ring;
each R4 is independently C1-6 alkyl or C3-8cycloalkyl;
each R5 is independently C1-6 alkyl, C3-8cycloalkyl; or
each R5 taken together with the atoms to which they are attached form an optionally substituted 5-7 membered ring;
each R6 is independently C1-6 alkyl, C3-8cycloalkyl, OC1-6 alkyl, or OC3-8cycloalkyl; and
M comprises a counterion.

US Pat. No. 11,028,104

XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME

FORSCHUNGSVERBUND BERLIN ...

1. A method for treating a serotonin-related disease or disorder comprising administering to a patient in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the serotonin-related disease or disorder is Crohn's disease, ulcerative colitis, inflammatory bowel disease, or systemic sclerosis, and wherein the compound has the Formula (I):wherein:R1 and R2 are each an optionally substituted group independently selected from the group consisting of a hydrogen (—H), one of a (C1-C10)-alkyl group, a (C2-C10)-alkenyl group, a (C2-C10)-alkynyl group, a (C6-C14)-aryl group, a (C6-C14)-heteroaryl group, a (C7-C15)-alkyl-arylene group, a (C7-C15)-alkyl-heteroarylene group, a (C8-C15)-alkenyl-arylene group, a (C8-C15)-alkenyl-heteroarylene group, a (C8-C15)-alkynyl-arylene group, a (C8-C15)-alkynyl-heteroarylene group, a (C7-C15)-aryl-alkylene group, a (C7-C15)-heteroaryl-alkylene group, a (C8-C15)-aryl-alkenylene group, a (C8-C15)-heteroaryl-alkenylene group, a (C8-C15)-aryl-alkynylene group, and a (C8-C15)-heteroaryl-alkynylene group, wherein alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene, when present in the aforementioned groups, may comprise one or more bivalent groups substituting a carbon moiety —C— and the one or more bivalent groups is selected from the group consisting of —O—, —S—, —S(O)—, —SO2—, —N?, —C(O)—, —C(O)O—, —OC(O)—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —N(R)C(O)N(R)—, (C3-C12)-heterocyclic alkylene, and (C3-C12)-heterocyclic alkenylene;
R3 is a group independently selected from the group consisting of hydrogen (—H), fluoro (—F), bromo (—Br), chloro (—Cl), a hydroxyl group (—OH), an acyl group (—C(O)R), a carboxyl group (—C(O)OH), a carboxy ester group (—CO2R), an alkoxy group (—OR), an aldehyde group (—C(O)H), a trihalide methyl ester group (—OCX3), a primary amine group (—NH2), a secondary amine group (—N(R)H), a tertiary amine group (—NR(R?)), an amide group (—N(R)—C(O)—R), an imide group (—C(O)—N(R)—C(O)—R?), a carbamate group (—N(R)—C(O)—OR?), a carboxamide group (—C(O)N(R)R?), a carbimide group (—N(R)—C(O)—N(R?)R?), a primary ketimine group —C(R)?NH, a secondary ketimine group (—C(R)?NR?), a nitrile group (—CN), an isonitrile group (—NC), a nitroxy group (—ONO), a nitro group (—NO2), a nitrate group (—ONO2), a nitroso group (—NO), a cyanate group (—OCN), an isocyanate group (—NCO), a sulfhydryl group (—SH), a sulfide group (—SR), a sulfurtrihalide group (—SX3), a sulfurpentahalide group (—SX5), a sulfinyl group (—S(O)R), a sulfonyl group (—SO2R), a sulfino group (—SO2H), and a sulfo group (—SO3H), or an optionally substituted and/or optionally linked group selected from the group consisting of a (C1-C10)-alkyl group, a (C2-C10)-alkenyl group, a (C2-C10)-alkynyl group, a (C6-C14)-aryl group, a (C6-C14)-heteroaryl group, a (C7-C15)-alkyl-arylene group, a (C7-C15)-alkyl-heteroarylene group, a (C8-C15)-alkenyl-arylene group, a (C8-C15)-alkenyl-heteroarylene group, a (C8-C15)-alkynyl-arylene group, a (C8-C15)-alkynyl-heteroarylene group, a (C7-C15)-aryl-alkylene group, a (C7-C15)-heteroaryl-alkylene group, a (C8-C15)-aryl-alkenylene group, a (C8-C15)-heteroaryl-alkenylene group, a (C8-C15)-aryl-alkynylene group, and a (C8-C15)-heteroaryl-alkynylene group, wherein alkyl, alkenyl, alkynyl, alkylene, alkenylene, or alkynylene, when present in the aforementioned groups of R3, may comprise one or more bivalent groups substituting a carbon moiety —C— and the one or more bivalent groups is selected from the group consisting of —O—, —S—, —S(O)—, —SO2—, —N?, —N(R)—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —N(R)C(O)N(R)—, (C3-C12)-heterocyclic alkylene, and (C3-C12)-heterocyclic alkenylene, and wherein X is a halide;
Q is selected from the group consisting of hydrogenated carbon, non-hydrogenated carbon, hydrogenated nitrogen, and non-hydrogenated nitrogen, oxygen, sulfur, —*CH2—CH(R??)—, —*CH?C(R??)—, —*CH2—O—, and —*CH2—N(R??)—, wherein:
R?? represents hydrogen, a methyl group, an ethyl group, a cyclopropyl group,
a —CH2-cyclopropyl group, or a halogen; and
the carbon marked with an asterisk is covalently linked to the imidazole group set forth in Formula (I);
Z is selected from the group consisting of hydrogenated carbon, and non-hydrogenated carbon, hydrogenated nitrogen, non-hydrogenated nitrogen, oxygen and sulfur;
the ring member A is a saturated, unsaturated, or aromatic ring;
the substituents for the optionally substituted groups are selected from the group consisting of a fluoro (—F), a bromo (—Br), a chloro (—CI), a hydroxyl group (—OH), a (C1-C3)-alkyl group, a (C2-C3)-alkenyl group, an acyl group (—C(O)R), a carboxyl group (—C(O)OH), a carboxylate group (—C(O)O?), a carboxy ester group (—CO2R), an alkoxy group (—OR), an aldehyde group (—C(O)H), a trihalide methyl ester group (—OCX3), a primary amine group (—NH2), a secondary amine group (—N(R)H), a tertiary amine group (—NR(R?)), an amide group (—N(R)—C(O)—R), an imide group (—C(O)—N(R)—C(O)—R?), a carbamate group (—N(R)—C(O)—OR?), a carboxamide group (—C(O)N(R)(R?)), a carbimide group (—N(R)—C(O)—N(R?)R?), a primary ketimine group(—C(R)?NH), a secondary ketimine group (—C(R)?NR?), a nitrile group (—CN), an isonitrile group (—NC), a nitroxy group (—ONO), a nitro group (—NO2), a nitrate group (—ONO2), a nitroso group (—NO), a cyanate group (—OCN), an isocyanate group (—NCO), a sulfhydryl group (—SH), a sulfide group (—SR), a sulfurtrihalide group (—SX3), a sulfurpentahalide group (—SX5), a sulfinyl group (—S(O)R), a sulfonyl group (—SO2R), a sulfino group (—SO2H), a sulfo group (—SO3H), and combinations thereof, and wherein X is a halide;
R is independently hydrogen, a (C1-C3)-alkyl group, or a (C2-C3)-alkenyl group;
R? is independently hydrogen, a (C1-C3)-alkyl group, or a (C2-C3)-alkenyl group; and
R? is independently hydrogen, a (C1-C3)-alkyl group, or a (C2-C3)-alkenyl group.

US Pat. No. 11,028,103

DERIVATIZED 3-STYRYL-CEPHALOSPORINS

GLADIUS PHARMACEUTICALS C...

1. A compound of formula:
or pharmacologically acceptable salts thereof wherein:
R2, R3, R4, R5, R7, R8 and R16 are hydrogen;
R6 is hydrogen or NO2;
L is —CH2;
n is 0 or an integer number ranging from 1 to 5;
Z is —S—;
X is
wherein,each R20 independently is selected from hydrogen or two adjacent R20 together with the atoms to which they are attached form a 5-6 member carbocyclic or heterocyclic ring which may contain one or more double bonds or be aromatic; and
R1 is a pharmacologically acceptable functional group which is a functionalized imine selected from the group consisting of
wherein R9 is hydrogen and R10 is C1-C6 alkyl or C1-C6 carboxylic acid.

US Pat. No. 11,028,102

METHODS OF USING 1-O-ACETYLBRITANNILATONE SPIRO ARYL ISOXAZOLINE COMPOUNDS

1. A method of inhibiting leukotriene comprising:administrating a therapeutically effective amount of a compound of chemical formula I or II or a pharmaceutical acceptable salt thereof to a subject,

wherein R1 is OH or OAc; X is C or N; and R2 is H, alkyl, alkoxy, benzyloxy, haloalkyl, OH, CN, NO2, or halogen, provided that when X is N, R2 is nil.

US Pat. No. 11,028,101

3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

CTXT PTY LTD, Victoria (...

1. A compound of formula:

US Pat. No. 11,028,100

POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION

Genentech, Inc., South S...

1. A crystalline, anhydrate polymorph of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide having the structure:
said polymorph is designated the Form A polymorph that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at approximately 5.7, 11.4, 17.2, 19.0, 19.7, and 24.4.

US Pat. No. 11,028,099

NRF2 ACTIVATORS

GLAXOSMITHKLINE INTELLECT...

1. A compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid:or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,098

4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE

The Trustees of Columbia ...

1. A method for treating a disease characterized by excessive lipofuscin accumulation in the retina in a mammal afflicted therewith comprising administering to the mammal an effective amount of a compound having the structure:
R1, R2, R3, and R4, are each independently H, halogen, CF3 or C1-C4 alkyl, and wherein R5 is CF3;
R6 is H, OH, or halogen;
B is a substituted or unsubstituted pyridazine, pyrimidine, pyrazine, or B has the structure:

wherein
n is 1;
R7 is H, C1-C4 alkyl, or oxetane;
Y1 and Y4 are each CH2; and
one of Y2 or Y3 is CH2 and the other of Y2 or Y3 is O, SO2, or N—R10,
wherein
R10 is H, C1-C4 alkyl, C1-C4 cycloalkyl, (C1-C4 alkyl)-CF3, (C1-C4 alkyl)-OCH3, (C1-C4 alkyl)-halogen, SO2—(C1-C4 alkyl), SO2—(C1-C4 alkyl)-CF3, SO2—(C1-C4 alkyl)-OCH3, SO2—(C1-C4 alkyl)-halogen, C(O)—(C1-C4 alkyl), C(O)—(C1-C4 alkyl)-CF3, C(O)—(C1-C4 alkyl)-OCH3, C(O)—(C1-C4 alkyl)-halogen, C(O)—NH—(C1-C4 alkyl), C(O)—N(C1-C4 alkyl)2, C1-C4 alkyl)-C(O)OH, or oxetane;
or B has the structure:

wherein
R7 is H, C1-C4 alkyl, or oxetane; and
Y1, Y2, Y3 and Y4 are each independently CR8 or N,
wherein each R8 is independently H, halogen, C1-C4 alkyl, C1-C4 cycloalkyl, O—(C1-C4 alkyl), C(O)OH, C(O)—NH2, C(O)—N(CH3)2, C(O)—NHCH3, NHC(O)—N(CH3)2, CN, or CF3;
or B has the structure:

wherein
Y1, Y2, Y3 and Y4 are each independently CR8 or N,
wherein each R8 is independently H, halogen, C1-C4 alkyl, C1-C4 cycloalkyl, O—(C1-C4 alkyl), C(O)OH, C(O)—NH2, C(O)—N(CH3)2, C(O)—NHCH3NHC(O)—N(CH3)2, CN, or CF3;
and
wherein the disease characterized by excessive lipofuscin accumulation in the retina is Age-Related Macular Degeneration, dry Age-Related Macular Degeneration, Geographic atrophy, Stargardt Disease, Best disease, adult vitelliform maculopathy, or Stargardt-like macular dystrophy;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,097

THIENOPYRIMIDINE COMPOUNDS

1. A method of treating a disorder which is responsive to antagonism of the adenosine A2B receptor in a subject in need thereof, the method comprising administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is:wherein:R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring;
R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring;
R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and
R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ring.

US Pat. No. 11,028,096

TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS AGAINST HIV/AIDS

Purdue Research Foundatio...

1. A compound of the formula (I)
or a pharmaceutically acceptable salt, polymorph, or solvate thereof, wherein: n is an integer from 0 to 3; X is (—CHR5—)m or —O—, wherein m is 1 or 2 and each R5 is, independently H, alkyl or alkoxy;
X1, X2, and X3 are each, independently, (—CHR5—)m;
R1 is alkyl, alkoxy, aryl, heterocycyl, halo, hydroxy or amino;
R2 is alkyl;
R3 is aryl, benzthiazole, benzoxazole, benzofuranyl or indolyl; and
R4 is H, alkyl or alkoxy.

US Pat. No. 11,028,095

SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Aptinyx Inc., Evanston, ...

1. A compound represented by Formula I or Formula II:or a pharmaceutically acceptable salt, a stereoisomer, and/or an N-oxide thereof, wherein:R1 and R2 are independently selected from the group consisting of hydrogen, —C1-C6alkyl, —C(O)—C1-C6alkyl, —C(O)—O—C1-C6alkyl, and —O—CH2-phenyl;
R3 is selected from the group consisting of hydrogen, —C1-C6alkyl, —C(O)—R31, and —C(O)—O—R32;
R31 is selected from the group consisting of hydrogen, —C1-C6alkyl; —C1-C6haloalkyl, —C3-C6cycloalkyl, and phenyl;
R32 is selected from the group consisting of hydrogen, —C1-C6alkyl; —C1-C6haloalkyl, —C3-C6cycloalkyl, and phenyl;
wherein any aforementioned C1-C6alkyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, hydroxyl, —SH, phenyl, —O—CH2-phenyl, and halogen; and any aforementioned phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, —C1-C3alkoxy, hydroxyl, and halogen;
Ra and Rb are each independently for each occurrence selected from the group consisting of hydrogen, —C(O)—O—CH2-phenyl, and —C1-C3alkyl; or Ra and Rb taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;
R4, R5, R6 and R7 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, phenyl, amido, amino, C1-4alkyl, C2-4alkenyl, —NH—C(O)—C1-6 alkyl, —NH—C(O)—C1-6alkylene-phenyl, —NH—C(O)—O—C1-6alkyl, and —NH—C(O)—O—C1-6 alkylene-phenyl; wherein C1-4alkyl, C1-6alkylene, C2-4alkenyl, and phenyl are optionally substituted by one or more substituents selected from RP; or
two R5s taken together form an oxo moiety; or
wherein for the compound of Formula I, R6 and R7 taken together with the adjacent carbons to which they are attached form a 3-membered carbocyclic ring which is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, —C1-C3alkyl, —C1-C3alkoxy, —C(O)NRaRb, and —NRaRb; and
RP is selected, independently for each occurrence, from the group consisting of carboxy, hydroxyl, halogen, amino, phenyl, C1-6alkoxy, and C1-6alkyl optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl and amino.

US Pat. No. 11,028,093

4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS

ARRAY BIOPHARMA INC., Bo...

1. A method for inhibiting JAK kinase activity in a cell comprising, contacting the cell with a compound of Formula Ior a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein:R1 is hydroxy(1-6C)alkyl, HOCH2(cyclopropylidine)CH2—, (1-4C alkoxy)(1-6C)hydroxyalkyl, (hydroxy)trifluoro(1-6C)alkyl, dihydroxy(2-6C)alkyl, H2N(3-6C)hydroxyalkyl, (1-3C alkyl)NH(3-6C)hydroxyalkyl, (1-3C alkyl)2N(3-6C)hydroxyalkyl, H2N(1-4C alkoxy)(3-6C)alkyl, Cyc1(CH2)m—, hetCyc1, hetCyc2CH2—, RaRbNC(?O)CH2—, hetCyc3a(1-3C)alkyl, hetCyc3b(2-3C)hydroxyalkyl, RcRdN(2-3C)alkyl, (1-3C alkyl)2NSO2(2-3C)alkyl, hetCyc4, (1-6C)alkyl or CH3SO2(1-6C)alkyl;
Cyc1 is a 4-6 membered cycloalkyl substituted with 1-2 substituents independently selected from the group consisting of HO, HOCH2—, (1-3C)alkyl, H2NHC(?O)—, (1-3C alkyl)2NC(?O)—, and HOCH2CH2NHC(?O)—;
m is 0 or 1;
hetCyc1 is a 4-6 membered heterocyclic ring having a ring heteroatom selected from N, O and S wherein the S is optionally oxidized to SO2, wherein said heterocyclic ring is optionally substituted with a substituent selected from the group consisting of OH, (1-3C alkyl)C(?O)—, (1-3C alkyl)SO2—, (1-3C alkyl)NHC(?O)— and NH2CH2C(?O)—;
hetCyc2 is a 4-6 membered heterocyclic ring having a ring S atom, wherein the S is oxidized to SO2;
Ra and Rb are independently H or (1-3C)alkyl, or
Ra and Rb together with the nitrogen atom to which they are attached form a 4-6 membered ring optionally having a ring oxygen atom;
hetCyc3a and hetCyc3b are independently a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterocyclic ring is optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, OH, (1-4C)alkoxy, HOCH2—, (1-3C alkyl)C(?O)— and oxo;
Rc is H or (1-3C)alkyl;
Rd is (1-3C)alkyl, (1-3C alkyl)SO2—, hetCyca, or (3-6C)cycloalkyl optionally substituted with HOCH2—;
hetCyca is a 5-6 membered azacyclic ring optionally substituted with 1-2 substituents independently selected from oxo and (1-3C)alkyl;
hetCyc4 is azetidinyl substituted with ((CH3)2N)2P(?O)— or Y—C(?O)—;
Y is ReRfN(CH2)n—, hetCycbCH2—, Cyc2, hydroxy(1-3C)alkyl, (1-3C alkyl)2NC(?O)—, (1-3C)alkylSO2- or (1-3C)alkyl;
n is 0 or 1;
Re and Rf are independently H or (1-3C)alkyl;
hetCycb is a 4-5 membered azacyclic ring optionally substituted with OH;
Cyc2 is a (3-6C)cycloalkyl optionally substituted with OH;
R2 is (1-6C)alkyl, trifluoro(1-6C)alkyl, difluoro(1-6C)alkyl, fluoro(1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkyl (optionally substituted with one or two halogens), (3-6C)cycloalkylCH2-, HOC(?O)— or phenyl, and
R3 is (1-6C)alkyl or (3-6C)cycloalkyl, or
R2 and R3 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring optionally substituted with one or two substituents independently selected from OH, (1-6C)alkyl and hydroxy(1-6C)alkyl, or
R2 and R3 together with the carbon atom to which they are attached form a 4-membered saturated azacyclic ring substituted with SO2CF3; and
R4 is hydrogen or (1-6C)alkyl.

US Pat. No. 11,028,092

SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES AS PDE9 INHIBITORS

20. A pharmaceutical composition comprising an inert carrier and a compound of claim 1, or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,091

METHOD FOR PRODUCING 3, 6-DISUBSTITUTED IMIDAZO[1, 2-B]PYRIDAZINE DERIVATIVE

Daiichi Sankyo Company, L...

1. A method for producing a compound represented by Formula (III) or a salt thereof:
wherein PG represents a protecting group for a nitrogen atom, the method comprising reacting a compound represented by Formula (I) or a salt thereof:

with a compound represented by Formula (II) or a salt thereof:
wherein each symbol is as defined above, in a solvent in the presence of a palladium catalyst and a base.

US Pat. No. 11,028,090

[1,2,4]TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BET PROTEIN-RELATED DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT

Dong Wha Pharm. Co., Ltd....

1. A compound represented by formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof:
wherein,
R1 is C1-20 straight or branched alkyl nonsubstituted or substituted with one or more halogens, or C6-20 aryl;
R2 is hydrogen, C1-20 straight or branched alkyl, or C1-20 straight or branched alkoxy;
R3 is hydrogen, nitro, halogen, nonsubstituted or substituted C1-20 straight or branched alkyl, nonsubstituted or substituted C1-20 straight or branched alkoxy, 5-10 membered heteroaryl nonsubstituted or substituted with one or more methyl groups containing one or more heteroatoms selected from the group consisting of N, O and S,
which forms 6 membered cycloalkyl containing one or more heteroatoms selected from the group consisting of S and O along with R4,wherein, the substituted C1-20 straight or branched alkyl and the substituted C1-20 straight or branched alkoxy can be independently substituted with one or more substituents selected from the group consisting of halogen, C1-3 straight or branched alkoxy, 5-10 membered heterocycloalkyl containing one or more heteroatoms selected from the group consisting of N, O and S, and C6-10 aryl nonsubstituted or substituted with one or more nitro groups,
A1 is hydrogen, or C1-20 straight or branched alkyl,
B1 and B2 are independently hydrogen, C1-20 straight or branched alkyl, diC1-3 straight or branched alkylamino C1-3 straight or branched alkyl, or C6-10 aryl, and B1 and B2 are linked to each other to form 5-10 membered heterocycloalkyl nonsubstituted or substituted with one or more benzyl groups containing one or more heteroatoms selected from the group consisting of N, O and S,
C1 is hydrogen, C1-20 straight or branched alkyl, or C1-20 straight or branched alkoxy,
D1 and D2 are independently hydrogen, hydroxy, C1-20 straight or branched alkyl saturated or containing one or more carbon?carbon unsaturated bonds, C1-20 straight or branched alkyl nonsubstituted or substituted with one or more cyano groups, or C1-20 straight or branched alkylsulfonyl,
E1 is C1-20 straight or branched alkyl, or C6-10 aryl C1-5 straight or branched alkyl,
F1 is C1-20 straight or branched alkyl, or C6-10 aryl,
G1 is C1-20 straight or branched alkyl, or C6-10 aryl;
R4 is hydrogen, hydroxy, halogen, nitro, C1-20 straight or branched alkyl nonsubstituted or substituted with one or more ?S groups, C1-20 straight or branched alkylsulfanyl nonsubstituted or substituted with one or more oxo (?O) groups, C1-20 straight or branched alkylsulfonyl, 5-10 membered heterocycloalkyloxy nonsubstituted or substituted with one or more C1-5 straight or branched alkoxycarbonyl containing one or more heteroatoms selected from the group consisting of N, O and S, nonsubstituted or substituted 5-10 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, O and S, nonsubstituted or substituted C1-20 straight or branched alkoxy,

wherein, the substituted 5-10 membered heteroaryl can be substituted with one or more substituents selected from the group consisting of C1-3 straight or branched alkyl, C1-3 straight or branched alkoxy and C1-3 straight or branched alkoxy C1-3 straight or branched alkyl,
wherein, the substituted C1-20 straight or branched alkoxy can be substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-3 straight or branched alkoxy, nonsubstituted or substituted 5-10 membered heterocycloalkyl containing one or more heteroatoms selected from the group consisting of N, O and S, and nonsubstituted or substituted C6-10 aryl,
wherein, the substituted 5-10 membered heterocycloalkyl and the substituted C6-10 aryl can be independently substituted with one or more substituents selected from the group consisting of cyano,
C1-5 straight or branched alkoxycarbonyl, and 5-8 membered heteroaryl nonsubstituted or substituted with one or more N groups,A3 is hydrogen, or C1-20 straight or branched alkyl,
B3 and B4 are independently hydrogen, C1-20 straight or branched alkyl, diC1-3 straight or branched alkylamino C1-3 straight or branched alkyl, nonsubstituted or substituted C6-10 aryl, nonsubstituted or substituted C6-10 aryl C1-3 straight or branched alkyl, and B3 and B4 are linked to each other to form 5-10 membered heterocycloalkyl nonsubstituted or substituted with one or more benzyl groups containing one or more heteroatoms selected from the group consisting of N, O and S,
wherein, the substituted C6-10 aryl can be substituted with one or more substituents selected from the group consisting of amine, halogen, C1-5 straight or branched alkyl and C1-5 straight or branched alkoxy,
C3, C4 and C5 are independently hydrogen, amine, halogen, C1-20 straight or branched alkyl, or C1-20 straight or branched alkoxy,
D3 and D4 are independently hydrogen, hydroxy, C1-20 straight or branched alkyl saturated or containing one or more carbon?carbon unsaturated bonds, C1-20 straight or branched alkyl nonsubstituted or substituted with one or more cyano groups, or C1-20 straight or branched alkylsulfonyl nonsubstituted or substituted with one or more halogens, and D3 and D4 are linked to each other to form 5-10 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, O and S, or 5-10 membered heterocycloalkyl fused with 5 membered heteroaryl nonsubstituted or substituted with one or more methyl groups or containing one S group and one or more heteroatoms selected from the group consisting of N, O and S,
E3 is C1-20 straight or branched alkyl, or C6-10 aryl C1-5 straight or branched alkyl,
F3 is C1-20 straight or branched alkyl, or C6-10 aryl,
G3 is C1-20 straight or branched alkyl, or C6-10 aryl,
H3 is C6-10 aryl, 5-10 membered heterocycloalkyl containing one or more heteroatoms selected from the group consisting of N, O and S, or 5-10 membered heteroaryl nonsubstituted or substituted with one or more methyl groups containing one or more heteroatoms selected from the group consisting of N, O and S,
I3 is diC1-3 straight or branched alkylamino;
R5 is hydrogen, halogen, C1-20 straight or branched alkyl nonsubstituted or substituted with one or more halogens, or C1-20 straight or branched alkoxy;
R6 is

B5 and B6 are independently hydrogen, C1-20 straight or branched alkyl, C6-10 aryl C1-3 straight or branched alkyl, or 5-10 membered heteroaryl C1-3 straight or branched alkyl containing one or more heteroatoms selected from the group consisting of N, O and S,
D5 and D6 are independently hydrogen, hydroxy, C1-20 straight or branched alkyl saturated or containing one or more carbon?carbon unsaturated bonds, C1-20 straight or branched alkyl nonsubstituted or substituted with one or more cyano groups, or C1-20 straight or branched alkylsulfonyl nonsubstituted or substituted with one or more halogens,
E5 is C1-20 straight or branched alkyl saturated or containing one or more carbon?carbon unsaturated bonds, C1-20 straight or branched alkoxy saturated or containing one or more carbon?carbon unsaturated bonds, C3-10 cycloalkyloxy, C3-10 cycloalkyl C1-3 straight or branched alkyl, C3-10 cycloalkyl, C6-10 aryloxy, C6-10 aryl C1-3 straight or branched alkoxy, C1-20 straight or branched alkylsulfanyl, nonsubstituted or substituted C6-10 aryl, diC1-3 straight or branched alkylamino, 5-10 membered heterocycloalkyl containing one or more heteroatoms selected from the group consisting of N, O and S, or nonsubstituted or substituted 5-10 membered heteroaryl containing one or more N groups,
wherein, the substituted C1-20 straight or branched alkyl can be substituted with one or more substituents selected from the group consisting of hydroxy, halogen, C1-3 straight or branched alkoxy, C1-3 straight or branched alkylcarbonyloxy, C1-3 straight or branched alkoxycarbonyl, hydroxycarbonyl, C6-10 aryl nonsubstituted or substituted with one or more hydroxyl groups, 5-10 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, O and S, and

T1 and T2 are independently hydrogen, C1-5 straight or branched alkyl, C1-5 straight or branched alkoxycarbonyl, C1-5 straight or branched alkylcarbonyl nonsubstituted or substituted with one or more halogens or hydroxyl groups, and T1 and T2 are linked to each other to form heterocycloalkyl nonsubstituted or substituted with one or more hydroxyl groups or C1-3 straight or branched alkyl groups containing one S group and one or more heteroatoms selected from the group consisting of N, O and S,
wherein, the substituted C6-10 aryl and the substituted 5-10 membered heteroaryl can be independently substituted with one or more substituents selected from the group consisting of halogen, nitro, C1-5 straight or branched alkyl and C1-5 straight or branched alkoxy,
F5 is C1-20 straight or branched alkyl, C3-10 cycloalkyl, or C6-10 aryl nonsubstituted or substituted with one or more halogens,
G5 is C1-20 straight or branched alkyl;
M is C1-20 straight or branched alkylene; and
X is —NH—.

US Pat. No. 11,028,089

PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS

DANA-FARBER CANCER INSTIT...

1. A method of treating pancreatic cancer in a subject, the method comprising administering to the subject a compound of formula F-1:
or a pharmaceutically acceptable salt thereof,wherein,R1 is

R2 is —CH2—CH2F, —CH2—CHF2, or —CH2—CF3;
R5 is hydrogen or methyl; and
R6 is hydrogen or optionally substituted alkyl;
each R7 is independently alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic, alkoxy, NH(alkyl), NH(aryl), N(alkyl)(alkyl), or N(alkyl)(aryl), each of which may be optionally substituted; halo, nitro, or cyano; and
p is 0-4.

US Pat. No. 11,028,088

MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE

Yale University, New Hav...

1. A compound, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, or prodrug thereof, having the structure:ULM-L-PTM,wherein:the ULM is an E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase;
the PTM is a Bruton's Tyrosine Kinase (BTK) targeting moiety having the structure:

wherein:
at each occurrence XPTM is independently N or optionally substituted CH;
RPTM1 is independently NRPTMP9PTM10, H, optionally substituted C3-C6 cycloalkyl,
optionally substituted C3-C6 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl,

RPTM9 and RPTM10 are each independently H, —(C?O)—RPTM9?, or optionally substituted C1-C6 alkyl;
RPTM9? is optionally substituted linear or branched alkyl, or optionally substituted alkene;
at each occurrence RPTM2 is independently H, —O—RPTM3, optionally substituted linear or branched alkyl;
at each occurrence RPTM3 is independently an optionally substituted aryl or optionally substituted heteroaryl; and
the indicates a site of attachment of at least one of a linker, ULM, ULM? or a combination thereof; and
the L is a bond or a linker connecting the ULM and the PTM.

US Pat. No. 11,028,087

2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS

UNIVERZITA PALACKEHO V OL...

1. 2,6-disubstituted-9-cyclopentyl-9H-purines of the general formula I
wherein R1 is selected from the group consisting of:

and
Q is ?CH— or ?N—;
X is CH2, NH or C?O;
m is 1 or 2 or 3;
n is 1 or 2 or 3;
A is selected from the group consisting of O, N, CH, and C; with the proviso that:
if A is O, then o=p=0 and R2, B and R3 are not present,
if A is N or CH, then R2 is selected from II, CH3, and CH2CH3, and o=p=0 and B and R1 are not present,
if A is C, then R2 is not present, o is 1 or 2 or 3, p is 1 or 2 or 3, and B and R3 are as defined below;
B is selected from O and N, with the proviso that:
if B is O, then R3 is not present,
if B is N, then R3 is selected from H, CH3, and CH2CH3; and
pharmaceutically acceptable salts thereof.

US Pat. No. 11,028,086

PYRIDO-IMIDAZO RIFAMYCINS

BIOFER S.P.A., Medolla (...

1. A compound of Formula (I) or pharmaceutically acceptable salts thereof
wherein
R and R1 may be H,

with the proviso that:
when
then R1?H and R2?CH3CO— or H;when
then R?H and R2?CH3CO— or H;when
then R1?H and R2?CH3CO— or H; andwhen
then R?H and R2?CH3CO— or H;wherein R3 and R4 are the same or different and selected from the group comprising hydrogen, linear or branched C1-C10 alkyl, optionally substituted with one or more substituents selected from aminoalkyl, alkoxy, phenoxy, or sulfo, and aryl, optionally mono- or disubstituted with C1-C4 alkyl or alkoxy groups, halogen, amino, nitro; or
R3 and R4 taken together with two consecutive carbon atoms of the pyridine core may form a phenyl ring, optionally substituted with C1-C4 alkyl, or a 5- or 6-membered heterocyclic ring, optionally substituted with C1-C4 alkyl,
R5 is selected from the group comprising hydrogen, hydroxy, linear or branched C1-C10 alkyl, optionally substituted with one or more substituents selected from aminoalkyl, alkoxy, phenoxy, or sulfo, and aryl optionally mono- or disubstituted with C1-C4 alkyl or alkoxy groups, halogen, amino, nitro.

US Pat. No. 11,028,085

SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS

Nimbus Saturn, Inc., Cam...

1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,084

SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-?B PATHWAYS

Forschungsverbund Berlin ...

1. A method of treatment of a cancer in a subject in need thereof comprising:(a) identifying the subject as having a cancer exhibiting genotoxic stress-induced IKK/NF-?B signaling activation that causes growth of the cancer,
(b) selectively blocking activation of IKK/NF-?B in response to the genotoxic stress upstream of the IKK complex in the subject without blocking NF-?B activation upon signaling caused by other pathways in the subject by administering to the subject a compound according to Formula I,
whereinR1=H, O;
R2=from 0-4, can be the same or different, H, OH, halogen, C1-C7 alkyl, alkenyl, alkynyl, alkoxy, carbonyl, carboxyl, alkoxycarbonyl, amine, or wherein R2 is alkoxyamine, alkoxyamide;
R3=from 0-4, can be the same or different, H, OH, halogen, C1-C7 alkyl, alkenyl, alkynyl, alkoxy, carbonyl, carboxyl, alkoxycarbonyl, amine, or wherein two (adjacent) R3 substituents can form an optionally aromatic cyclic structure of 5 or 6 members, optionally comprising 0, 1, or 2 heteroatoms;
X1 and X2=N or C;
X3=C;
ring A is an aromatic cyclic structure of 5 or 6 members, optionally comprising 0, 1, or 2 heteroatoms selected from the group consisting of O and N,
wherein said cyclic structure is optionally substituted with 0-3 substituents that can be the same or different, selected from the group consisting of H, OH, halogen, C1-C7 alkyl, alkenyl, alkynyl, alkoxy, carbonyl, alkoxycarbonyl, amine, aryl, (optionally substituted with halogen, C1-C3 alkyl, alkoxy, amine) and alkoxyamine;
the bond z may be present or not present, wherein when bond z is not present:
the C of bond z of ring C is potentially substituted with R3, and X3 of the A ring is optionally substituted with H, OH, halogen, C1-C7 alkyl, alkenyl, alkynyl, alkoxy, carbonyl, carboxyl, alkoxycarbonyl, amine.

US Pat. No. 11,028,083

ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES

Board of Regents, The Uni...

1. A compound of structural Formula Ior a salt thereof, wherein:A is a monocyclic heterocycloalkyl ring comprising 5 to 7 ring members including:
X1 and X2,
Z, which is chosen from —CH2—, —CHR3—, —C(R3)2—, —N(R5a)—, N(COR5a)—,
N(CONR5aR5b)—, N(SO2R5a)—, —O—, and —SO2—, and
all other ring members Y, which are chosen from —CH2—, —CHR2—, and —C(R2)2—;
R1a, R1b, and R1c are independently chosen from H and CH3;
either X1 is C and X2 is N, or X1 is N and X2 is C;
each R2 and R3 is independently chosen from cyano, halo, hydroxy, C1-6alkyl,
C1-6haloalkyl, C1-6hydroxyalkyl, (C1-6alkoxy)C1-6 alkyl; OR5a, C(O)R5a, C(O)OR5a, C(O)NR5aR5b, SO2R5a; SO2NR5aR5b, NR5aR5b, NR5aC(O)R5b, NR5cC(O)OR5b, NR5cC(O)NR5aR5b, and NR5aSO2R5b, or
any two R2 or R3, when directly attached to the same atom, forms a 3-7 membered cycloalkyl or heterocycloalkyl ring;
R4 is chosen from cycloalkyl, heterocycloalkyl, aryl and heteroaryl, any of which is optionally substituted with 1, 2, 3, or 4 R6 groups;
each R5a and R5b is independently chosen from H, C1-6alkyl, cyanoC1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, (C1-6alkoxy)C1-6 alkyl; C3-6 cycloalkyl, cyanoC3-6 cycloalkyl, haloC3-6 cycloalkyl, hydroxyC3-6 cycloalkyl, and (C3-6 alkoxy)C3-6 cycloalkyl, or
R5a and R5b, when directly attached to the same atom, forms a 3-7 membered cycloalkyl or heterocycloalkyl ring;
R5c is chosen from H, C1-6alkyl, cyanoC1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, (C1-6 alkoxy)C1-6 alkyl; C3-6 cycloalkyl, cyanoC3-6 cycloalkyl, haloC3-6 cycloalkyl, hydroxyC3-6 cycloalkyl, and (C3-6 alkoxy)C3-6 cycloalkyl;
each R6 is independently chosen from C1-6alkyl, cyanoC1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, (C1-6 alkoxy)C1-6 alkyl, (haloC1-6alkoxy)C1-6alkyl, C3-6 cycloalkyl, cyanoC3-6 cycloalkyl, haloC3-6 cycloalkyl, hydroxyC3-6 cycloalkyl, (C3-6 alkoxy)C3-6 cycloalkyl, (C3-6 cycloalkyl)C1-6alkyl, (heterocycloalkyl)C1-6alkyl, (aryl)C1-6alkyl, (heteroaryl)C1-6alkyl, ((C1-6alkyl)aryl)C1-6alkyl, ((C1-6alkyl)heteroaryl)C1-6alkyl, OR7, CH2OR7, CH2CH2OR7, COR7, COOH, COOR7, CONH2, CONHR7, CON(R7)2, NHCOR7, NR7COR7, NHCONH2, NHCONHR7, NHCON(R7)2, NR7CONH2, NR7CONHR7, NR7CON(R7)2, SO2R7, SO2NHR7, SO2N(R7)2, NHSO2R7, NR7SO2R7, carboxy, cyano, halo, hydroxy, and oxo;
each R7 is independently chosen from C1-6alkyl, haloC1-6alkyl, aryl, heteroaryl, C3-6cycloalkyl, heterocycloalkyl, (aryl)C1-6alkyl, (heteroaryl)C1-6 alkyl, (cycloalkyl)C1-6alkyl, and (heterocycloalkyl)C1-6 alkyl, any of which is optionally substituted with 1 or 2 R8 groups; and
each R8 is independently chosen from C1-6 alkyl, haloC1-6 alkyl, C3-6 cycloalkyl, and haloC3-6 cycloalkyl.

US Pat. No. 11,028,082

PROCESS FOR THE PREPARATION OF A NOVEL UMECLIDINIUM SYNTHESIS INTERMEDIATE

OLON S.P.A., Rodano MI (...

1. A Process for the preparation of a compound of formula (I) or one of its salts
which comprises reacting a compound of formula (II)

with a compound selected from phenyl lithium and phenyl magnesium bromide, in a suitable solvent, optionally isolating the so-obtained compound of formula (I) and optionally transforming it into one of its salts.

US Pat. No. 11,028,081

DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE

Aerie Pharmaceuticals, In...

1. A method of treating glaucoma or ocular hypertension, comprising administration of a composition comprising a Rho kinase inhibitor and a pharmaceutically acceptable carrier to a subject in need thereof,wherein the administration is daily administration, weekly administration, or monthly administration,
wherein the Rho kinase inhibitor is:

or a pharmaceutically acceptable salt thereof,
wherein
R1, R2, and R3 are independently hydrogen, C1-C4 alkyl, aryl, C1-C4 alkyl aryl, C1-C4 alkyl heteroaryl, C1-C4 alkyl heterocyclyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 carbonyl, C1-C4 carbonylamino, C1-C4 alkoxy, C1-C4 sulfonyl, C1-C4 sulfonylamino, C1-C4 thioalkyl, C1-C4 carboxyl, or form a ring with each other or with A;
A is C1-C4 alkyl, C1-C4 alkyl aryl, C1-C4 alkyl heteroaryl, or forms a ring structure with R1, R2 or R3;
B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C1-C22 alkyl, C1-C22 alkyl aryl, C1-C22 alkyl heteroaryl, C2-C22 alkenyl, C2-C22 alkynyl, C1-C22 carbonyl, C1-C22 carbonylamino, C1-C22 alkoxy, C1-C22 sulfonyl, C1-C22 sulfonylamino, C1-C22 thioalkyl, or C1-C22 carboxyl;
X1, X2, and X3 are, independently, hydrogen, hydroxyl, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, amino, aminocarbonyl, nitro, cyano, C1-C4 carbonyl, C1-C4 carbonylamino, C1-C4 alkoxy, C1-C4 sulfonyl, C1-C4 sulfonylamino, C1-C4 thioalkyl, or C1-C4 carboxyl;
the double circle
indicates an aromatic or heteroaromatic ring; andeach Z is independently a bond, is C1-C4 alkyl, heteroalkyl, or an O atom.

US Pat. No. 11,028,080

SUBSTITUTED PYRIMIDINES AS LRKK2 INHIBITORS

DENALI THERAPEUTICS INC.,...

36. The compound of claim 1, or a pharmaceutically acceptable salt, deuterated isotope, or stereoisomer thereof, wherein:m is 2;
ring A is thiazolyl; and
each R3 is independently halo, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, or heterocyclyl, wherein each C1-6 alkyl, cycloalkyl, and heterocyclyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of oxo, halo, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, and heterocyclyl;
wherein one, two, three, four, five, or six hydrogens of each C1-6 alkyl is optionally and independently replaced by deuterium.

US Pat. No. 11,028,079

SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF

ConverGene, LLC, Cambrid...

1. A compound of Formula I, or a-pharmaceutically acceptable salt or isomer thereof:
wherein:
X is N;
Z is N;
R1 and R2, together with the included nitrogen atom and L1, form

Y is pyrazolyl and may optionally be substituted with 1 or 2 independently selected R8,
R3 is 2-oxopyridinyl and is optionally substituted by one or two methyl groups;
R4 is H;
each R8 is independently selected from the group consisting of H, C3-6 cycloalkyl, phenyl, and C1-6 alkyl, wherein said phenyl or C1-6 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R14; and
R14 is H, OH, or halogen.

US Pat. No. 11,028,077

CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF

NOVARTIS PHARMACEUTICALS ...

1. A crystalline form of the compound of Formula I:
or a pharmaceutically acceptable salt thereof, having an X-ray powder diffraction pattern comprising the following peaks, in terms of 2?, of about 18.2°, 21.4° and 22.7°.

US Pat. No. 11,028,076

INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR)

CELATOR PHARMACEUTICALS, ...

1. A liposome composition comprising an ATR protein kinase inhibitor, or a pharmaceutically acceptable salt thereof, encapsulated in a liposome and having a plasma half-life of at least about 5 hours in mice, wherein the ATR protein kinase inhibitor is a compound of formula (I):
wherein R is a moiety comprising an amine with a pKa of greater than 7.0;
and the liposome comprises cholesterol.

US Pat. No. 11,028,075

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

Genentech, Inc., South S...

1. A compound selected from the group consisting of:or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,074

CD73 INHIBITORS

Eli Lilly and Company, I...

1. A compound of the formula:
wherein n is 0-3;
R1 is —H, —F, -gem-difluoro, -gem-dimethyl,—C1-4 alkyl, —CHF2, —CF2CH3 or —CH2CH2F; andR2 is selected from —H, —CH3, —F, —Cl, —CN, or —OCH3;or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,073

BUTYLPHTHALIDE-TELMISARTAN HYBRIDS, PREPARATION METHOD AND APPLICATION THEREOF

GUANGDONG LONGFU MEDICINE...

1. A compound which is an optically active butylphthalide-telmisartan hybrid as shown in general formula I, or an optical isomer, an enantiomer, a diastereomer, a racemate or a racemic mixture thereof, or a pharmaceutically acceptable salt thereof:
wherein, R represents a hydrogen atom H, linear or branched C1-C10 alkyl, or (linear or branched C1-C10 alkylene)-Q, wherein Q represents hydroxyl or halogen;
n represents 1 to 20;
X represents an oxygen atom, a nitrogen atom or a sulfur atom;
Y represents an oxygen atom, a nitrogen atom or a sulfur atom; and
chiral center * is S or R configurated.

US Pat. No. 11,028,072

2,4-DIAMINO-6-ETHYLPYRIMIDINE DERIVATIVES WITH ANTIMALARIAL ACTIVITIES AGAINST PLASMODIUM FALCIPARUM

National Science and Tech...

1. Derivatives of 2,4-diamino-6-ethylpyrimidine of Formula (I):
Wherein X1, X2 are oxygen or absent, Y1, Y2 are (CH2)1-3alkyl or absent, Z is (1-substituted-1H-1,2,3-triazol-4-yl) ring, (3-(substituted(isoxazol-5-yl) ring, (2-(substituted(oxazol-4-yl) ring, (2-(substituted)thiazol-4-yl) ring; wherein Ar is an aromatic ring or substituted aromatic ring as below:
a. Z is a ring of (1-substituted-1H-1,2,3-triazol-4-yl); Ar is phenyl or carboxyl substituted phenyl; no group X1, X2, Y1 and Y2
b. Z is a ring of (1-substituted-1H-1,2,3-triazol-4-yl); Ar is phenyl, carboxymethyl substituted phenyl, carboxyl-substituted phenyl or diphenylcarbamoyl substituted phenyl; Y2 is C1-3 alkyl; no group X1, X2 and Y1
c. Z is a ring of (1-substituted-1H-1,2,3-triazol-4-yl); Ar is chloro-substituted phenyl or carboxymethyl-substituted phenyl; X2 is oxygen; Y2 is C2-3 alkyl; no group X1 and Y1
d. Z is a ring of (3-(substituted)isoxazol-5-yl); Ar is phenyl, fluoro-substituted phenyl, chloro-substituted phenyl, bromo-substituted phenyl, trifluoromethyl-substituted phenyl, methoxy-substituted phenyl, nitro-substituted phenyl, cyano substituted phenyl, carboxymethyl-substituted phenyl or carboxyl-substituted phenyl; X1 is oxygen; Y1 is C1-3 alkyl; no group X2 and Y2
e. Z is a ring of (2-(substituted)oxazol-4-yl); Ar is phenyl, chloro-substituted phenyl, methyl-substituted phenyl, nitro-substituted phenyl, alkoxy carbonylmethoxy substituted phenyl, carboxymethoxy-substituted phenyl, alkoxy carbonyl-substituted phenyl or carboxy-substituted phenyl; X1 is oxygen; Y1 is C1-2 alkyl; no group X2 and Y2
f. Z is a ring of (2-(substituted)thiazol-4-yl); Ar is phenyl, fluoro-substituted phenyl, chloro-substituted phenyl, bromo-substituted phenyl, methyl-substituted phenyl, m ethoxy-substituted phenyl, nitro-substituted phenyl, alkoxy carbonylmethoxy substituted phenyl, carboxymethoxy-substituted phenyl, alkoxy carbonyl-substituted phenyl or carboxyl-substituted phenyl; X1 is oxygen; Y1 is C1-2 alkyl; no group X2 and Y2.

US Pat. No. 11,028,071

INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS

Bristol-Myers Squibb Comp...

1. A compound of Formula (Ia) or (Ib):
wherein:
A, E, G, and J are independently N, C, or CH with the provisos that one of A, E, G, and J is N and one of A, E, G, and J is C attached to Y;
X is a C1-4 alkylene substituted with 0, 1, or 2 R8a;
Y is a covalent bond or O;
R1 is:

R2 is hydrogen, halo, or C1-6 alkyl;
R3 is hydrogen, C1-6 alkyl, 3- to 10-membered carbocyclyl, carbocyclylalkyl, 6- to 10-membered aryl, arylalkyl, 3- to 14-membered heterocyclyl, heterocyclylalkyl, 5- to 14-membered heteroaryl, or heteroarylalkyl, wherein the alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl, by themselves or as part of another group, are each independently substituted with 0, 1, 2, or 3 R6;
R3a is hydrogen;
R4 is hydrogen, C1-6 alkyl, 3- to 10-membered carbocyclyl, carbocyclylalkyl, 3- to 10-membered heterocyclyl, heterocyclylalkyl, 6- to 10-membered aryl, arylalkyl, 5- to 14-membered heteroaryl, heteroarylalkyl, —S(O)mR7, —C(O)NRaRb, —NHC(O)ORa, —NHC(O)NRaRb, —OC(O)NRaRb, —OC(O)R7, —NHS(O)mNRaRb, or —NHS(O)mR7; wherein the alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl, by themselves or as part of another group, are each independently substituted with 0, 1, 2, or 3 R9;
R5 is hydrogen, R5a, or a structural moiety selected from

L1 and L2 are each independently C1-4 alkylene;
R5a and R5b are each independently C1-6 alkyl, phenyl, benzyl, or 5- to 7-membered heterocyclyl; wherein the alkyl, phenyl, and heterocyclyl are each independently substituted with 0 to 3 R5?;
R5c is C1-6 alkyl or 5- to 7-membered carbocyclyl; wherein the C1-6 alkyl, and heterocyclyl are each independently substituted with 0 to 3 R5d;
R5d, at each occurrence, is independently halo, OH, alkoxy, oxo, or alkyl; or alternatively, two adjacent R5d, together with the atoms to which they are attached, form a carbocyclyl moiety;
R6 is halo, cyano, hydroxyl, amino, oxo, nitro, —S(O)mR12, C1-6 alkyl, alkoxy, haloalkyl, haloalkoxy, haloaminoalkyl, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, 6- to 10-membered aryl, aryloxy, arylalkoxy, 5- to 10-membered heteroaryl, 3- to 6-membered carbocyclyl, or 3- to 7-membered heterocyclyl; wherein the alkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, by themselves or as part of another group, are each independently substituted with 0, 1, or 2 R10;
R7 is each independently C1-6 alkyl, C1-6 alkoxy, C1-6 aminoalkyl, C1-6 haloalkyl, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, by themselves or as part of another group, are each independently substituted with 0, 1, 2, or 3 R11;
R9 is each independently halo, cyano, hydroxyl, amino, oxo, nitro, C1-6 alkyl, alkoxy, haloalkyl, haloalkoxy, haloaminoalkyl, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, 6- to 10-membered aryl, aryloxy, arylalkoxy, 5- to 10-membered heteroaryl, 3- to 6-membered carbocyclyl, or 3- to 7-membered heterocyclyl; wherein the alkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, by themselves or as part of another group, are each independently substituted with 0, 1, or 2 R13;
R10 is halo, cyano, hydroxyl, amino, oxo, C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, or sulfonamide;
R11, at each occurrence, is independently halo, cyano, hydroxyl, amino, oxo, C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, or haloalkoxy;
R12 is —N(RxRy)C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, or C1-6 aminoalkyl;
R13 is halo, cyano, hydroxyl, amino, oxo, C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, or sulfonamide;
Ra and Rb, at each occurrence, are independently hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or alkoxyalkyl; or alternatively, Ra and Rb, taken together with the atoms to which they are attached, form a 3- to 8-membered carbocyclic or heterocyclic ring; wherein the aryl and heteroaryl, by themselves or as part of another group, are each independently substituted with one or more groups independently selected from halo, cyano, hydroxyl, amino, C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, and sulfonamide; and the carbocyclyl and heterocyclyl, by themselves or as part of another group, are each independently substituted with one or more groups independently selected from halo, cyano, hydroxyl, amino, oxo, C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, and sulfonamide;
Re is OH, amino, amido, carbamate, sulfonamide, C1-4 alkyl, halo, C1-4 haloalkyl, or C3-6 cycloalkyl;
Rx and Ry are each independently hydrogen or C1-6 alkyl;
m is an integer of 1 or 2;
r is an integer of 0, 1, 2, or 3; and
or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,070

ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

LES LABORATOIRES SERVIER,...

1. A process for the preparation of a compound of formula (I):
wherein:
Het represents a heteroaryl group,
T represents a hydrogen atom, a linear or branched (C1-C6)alkyl group optionally substituted by one to three halogen atoms, an alkyl(C1-C4)—NR1R2 group or an alkyl(C1-C4)—OR6 group,
R1 and R2 independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group,
or R1 and R2, together with the nitrogen atom carrying them, form a heterocycloalkyl group,
R3 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl group, a (C3-C10)cycloalkyl-(C1-C6)alkyl group wherein the alkyl group may be linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, wherein one or more carbon atoms of the groups defined hereinbefore, or carbon atoms of their possible substituents, may be deuterated,
R4 represents an aryl, heteroaryl, cycloalkyl or linear or branched (C1-C6)alkyl group, wherein one or more carbon atoms of the groups defined hereinbefore, or carbon atoms of their possible substituents, may be deuterated,
R5 represents a hydrogen atom or a halogen atom, a linear or branched (C1-C6)alky group, or a linear or branched (C1-C6)alkoxy group,
R6 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group,
R7 represents a group selected from R?7, R?7—CO—, R?7—O—CO—, NR?7R?7—CO—, R?7—SO2—, R?7—NR?7—SO2— wherein R?7 and R?7, independently of one another, represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl, a heterocycloalkyl, an aryl group, or a heteroaryl,
R8 and R9 represent, independently of one another, an oxo group or a halogen atom,
p and p? are, independently of one another, integers equal to 0, 1, 2, 3 or 4,
q and q? are, independently of one another, integers equal to 1, 2 or 3,
wherein, when the compound of formula (I) contains a hydroxy group, this latter group may be optionally substituted by one of the following groups: —PO(OM)(OM?), —PO(OM)(O?M+), —PO(O?M1+)(O?M2+), —PO(O?)(O?)M32+, —PO(OM)(O[CH2CH2O]nCH3), or —PO(O?M1+)(O[CH2CH2O]nCH3), wherein M and M? independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl or a heterocycloalkyl, both of the cycloalkyl and heterocycloalkyl being composed of from 5 to 6 ring members, M1+ and M2+, independently of one another, represent a pharmaceutically acceptable monovalent cation, M32+ represents a pharmaceutically acceptable divalent cation and n is an integer between 1 to 5,
wherein:
“aryl” means a phenyl, naphthyl, biphenyl or indenyl group,
“heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and having from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen,
“cycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group having from 3 to 10 ring members, which may include fused, bridged or spiro ring systems,
“heterocycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group, composed of from 3 to 10 ring members, and having from one to 3 hetero atoms selected from oxygen, sulphur, SO, SO2 and nitrogen,
wherein bicyclic group may be fused or spiro type, wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy, may be substituted by from 1 to 3 groups selected from: optionally substituted linear or branched (C1-C6)alkyl; optionally substituted linear or branched (C2-C6)alkenyl group; optionally substituted linear or branched (C2-C6)alkynyl group; (C3-C6)spiro; optionally substituted linear or branched (C1-C6)alkoxy; (C1-C6)alkyl-S—; hydroxyl; oxo (or N-oxide where appropriate); nitro; cyano; —COOR?; —OCOR?; —NR?R?; R?CONR?—; NR?R?CO—; linear or branched (C1-C6)polyhaloalkyl; trifluoromethoxy; (C1-C6)alkylsulphonyl; halogen; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted aryloxy; optionally substituted arylthio; optionally substituted cycloalkyl or optionally substituted heterocycloalkyl, wherein R? and R?, independently of one another, represent a hydrogen atom, an optionally substituted linear or branched (C1-C6)alkyl group or an aryl group,
its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,
which process comprises subjecting a compound of formula (II):

wherein Alk represents a linear or branched (C1-C6) alkyl group,
the ester function of which compound of formula (II) is hydrolysed to yield the corresponding carboxylic acid which is then subjected to peptide coupling with a compound of formula (III):

to yield a compound of formula (IV):

which compound of formula (IV) is deprotected and subjected to an acylation or a sulfonylation reaction, and which can optionally be subjected to the action of a pyrophosphate or a phosphonate derivative in basic conditions, to yield the compound of formula (I),
which compound of formula (I) may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,
wherein some groups (including hydroxy, amino) of the starting reagents or of the synthesis intermediates can be protected and subsequently deprotected, as required by the synthesis.

US Pat. No. 11,028,068

SOMATOSTATIN MODULATORS AND USES THEREOF

CRINETICS PHARMACEUTICALS...

1. A compound that has the structure of Formula (I), or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof:
wherein:
R1 and R2 are taken together with the carbon atom to which they are attached to form —C(?O)—;
or R1 and R2 are each independently selected from the group consisting of hydrogen, and unsubstituted or substituted C1-C6alkyl;
RA is a cyclic ring that is an unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted bicyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, or unsubstituted or substituted bicyclic heterocycle, wherein if RA is substituted then RA is substituted with 1-2 R10 and 0-2 R11;
RB is a cyclic ring that is an unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted bicylcic carbocycle, unsubstituted or substituted monocyclic heterocycle, unsubstituted or substituted bicyclic heterocycle, wherein if RB is substituted then RB is substituted with 1-2 R12 and 0-2 R13;
A1, A2, and A3 are independently CRC or N;
each RC is independently hydrogen, F, Cl, Br, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, —CN, —OH, —CO2R14, —C(?O)NR14R15, —C(?NOR14)R15, —SR14, —S(?O)(C1-C4alkyl), —SO2(C1-C4alkyl) or —SO2NR14R15;
R3 and R4 are independently hydrogen, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C1-C6fluoroalkyl, or unsubstituted or substituted C3-C6cycloalkyl, wherein any substituted group of R3 and R4 is substituted with 1-4 R16;
or R3 and R4 are taken together with the nitrogen atom to which they are attached to form an unsubstituted or substituted monocyclic or bicyclic heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R16;
R5, R6, R7, and R8 are each independently selected from the group consisting of hydrogen, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C1-C6fluoroalkyl, unsubstituted or substituted monocyclic carbocycle, and unsubstituted or substituted monocyclic heterocycle, wherein any substituted group of R5, R6, R7, and R8 is substituted with 1-4 R16;
R9 is hydrogen, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted benzyl, wherein if R9 is substituted then R9 is substituted with 1-4 R16;
or R4 and any one of R5, R7, or R9 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring or an unsubstituted or substituted bicyclic 9- to 12-membered heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R16;
or R5 and any one of R6, R7 or R9 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered ring or a bicyclic 9- to 12-membered ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R16;
or R7 and R9 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring or an unsubstituted or substituted bicyclic 9- to 12-membered heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R16;
each R10, R11, R12 and R13 is independently hydrogen, halogen, unsubstituted or substituted C1-C4alkyl, unsubstituted or substituted C1-C4alkoxy, unsubstituted or substituted C1-C4fluoroalkyl, unsubstituted or substituted C1-C4fluoroalkoxy, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —CO2R14, —CH2CO2R14, —C(?O)NR14R15, —CH2C(?O)NR14R15, —NR14R15, —CH2NR14R15, —NR14C(?O)R15, —CH2NR14C(?O)R15, —SR14, —S(?O)R15, —SO2R15, or —SO2NR14R15, wherein if any group of R10, R11, R12 and R13 is substituted then the substituted group of R10, R11, R12 and R13 is substituted with 1-4 R16;
each R16 is independently halogen, C1-C6alkyl, heterocycle, —CN, —OR14, —CO2R14, —C(?O)NR14R15, —NR14R15, —NR14C(?O)R15, —SR14, —S(?O)R15, —SO2R15, or —SO2NR14R15;
each R14 is independently selected from H, unsubstituted or substituted C1-C6alkyl, unsubstituted or substituted C1-C6heteroalkyl, unsubstituted or substituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
each R15 is independently selected from H, unsubstituted or substituted C1-C6alkyl, unsubstituted or substituted C1-C6heteroalkyl, unsubstituted or substituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R14 and R15 are taken together with the N atom to which they are attached to a substituted or unsubstituted N-containing heterocycle; and
m is 1, 2, 3, or 4.

US Pat. No. 11,028,067

HETEROARYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER

Oblique Therapeutics AB, ...

1. A compound of formula I
or a pharmaceutically acceptable salt thereof, wherein:
L represents —S(O)n—;
n represents 2 or 1;
X represents a heteroaryl group, attached to L via a carbon atom, optionally substituted by one or more groups independently selected from Y;
R1, R2 and R3 each independently represent H, halo, Ra1, —CN, -Aa1-C(Qa1)Rb1, -Ab1-C(Qb1)N(Rc1)Rd1, -Ac1-C(Qc1)ORe1, -Ad1-S(O)pRf1, -Ae1-S(O)pN(Rg1)Rh1, -Af1-S(O)pORi1, —N3, —N(Rj1)Rk1, —N(H)CN, —NO2, —ONO2, —ORl1 or —SRm1;
each Aa1 to Af1 independently represents a single bond, —N(Rp1)— or —O—;
each Qa1 to Qc1 independently represents ?O, ?S, ?NRn1 or ?N(ORo1);
each Ra1 and Rf1 independently represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G1a, heterocyclyl optionally substituted by one or more groups independently selected from G1b, aryl optionally substituted by one or more groups independently selected from G1c, or heteroaryl optionally substituted by one or more groups independently selected from G1d;
each Rb1, Rc1, Rd1, Re1, Rg1, Rh1, Ri1, Rj1, Rk1, Rl1, Rm1, Rn1, Ro1 and Rp1 independently represents H, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G1a, heterocyclyl optionally substituted by one or more groups independently selected from G1b, aryl optionally substituted by one or more groups independently selected from G1c, or heteroaryl optionally substituted by one or more groups independently selected from G1d;
any of Rc1 and Rd1, Rg1 and Rh1 and/or Rj1 and Rk1 are linked together to form, together with the nitrogen atom to which they are attached, a 3-to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from halo, and C1-3 alkyl, C2-3 alkenyl or C2-3 alkynyl each optionally substituted by one or more halo, and ?O;
each G1a and G1b independently represents halo, —CN, —N(Ra2)Rb2, —ORc2, —SRd2 or ?O;
each G1c and G1d independently represents halo, —CN, —N(Ra2)Rb2, —ORc2 or —SRd2;
each Ra2, Rb2, Rc2 and Rd2 independently represents H or C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more fluoro; or
Ra2 and Rb2 are linked together to form, along with the nitrogen atom to which they are attached, a 3- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from fluoro, C1-3 alkyl, C2-3 alkenyl or C2-3 alkynyl each optionally substituted by one or more fluoro;
each Y independently represents halo, Ra3, —CN, -Aa2-C(Qa2)Rb3, -Ab2-C(Qb2)N(Rc3)Rd3, -Ac2-C(Qc2)ORe3, -Ad2-S(O)qRf3, -Ae2-S(O)qN(Rg3)Rh3, -Af2-S(O)qORi3, —N3, —N(Rj3)Rk3, —N(H)CN, —ONO2, —OR13 or —SRm3;
each Qa2 to Qc2 independently represents ?O, ?S, ?NRn3 or ?N(ORo3);
each Aa2 to Ar2 independently represents a single bond, —N(Rp3)— or —O—;
each Ra3 and Rf1 independently represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G2a, heterocyclyl optionally substituted by one or more groups independently selected from G2b, aryl optionally substituted by one or more groups independently selected from G2c, or heteroaryl optionally substituted by one or more groups independently selected from G2d;
each Rb3, Rc3, Rd3, Re3, Rg3, Rh3Ri3, Rj3, Rk3, Rl3, Rm3, Rn3, Ro3 and Rp3 independently represents H, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G2a, heterocyclyl optionally substituted by one or more groups independently selected from G2b, aryl optionally substituted by one or more groups independently selected from G2c, or heteroaryl optionally substituted by one or more groups independently selected from G2d; or
any two Rc3 and Rd3, Rg3 and Rh3 and/or Rj3 and Rk3 are linked together to form, along with the nitrogen atom to which they are attached, a 3-to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from heterocyclyl optionally substituted by one or more groups independently selected from G2b, aryl optionally substituted by one or more groups independently selected from G2c, or heteroaryl optionally substituted by one or more groups independently selected from G2d, and ?O;
each G2a independently represents halo, —CN, —N(Rj4)Rk4, —ORl4, —SRm4 or ?O;
each G2b independently represents halo, Ra4, —CN, —N(Rj4)Rk4, —ORl4, —SRm4 or ?O;
each G2C and G2d independently represents halo, Ra4, —CN, -Aa3-C(Qa3)Rb4, -Ab3-C(Qb3)N(Rc4)Rd4, -Ac3-C(Qc3)ORe4, -Ad3-S(O)qRf4, -Ae3-S(O)qN(Rg4)Rh4, -Af3-S(O)qOR14, —N3, —N(Rj4)Rk4, —N(H)CN, —NO2, —ONO2, —OR14 or —SRm4;
each Qa3 to Qc3 independently represents ?O, ?S, ?NRn4 or ?N(ORo4);
each Aa3 to A13 independently represents a single bond, —N(Rp4)— or —O—;
each Ra4 and Rf4 independently represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G3a, heterocyclyl optionally substituted by one or more groups independently selected from G3b, aryl optionally substituted by one or more groups independently selected from G3c, or heteroaryl optionally substituted by one or more groups independently selected from G3d;
each Rb4, Rc4, Rd4, Re4, Rg4, Rh4, Ri4, Rj4, Rk4, Rl4, Rm4, Rn4, Ro4 and Rp4 independently represents H, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G3a or heterocyclyl optionally substituted by one or more groups independently selected from G3b, aryl optionally substituted by one or more groups independently selected from G3c, or heteroaryl optionally substituted by one or more groups independently selected from G3d; or
any of Rc4 and Rd4, Rg4 and Rh4 and/or Rj4 and Rk4 are linked together to form, together with the nitrogen atom to which they are attached, a 3-to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected G3b;
each G3a and G3b independently represents halo, Ra5, —CN, —N(Rb5)Rc5, —ORd5, —SRe5 or ?O;
each Ra5 independently represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G4;
each Rb5, Rc5, Rd5 and Re5 independently represents H, or C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more groups independently selected from G4;
or
each Rb5 and Rc5 are linked together to form, together with the nitrogen atom to which they are attached, a 3- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from G4;
each G4 independently represents halo, Ra6, —CN, —N(Rb6)Rc6, —ORd6 or ?O;
each Ra6 independently represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more fluoro;
each Rb6, Rc6 and Rd6 independently represents H, or C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl each optionally substituted by one or more fluoro; and
each p and q independently represents 1 or 2,
with the provisos that the compound of formula I does not represent:
3-nitro-2-(pyridin-2-ylsulfonyl)pyridine,
2-((3-nitropyridin-2-yl)sulfonyl)pyrimidine, or
N-(6-chloro-2-((5-chloro-3-nitropyridin-2-yl)sulfonyl)pyridin-3-yl)acetamide.

US Pat. No. 11,028,066

INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1

Celgene Quanticel Researc...

1. A compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof,wherein:A is C—R, wherein R is optionally substituted alkyl;
W1 and W2 are independently chosen from N, C—H, or C—F;
X is hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclylalkyl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted alkynyl, optionally substituted carbocyclylalkynyl, optionally substituted aryl, or optionally substituted heteroaryl;
Y is optionally substituted alkyl, optionally substituted cycloalkylalkyl, heterocyclylalkyl or aralkyl; and
Z is an optionally substituted group chosen from N-heterocyclyl, —O-heterocyclylalkyl, —N(H)-heterocyclylalkyl, or —N(Me)-heterocyclylalkyl;
wherein if Z is an optionally substituted heterocyclylalkyl group selected from —O— heterocyclylalkyl, —N(H)-heterocyclylalkyl or —N(Me)-heterocyclylalkyl, then heterocyclylalkyl group has the formula —Rc-heterocyclyl, wherein Rc is an optionally substituted C1-C3 alkylene chain and the heterocyclyl is an optionally substituted nitrogen-containing 5-membered heterocyclyl.

US Pat. No. 11,028,065

CONTINUOUS METHOD FOR PREPARING CARBONATE ESTERS

UCHICAGO ARGONNE, LLC, A...

6. A continuous processes for preparing an organic carbonate solvent of Formula (I):comprising the steps of:(a) contacting a first reactant with a reactive carbonyl source in reaction stream containing a catalyst flowing through a continuous flow reactor at a temperature in the range of about 20° C. to about 160° C., and at a flow rate providing a residence time in the range of about 0.1 minute to about 24 hours;
(b) optionally quenching any remaining reactive carbonyl source;
(c) collecting a reactor effluent exiting from the continuous flow reactor;
(d) recovering a crude product from the reactor effluent; and
(e) purifying the crude product to obtain the organic carbonate compound of Formula (I);
wherein:
Z is a covalent bond;
x is 0;
R1 is C1-C6 alkyl or C1-C6 fluoroalkyl bearing at least one fluoro substituent;
R2 is H, C1-C6 alkyl or C1-C6 fluoroalkyl bearing at least one fluoro substituent;
both R3 and R4 are CH2 and are not directly bonded together;
R is C1-C6 alkyl or C1-C6 fluoroalkyl comprising at least one fluoro substituent;
and wherein the first reactant is an alcohol of Formula (II):
the carbonyl source is carbonyldiimidazole (CDI); the catalyst is selected from the group consisting tertiary amine, an aromatic nitrogen-containing heterocycle, and a quaternary ammonium hydroxide; the catalyst is present in the reaction stream at a concentration of about 2 to 15 mol % relative to the alcohol; and the reaction stream comprises an aprotic organic solvent selected from the group consisting of a nitrile, an ester, an organic carbonate ester, an amide, a ketone, a sulfone, a sulfoxide, a halogenated hydrocarbon, a phosphoramide, and an ionic liquid, in which the alcohol, the CDI, and the catalyst are dissolved.

US Pat. No. 11,028,064

TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF

AUCKLAND UNISERVICES LIMI...

1. A compound of formula (I):
wherein:
X is NR4, O, S, SO, SO2, Se or Te and R2 is G at any one of positions 2 to 4; or
X is NG1 and R2 is H, D, NR6R7, OR6, SR8, halogen, CF3, OCF3, CN, NR6COR8, NR6S2R8, or C1-4alkyl optionally substituted with one or more independently selected Ra;
Y is CHR6, CO, CHR6NR5, CHR6O, CHR6S, CHR6SO2, CONR5, NR5, NR5CO, NR5SO2, O, OCHR6, S, SO, SO2, SCHR6, SO2CHR6, or SO2NR5;
Z is W or —W1—Y1—W2;
R1 and R3 are each independently H, D, NR6R7, OR6, SR8, halogen, CF3, OCF3, CN, NR6COR8, NR6SO2R8, or C1-4alkyl optionally substituted with one or more independently selected Ra;
R4 is H or C1-6alkyl optionally substituted with one or more independently selected Rb;
R5 is H or C1-4alkyl optionally substituted with one or more independently selected Rc;
R6 and R7 at each instance are each independently H or unsubstituted C1-4alkyl;
R8 at each instance is independently unsubstituted C1-4alkyl;
G is -J1-L1-NR9aR10a, -J1-L2-NR9bR10b, -J1-L3CR11R12R13, -L10-NR9aR10a, -L20-NR9bR10b, or -L30-CR11R12R13;
G1 is -L1-NR9aR10a, -L2-NR9bR10b, or -L3-cR11R12R13;
J1 is O, NR6S, —(C1-3alkylene)O—*, —(C1-3alkylene)NR6—*, or —(C1-3alkylene)S—*, wherein each alkylene is unsubstituted and wherein * denotes the bond to L1, L2, or L3;
L1 and L2 are each independently C2-6alkylene, —C2-3alkylene-J2-C2-3alkylene-*, —(C1-3alkylene)a-A-(C1-3alkylene)b-*, —C2-3alkylene-J2-(C1-3alkylene)a-A-(C1-3alkylene)b-*, or —(C1-3alkylene)a-A-(C1-3alkylene)b-J2C2-3alkylene-*, wherein each alkylene is unsubstituted and wherein * denotes the bond to NR9aR10a or NR9bR10b;
L3 is a bond, C1-6alkylene, —C2-6alkylene-J2-*, —C2-3alkylene-J2-C1-3alkylene-*, —(C1-3alkylene)a-A-(C1-3alkylene)b-*, —C2-3alkylene-J2-(C1-3alkylene)a-A-(C1-3alkylene)b-*, or —(C1-3alkylene)a-A-(C1-3alkylene)b-J2-(C1-3alkylene)-*, wherein each alkylene is unsubstituted and wherein * denotes the bond to CR11R12R13;
L10 and L20 are each independently C1-6alkylene, —C1-3alkylene-J2-C2-3alkylene-*, —(C1-3alkylene)a-A-(C1-3alkylene)b-*, —C1-3alkylene-J2-(C1-3alkylene)a-A-(C1-3alkylene)b-*, or —(C1-3alkylene)a-A-(C1-3alkylene)b-J2-C2-3alkylene-*, wherein each alkylene is unsubstituted and wherein * denotes the bond to NR9aR10a or NR9bR10b;
L30 is C1-6alkylene, —C1-6alkylene-J2-*, —C1-3alkylene-J2-C1-3alkylene-*, —(C1-3alkylene)a-A-(C1-3alkylene)b-*, —C1-3alkylene-J2-(C1-3alkylene)a-A-(C1-3alkylene)b-*, or —(C1-3alkylene)a-A-(C1-3alkylene)b-J2-(C1-3alkylene)c-*, wherein each alkylene is unsubstituted and wherein * denotes the bond to CR11R12R13;
A is 3 to 7-membered cycloalkylene optionally substituted with one or more independently selected Rd;
J2 is O, NR6, or S;
a, b, and c are each independently 0 or 1;
R9a and R10a are each independently H, unsubstituted C1-6alkyl, or unsubstituted 3 to 10-membered cycloalkyl;
R9b and R10b together with the nitrogen atom to which they are attached form a 4 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl, optionally substituted with one or more independently selected Rg;
R11 and R12 together with the carbon atom to which they are attached form a 4 to 10-membered heterocyclyl comprising at least one ring nitrogen atom, optionally substituted with one or more independently selected Rg; and R13 is H, C1-4alkyl optionally substituted with one or more independently selected Rh, or the second bond of a double bond between R11 or R12 and the carbon atom to which they are attached; or
R11 and R12 together with the carbon atom to which they are attached form a 5 to 10-membered heteroaryl comprising at least one ring nitrogen atom, optionally substituted with one or more independently selected Rg; and R13 is the second bond of a double bond between R11 or R12 and the carbon atom to which they are attached;
W is 6 to 10-membered aryl or 5 to 10-membered heteroaryl, optionally substituted with one or more independently selected Ri;
W1 is phenylene or 5 or 6-membered hetereoarylene, optionally substituted with one or more independently selected Rx;
Y1 is C1-6alkylene-J4-*, —(C1-3alkylene)-J4-*, —(C1-3alkylene)-J5-(C1-3alkylene)-*, -J5-(C1-3alkylene)-*, or -J6-C1-3alkylene-J7-*, wherein each alkylene is unsubstituted and wherein * denotes the bond to W2;
J4 is O, NR14, S, NR15CO, CONR14, NR15CONR14, OCONR14, or NR15COO;
J5 is O, NR15, S, NR15CO, CONR15, NR15CONR15, OCONR15, or NR15COO;
J6 is O, NR15, or S;
J7 is O, NR14, S, NR15CO, or CONR14;
R14 and R15 at each instance are each independently H or C1-3alkyl optionally substituted with one or more independently selected Rj;
W2 is:
(a) 3 to 10-membered cycloalkyl or 4 to 10-membered heterocyclyl, optionally substituted with one or more independently selected Rm, or
(b) 6 to 10-membered aryl or 5 to 10-membered heteroaryl, optionally substituted with one or more independently selected Rn;
or R14 and W2 together with the nitrogen atom to which they are attached form:
(a) a 4 to 10-membered heterocyclyl, optionally substituted with one or more independently selected Rm, or
(b) a 5 to 10-membered heteroaryl, optionally substituted with one or more independently selected Rn;
Ra, Rb, Rc, and Rh at each instance are each independently selected from F, OCF3, and O(unsubstituted C1-4alkyl);
Rd and Rg at each instance are each independently selected from D, NR6R7, OR6, SR8, halogen, CF3, OCF3, CN, SO2R8, NR6COR8, NR6SO2R8, and C1-4alkyl optionally substituted with one or more substituents independently selected from F, OCF3, and O(unsubstituted C1-4alkyl);
Ri, Rx, and Rn at each instance are each independently selected from D, NR6R7, OR6, SR8, halogen, CF3, OCF3, CN, SO2R8, and C1-4alkyl optionally substituted with one or more substituents independently selected from F, OCF3, and O(unsubstituted C1-4alkyl);
Rj at each instance is independently selected from F and D;
Rm at each instance is independently selected from D, NR6R7, OR6, SR8, F, CF3, OCF3, CN, SO2R8, and C1-4alkyl optionally substituted with one or more substituents independently selected from F, OCF3, and O(unsubstituted C1-4alkyl);
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

US Pat. No. 11,028,063

PROCESSES FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID AND DERIVATIVES THEREOF AND POLYMERS MADE THEREFROM

DUPONT INDUSTRIAL BIOSCIE...

1. An integrated process for producing 2,5-furandicarboxylic acid and/or a derivative thereof from a six-carbon sugar-containing feed, comprising:a) dehydrating a feed comprising a six-carbon sugar unit, in the presence of a bromine source and of a solvent, at an elevated temperature and for a time sufficient to generate an oxidation feed comprised of at least one of 5-hydroxymethylfurfural and/or a derivative or derivatives of 5-hydroxymethylfurfural in the solvent, together with at least one bromine containing species;
b) removing water from the oxidation feed from step a);
c) contacting the oxidation feed from step b) with a homogeneous metal catalyst based on Co and Mn and with an oxygen source at an elevated temperature for a time sufficient to produce an oxidation product mixture comprising 2,5-furandicarboxylic acid (FDCA) and/or a derivative thereof, the solvent, and a residual catalyst;
d) purifying and separating the mixture obtained in step c) to obtain FDCA and/or a derivative thereof and the solvent;
e) recycling at least a portion of the solvent obtained in step d) to step a); and
f) providing more or less of the at least one bromine containing species used in step a) in step c), together with optionally other bromine containing species,
wherein each optionally present derivative is at least one selected from the group consisting of diacid, diether, diester, ether-acid, ether-ester, ester-acid, ester-aldehyde, ether-aldehyde, ether-acetal, ester-acetal, acetal-acid, alcohol-acid, alcohol-ester, alcohol-acetal, diol, diacetal, and aldehyde-acetal.

US Pat. No. 11,028,061

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

SANFORD BURNHAM PREBYS ME...

6. A compound represented by the Formula:

US Pat. No. 11,028,059

OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT

DIC Corporation, Tokyo (...

1. An oxazine compound comprising:a structure which is represented by General Formula (1-1):

wherein, in General Formula (1-1),
Ar1 represents a substituted or unsubstituted aromatic group,
a ring A represents a substituted or unsubstituted aromatic ring,
each R1 is indenpendtly a functional group represented by General Formula (2)
a1-X1—Y1—X2—?—R2  (2),
and R3 and R4 each independently represent a hydrogen atom, or an alkyl group having 1 to 3 carbon atoms;
and wherein, in General Formula (2),
X1, X2, and Y1 each independtly represent a single bond or a divalent linking group,
R2 represents a hydrogen atom, a hydrocarbon group, or a hydrocarbon group in which one or more hydrogen atoms contained in the hydrocarbon group are substituted with any one of a hydroxyl group, an alkoxy group, and a halogen atom,
and a1 represents a bonding point to the oxazinc compound (1-1);
and wherein the divalent linking group in each of X1, X2, and Y1 in General Formula (2) is an oxygen atom; a divalent hydrocarbon group; a divalent group in which one or more hydrogen atoms contained in a divalent hydrocarbon group are substituted with a hydroxyl group, an alkoxy group, or a halogen atom; a carbonyl group; an ester group; an amide group; an imino group; an azo group; a sulfide group; a sulfone group; or a divalent linking group formed by combining two or more these groups.

US Pat. No. 11,028,058

HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS

NUVATION BIO INC., New Y...

1. A compound of the formula (I):
or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:
A is 4-hydroxyphenyl optionally further substituted by R3, 4-hydroxy-2-pyridyl optionally further substituted by R4, a naphthyl substituted by R4, a 9- or 10-membered bicyclic heterocyclyl optionally substituted by R4, or a 10-membered bicyclic heteroaryl optionally substituted by R4;
B is a phenyl optionally substituted by R3, C3-C6 cycloalkyl optionally substituted by R4, 3- to 6-membered heterocyclyl optionally substituted by R4 or a 5- to 10-membered heteroaryl optionally substituted by R4;
R1 is a hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, —(C1-C3 alkylene)(C3-C6 cycloalkyl), —(C1-C3 alkylene)(3-6-membered heterocyclyl), —(C1-C3 alkylene)(5-6-membered heteroaryl), —(C1-C3 alkylene)(C6 aryl), —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —NR1bR1c, —S(O)2R1a, —(C1-C3 alkylene)C(O)NR1bR1c, —(C1-C3 alkylene)C(O)R1a or —(C1-C3 alkylene)NR1bR1c, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, —(C1-C3 alkylene)(C3-C6 cycloalkyl), —(C1-C3 alkylene)(3-6-membered heterocyclyl), —(C1-C3 alkylene)(5-6-membered heteroaryl), and —(C1-C3 alkylene)(C6 aryl) of R1 are independently optionally substituted by R4;
each R1a is independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3-6-membered heterocyclyl, C6 aryl, 5-6-membered heteroaryl, —(C1-C3 alkylene)(C3-C6 cycloalkyl), —(C1-C3 alkylene)(3-6-membered heterocyclyl), —(C1-C3 alkylene)(C6 aryl) or —(C1-C3 alkylene)(5-6-membered heteroaryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF3, —OH, —OCH3, —CN, —C(O)OCH3, —C(O)OC2H5, —NH2 or —NHCH3;
each R1b and R1c is independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3-6-membered heterocyclyl, C6 aryl, 5-6-membered heteroaryl, —(C1-C3 alkylene)(C3-C6 cycloalkyl), —(C1-C3 alkylene)(3-6-membered heterocyclyl), —(C1-C3 alkylene)(C6 aryl) or —(C1-C3 alkylene)(5-6-membered heteroaryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF3, —OH, —OCH3, —CN, —C(O)OCH3, —C(O)OC2H5, —NH2 or —NHCH3;
or R1b and R1c are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered heterocyclyl;
R2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C14 aryl, C5-C14 heteroaryl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, —CN, halogen, —OR2a, —SR2a, —NR2bR2c, —C(O)R2a, —NR2bC(O)R2c, —NR2aC(O)NR2bR2c, —C(O)OR2a, —C(O)ONR2bR2c or —C(O)NR2bR2c, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C14 aryl, C3-C6 cycloalkyl and 3- to 6-membered heterocyclyl of R2 are independently optionally substituted by R4;
each R2a is independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6-aryl, 5- to 6-membered heteroaryl, —(C1-C3 alkylene)N(C2H5)2, —(C1-C3 alkylene)(C3-C6 cycloalkyl), —(C1-C3 alkylene)(3-6-membered heterocyclyl), —(C1-C3 alkylene)(5-6-membered heteroaryl) or —(C1-C3 alkylene)(C6 aryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF3, —OH, —OCH3, —CN, —C(O)OCH3, —C(O)OC2H5, —NH2 or —NHCH3;
each R2b and R2c is independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6-aryl, 5- to 6-membered heteroaryl, —(C1-C3 alkylene)N(C2H5)2, —(C1-C3 alkylene)(C3-C6 cycloalkyl), —(C1-C3 alkylene)(3-6-membered heterocyclyl), —(C1-C3 alkylene)(C6 aryl) or —(C1-C3 alkylene)(5-6-membered heteroaryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF3, —OH, —OCH3, —CN, —C(O)OCH3, —C(O)OC2H5, —NH2 or —NHCH3;
or R2b and R2? are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered heterocyclyl;
each R3 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, —CN, —OR5, —SR5, —NR6R7, —NO2, —C?NH(OR5), —C(O)R5, —OC(O)R5, —C(O)OR5, —C(O)NR6R7, —OC(O)NR6R7, —NR5C(O)R6, —NR5C(O)OR6, —NR5C(O)NR6R7, —S(O)R5, —S(O)2R5, —NR5S(O)R6, —C(O)NR5S(O)R6, —NR5S(O)2R6, —C(O)NR5S(O)2R6, —S(O)NR6R7, —S(O)2NR6R7, —P(O)(OR6) (OR7), C3-C6 cycloalkyl, 3-12-membered heterocyclyl, 5- to 10-membered heteroaryl, C6-C14 aryl, —(C1-C3 alkylene)CN, —(C1-C3 alkylene)OR5, —(C1-C3 alkylene)SR5, —(C1-C3 alkylene)NR6R7, —(C1-C3 alkylene)CF3, —(C1-C3 alkylene)NO2, —C?NH(OR5), —(C1-C3 alkylene)C(O)R5, —(C1-C3 alkylene)OC(O)R5, —(C1-C3 alkylene)C(O)OR5, —(C1-C3 alkylene)C(O)NR6R7, —(C1-C3 alkylene)OC(O)NR6R7, —(C1-C3 alkylene)NR5C(O)R6, —(C1-C3 alkylene)NR5C(O)OR6, —(C1-C3 alkylene)NR5C(O)NR6R7, —(C1-C3 alkylene)S(O)R5, —(C1-C3 alkylene)S(O)2R5, —(C1-C3 alkylene)NR5S(O)R6, —C(O)(C1-C3 alkylene)NR5S(O)R6, —(C1-C3 alkylene)NR5S(O)2R6, —(C1-C3 alkylene)C(O)NR5S(O)2R6, —(C1-C3 alkylene)S(O)NR6R7, —(C1-C3 alkylene)S(O)2NR6R7, —(C1-C3 alkylene)P(O)(OR6)(OR7), —(C1-C3 alkylene)(C3-C6 cycloalkyl), —(C1-C3 alkylene)(3-12-membered heterocyclyl), —(C1-C3 alkylene)(5-10-membered heteroaryl) or —(C1-C3 alkylene)(C6-C14 aryl), wherein each R3 is independently optionally substituted by halogen, oxo, —OR8, —NR8R9, —C(O)R8, —CN, —S(O)R8, —S(O)2R8, —P(O)(OR8)(OR9), —(C1-C3 alkylene)OR8, —(C1-C3 alkylene)NR8R9, —(C1-C3 alkylene)C(O)R8, —(C1-C3 alkylene)S(O)R8, —(C1-C3 alkylene)S(O)2R8, —(C1-C3 alkylene)P(O)(OR8)(OR9), C3-C8 cycloalkyl, or C1-C6 alkyl optionally substituted by oxo, —OH or halogen;
each R4 is independently oxo or R3;
R5 is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C14 aryl, 5-6-membered heteroaryl or 3-6-membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C14 aryl, 5-6-membered heteroaryl and 3-6-membered heterocyclyl of R5 are independently optionally substituted by halogen, oxo, —CN, —OR9, —NR9R10, —P(O)(OR9)(OR10), phenyl optionally substituted by halogen, or C1-C6 alkyl optionally substituted by halogen, —OH or oxo;
R6 and R7 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C14 aryl, 5-6-membered heteroaryl, —(C1-C3 alkylene)(C6 aryl) or 3-6 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C14 aryl, 5-6-membered heteroaryl, —(C1-C3 alkylene)(C6 aryl) and 3-6 membered heterocyclyl of R6 and R7 are independently optionally substituted by halogen, oxo, —CN, —OR9, —NR9R10 or C1-C6 alkyl optionally substituted by halogen, —OH or oxo;
or R6 and R7 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo, —OR9, —NR9R10 or C1-C6 alkyl optionally substituted by halogen, oxo or —OH;
R8 and R9 in R3 are each independently hydrogen, C1-C6 alkyl optionally substituted by halogen or oxo, C2-C6 alkenyl optionally substituted by halogen or oxo, or C2-C6 alkynyl optionally substituted by halogen or oxo;
or R8 and R9 in R3 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo or C1-C6 alkyl optionally substituted by halogen or oxo; and
R9 and R10 in R5, R6 and R7 are each independently hydrogen, C1-C6 alkyl optionally substituted by halogen or oxo, C2-C6 alkenyl optionally substituted by halogen or oxo, or C2-C6 alkynyl optionally substituted by halogen or oxo;
or R9 and R10 in R5, R6 and R7 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo or C1-C6 alkyl optionally substituted by oxo or halogen.

US Pat. No. 11,028,056

METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND AND 3-ARYLPROPIONIC ACID ESTER COMPOUND

SUMITOMO CHEMICAL COMPANY...

1. A method for producing a compound represented by formula (2)
(wherein
Y represents an alkyl group optionally substituted with fluorine atom(s), an alkoxy group optionally substituted with fluorine atom(s), an alkoxyalkyl group optionally substituted with fluorine atom(s), an alkylthio group optionally substituted with fluorine atom(s), an alkylsulfonyl group optionally substituted with fluorine atom(s), a hydrogen atom, a fluorine atom, a cyano group, an alkylcarbonyl group, or a dialkylamino group; and
Z represents a NH2
the method comprising
Step (a): reacting a compound represented by formula (1)

(wherein X represents a chlorine atom; and Y is the same as defined above)
with a compound represented by formula (5)

(wherein Z is the same as defined above)
in the presence of a nickel compound and zinc to produce the compound represented by formula (2).

US Pat. No. 11,028,055

COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES

Beth Israel Deaconess Med...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl;
R2 is of the formula

RA2 is —N(RC)2, and each instance of RC is independently substituted or unsubstituted alkyl, or substituted or unsubstituted heterocyclyl;
RA3 is —N(RA4)2, and two instances of RA4 are joined to form a substituted or unsubstituted, heteroaryl ring;
RA6 is —N(RA7)2, and two instances of RA7 are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;
R3 is independently hydrogen, substituted or unsubstituted C1-6 alkyl, or a nitrogen protecting group; and
R4 is independently hydrogen, substituted or unsubstituted C1-6 alkyl, or a nitrogen protecting group.

US Pat. No. 11,028,054

1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS

Merck Patent GmbH, Darms...

1. A compound of formula (I):
or a pharmaceutically acceptable salt, solvate, tautomer, hydrate, stereoisomer and mixture of isomers, or N-oxide thereof;
wherein;
R1 is hydrogen or linear or branched C1-C6 alkyl;
R2 is an optionally substituted Cb, an optionally substituted Het or —O—(CH2)pCb?; wherein the optional substituent, at each occurrence, is independently selected from one or more occurrences of R4;
R3 is hydrogen, halogen, linear or branched C1-C6 alkyl or —OR5;
R4 is independently selected from hydrogen, halogen, linear or branched C1-C6 alkyl, —(CH2)pO(CH2)qR7, —(CH2)pS(?O)xR5, —C(R5)?NOR5, —(CH2)pHet? and —(CH2)pNR5(CH2)qR6;
R5 is independently selected from hydrogen and linear or branched C1-C6 alkyl;
R6 is independently selected from hydrogen, linear or branched C1-C6 alkyl, —(CO)Het, Cb?, Het?, —CF3, —C?CR5, —N(R5)2, —S(?O)xR5 and OR5;
R7 is independently selected from hydrogen, linear or branched C1-C6 alkyl, Cb?, Het?, —CF3, —C?CR5, —N(R5)2 or —S(?O)xR5;
Cb and Cb? independently represents a monocyclic, a fused or non-fused bicyclic, saturated, unsaturated or aromatic carbocyclic ring system having 3 to 14 carbon atoms; wherein the Cb and Cb? are optionally substituted with ‘n’ occurrences of R7;
Het and Het? independently represents a 3- to 14-membered, monocyclic, a fused or non-fused bicyclic, saturated, unsaturated or aromatic heterocyclic ring system having at least 1 to 4 heteroatom or heterogroup selected from N, O, S, CO, NH, SO and SO2; wherein the Het and Het? are optionally substituted with ‘n’ occurrences of R8;
R8, at each occurrence, is independently selected from halogen, hydroxy, oxo and linear or branched C1-C6 alkyl;
‘m’ is 0 to 4; ‘n’, ‘p’ and ‘q’ independently represents 0 to 3; and ‘x’ is 0 to 2.

US Pat. No. 11,028,053

ELECTRICALLY CONDUCTING OLIGO(PYRAZOLES)

The Government of the Uni...

1. An electrically conducting organic oligomer made from the steps of preparing an acidic aqueous solution with a monomer; preparing the acidic aqueous solution by mixing a solution of about 1.6 wt % HCl in DI water with a monomer; forming about a 0.3 M solution preparing a second aqueous solution with a sodium persulfate oxidant; mixing the acidic aqueous solution with the second aqueous solution; and allowing a reaction to proceed at about 40° C.

US Pat. No. 11,028,052

COMPOUNDS USEFUL AS MODULATORS OF TRPM8

Firmenich Incorporated, ...

1. A compound having structural Formula (Ib):
or a salt or solvate thereof; wherein
R5 or R6 is selected from C1-C3 alkyl, and the remaining R5 or R6 is selected from the group consisting of optionally substituted C3-C8 cycloalkyl and optionally substituted C3-C8 cycloalkenyl;
X and X1 are N;
R7 is C1-C3 alkyl;
R8 is represented by (a) or (b):

A is O;
B is CH2, or C?O;
C is CH2, or C?O;
Ar and Ar1 are independently optionally substituted phenyl, or optionally substituted heteroaryl; and
R11 is selected from the group consisting of hydrogen or optionally substituted C1-C4 alkyl.

US Pat. No. 11,028,051

TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS

1. A compound having a structure represented by a formula:
wherein R1 is selected from C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 deuterated alkyl;
wherein R2 is C1-C4 alkyl;
wherein R3a is selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, Cy2, —(C1-C6 alkyl)Cy2, —(C1-C6 alkyl)Ar4, —C(O)(C1-C6 alkyl), —C(O)(CH2)mCy2, —C(O)(CH2)mAr4, —C(O)(C1-C4 alkyl)CCH, —CO2(C1-C6 alkyl), and amine protecting group, and wherein R3b is selected from —C(O)(unsubstituted C1-C6 alkyl), —C(O)(CH2)mCy2, —C(O)(CH2)mAr4, —C(O)(C1-C4 alkyl)CCH, and -CO2(C1-C6 alkyl);
wherein m, when present, is selected from 0, 1, 2, and 3;
wherein Cy2, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —OH, —CN, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
wherein Ar4, when present, is selected from aryl and heteroaryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —OH, —CN, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
or wherein each of R3a and R3b are optionally covalently bonded together and, together with the intermediate atoms, comprise a 5- to 7-membered heteroaryl and are substituted with 0-4 non-hydrogen groups independently selected from halogen, —OH, —CN, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
wherein Ar1 is selected from aryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —OH, —CN, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
wherein R4a is selected from hydrogen, C1-C4 alkyl, and amine protecting group and wherein R4b is selected from C4-C8 alkyl, —(CH2)nCy1, —(CH2)oAr2, and —COR6;
wherein each of n and o, when present, is selected from 0, 1, 2, and 3;
wherein Cy1, when present, is selected from cycloalkyl, five-membered heterocycle, and six-membered heterocycle and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —OH, —CN, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
wherein Ar2, when present, is selected from aryl and 5- to 12-membered heteroaryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —OH, —CN, —NO2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 aminoalkyl, C3-C6 cycloalkyl, —COR21, —CO2R21, —CONR22aR22b, —(CH2)qNR22aR22b, —SO2NR22aR22b, —NR23C(O)R24, —NR23(CH2)q(C3-C6 cycloalkyl), —NR23(CH2)q(heterocycloalkyl), and 3- to 5-membered heterocycloalkyl;
wherein q, when present, is selected from 0, 1, 2, 3, and 4;
wherein each occurrence of R21, when present, is independently selected from hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, —COR30, —(C1-C4 alkyl)OC(O)(C1-C4 alkyl), and —(C1-C6 alkyl)NHC(O)A;
wherein A has a structure:

wherein each occurrence of R30, when present, is independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, C3-C6 cycloalkyl, and C3-C6 heterocycloalkyl;
wherein each occurrence of each of R22a and R22b, when present, is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, and —COR30;
wherein R23, when present, is selected from hydrogen and C1-C4 alkyl;
wherein R24, when present, is selected from C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 alkyl (C1-C4 alkoxy), C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-4 alkylamino(C1-C4 alkyl), (C1-C4)(C1-C4) dialkylamino(C1-C4 alkyl), —(CH2)r(C3-C6 cycloalkyl), and —(CH2)s(C3-C6 heterocycloalkyl);
wherein r, when present, is selected from 0, 1, 2, and 3;
wherein R6, when present, is selected from C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, and —(CH2)sCy3;
wherein s, when present, is selected from 0, 1, and 2; and
wherein Cy3, when present, is selected from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —OH, —CN, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 haloalkyl;
or wherein each of R4a and R4b is hydrogen,
provided that when o is 0 and Ar2 is monoaryl then Ar2 is substituted with at least one non-hydrogen group,
or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,028,046

TOLUENE DIISOCYANATE PURIFICATION METHOD

HANWHA CHEMICAL CORPORATI...

1. A toluene diisocyanate purification method comprising:separating and purifying toluene diisocyanate by feeding a mixture containing toluene diisocyanate as a main component to a reactive dividing wall column equipped with a condenser and a reboiler,
wherein a pressure of the condenser is maintained at 50 torr or less, and a temperature of the condenser is maintained at 130° C. or less,
a total pressure difference in the reactive dividing wall column is maintained at 40 torr or less,
a retention time of the reaction mixture in the reactive dividing wall column is maintained within 10 seconds to 150 seconds, and
a pressure of the reboiler is maintained at 30 torr or less, and a temperature of the reboiler is maintained at 160° C. or less.

US Pat. No. 11,028,044

VERSATILE, CONCISE AND CONVENIENT PROCESS FOR THE COMMERCIAL SCALE PREPARATION OF HIGHEST PURE 3,3?5,5?-TETRAMETHYLBENZIDINE (TMB) AND ITS SALTS, A CHROMOGENIC SUBSTRATE USED IN STAINING PROCEDURES IN IMMUNOHISTOCHEMISTRY AND VISUALIZING REAGENT IN ENZYME

SLR Biosciences, LLC, Bu...

1. A process for the preparation of 1,2-bis(2,6-dimethylphenyl)diazene (III), which comprises reacting 2,6-dimethylaniline of Formula (II) with KMnO4 in an aprotic solvent dialkyl ketone with a boiling point greater than about 55° C.; wherein Formula (II) isand Formula (III) isand wherein the solvent is acetone and the reaction temperature is between 0° C. and 60° C.

US Pat. No. 11,028,043

N-HYDROXYALKYLATED POLYAMINES, METHODS OF MAKING N-HYDROXYALKYLATED POLYAMINES, AND FLUIDS CONTAINING AN N-HYDROXYALKYLATED POLYAMINE

Saudi Arabian Oil Company...

1. A method of making an N-hydroxyalkylated polyamine comprising:reacting a polyamine of Formula (XXIV):

with a cyclic oxide to produce the N-hydroxyalkylated polyamine;where:R1 and R2 are independently a —C or —CH group;
R3 is an aliphatic hydrocarbyl; and
R4 and R5 are independently acyclic hydrocarbyls, or R1, R2, R4, and R5 are covalently connected to form an unsaturated cyclic hydrocarbyl, wherein the unsaturated cyclic hydrocarbyl is substituted with one or more of alkyl, aminoalkyl, aminoalkoxy, hydroxyl, alkoxyl, alkylthio, amino, halo, haloalkyl, silyl, phosphoryl, sulfonyl, saturated C2-C20 acyclic hydrocarbyls, or unsaturated C2-C20 acyclic hydrocarbyls.

US Pat. No. 11,028,041

SECOND GENERATION GRP94-SELECTIVE INHIBITORS

University of Kansas, La...

12. A compound of Formula III
or a pharmaceutically acceptable salt thereof, wherein
X3 is Cl or F;
X4 is CH2, O, S, or NH; and
R7 is alkoxy, hydroxyl, thiol, or halo.

US Pat. No. 11,028,038

PREPARATION METHOD OF ACRYLIC ESTER COMPOUND

LG Chem, Ltd.

1. A preparation method of an acrylic ester compound represented by the following Chemical Formula 4, comprising a step of reacting a compound represented by the following Chemical Formula 1 with a compound represented by the following Chemical Formula 2 in the presence of a catalyst represented by the following Chemical Formula 3:
wherein, in Chemical Formula 1,
R1 is a substituted or unsubstituted C1-30 alkylene, a substituted or unsubstituted C2-30 alkenylene, or a substituted or unsubstituted C2-30 alkynylene, and
R2 and R3 are each independently hydrogen or a C1-20 alkyl,

wherein, in Chemical Formula 2,
R4 and R5 are each independently hydrogen or a methyl,

wherein, in Chemical Formula 3,
R6 to R9 are each independently hydrogen or a substituted or unsubstituted C1-10 alkyl, and
R10 is a substituted or unsubstituted C1-10 alkylene,

wherein, in Chemical Formula 4,
R1 to R5 are as defined above.

US Pat. No. 11,028,036

PROCESS FOR THE HYDROLYSIS OF DICARBOXYLIC ACID TRIGLYCERIDES

NOVAMONT S.P.A., Novara ...

1. A process for the preparation of dicarboxylic acids from triglycerides of carboxylic acids having more than one acid functional group comprising the steps of:a) mixing water with an organic phase consisting of triglycerides of carboxylic acids having more than one acid function and from 3 to 20% by weight with respect to the weight of the organic phase of a mixture comprising partial esters of glycerine with at least a dicarboxylic acid; and
b) hydrolysing the mixture obtained at the end of step a) in one or more hydrolysis reactors at temperatures of between 150 and 350° C., and at pressures corresponding to or higher than the equilibrium vapor pressure;
c) separating the dicarboxylic acids from the hydrolysis product obtained in step b).

US Pat. No. 11,028,035

METHOD AND DEVICE FOR PURIFYING ACETONE/WATER MIXTURES BY MEANS OF DOUBLE-EFFECT DISTILLATION

Rhodia Acetow GmbH, Feib...

1. A method for separating acetone from an acetone/water mixture, comprising:concentrating a partial first flow of the acetone/water mixture in at least one first column to produce a product having an acetone concentration of at least 80 wt %,
wherein the at least one first column is operated under positive pressure;
concentrating a partial second flow of the acetone/water mixture in at least one second column,
wherein the at least one second column is operated under normal pressure,
wherein a top product from the at least one first column is used to heat a bottom product of the at least one second column via a heat exchanger, and
wherein the top product is subsequently introduced into the at least one second column above a supply of the partial second flow of the acetone/water mixture.

US Pat. No. 11,028,032

PROCESS AND APPARATUS FOR SEPARATING METHANOL FROM OTHER OXYGENATES

UOP LLC

1. A process for separating methanol from other oxygenates comprising:separating water from a stream comprising water, methanol and at least one other oxygenate to provide a water rich stream and a methanol and oxygenate rich stream, said other oxygenate comprising at least one of acetaldehyde, acetone and methyl ethyl ketone;
feeding said methanol and oxygenate rich stream and water to an extractive distillation column to provide an oxygenate rich stream and a methanol and water extract stream.

US Pat. No. 11,028,030

PLANT EXTRACT COMPOSITIONS FOR FORMING PROTECTIVE COATINGS

Apeel Technology, Inc., ...

1. A method of preparing a composition comprising monomers, oligomers, or combinations thereof derived from cutin-containing plant matter, the method comprising:adding cutin-containing plant matter to a solvent to form a mixture, the solvent having a boiling point at a first temperature at a pressure of one atmosphere; and
heating the mixture to a second temperature, wherein the second temperature is higher than the first temperature, and to a second pressure, wherein the second pressure is higher than one atmosphere, thereby forming the composition comprising the monomers, oligomers, or combinations thereof,
wherein the solvent comprises a nucleophilic solvent, liquid CO2, supercritical CO2, or combinations thereof.

US Pat. No. 11,028,026

REACTOR FOR NON-OXIDATIVE DIRECT CONVERSION OF METHANE AND METHOD OF MANUFACTURING ETHYLENE AND AROMATIC COMPOUND USING SAME

KOREA RESEARCH INSTITUTE ...

1. A reactor for non-oxidative direct conversion of methane, the reactor comprising:an introduction unit for introducing a methane-containing feed;
a reaction unit for reacting the methane-containing feed introduced through the introduction unit to produce a product containing ethylene and an aromatic compound; and
a discharge unit for discharging the product containing the ethylene and the aromatic compound produced in the reaction unit,
wherein the reaction unit includes a first reaction region unit, for reacting the methane-containing feed introduced through the introduction unit to produce acetylene, and a second reaction region unit, for hydrogenating the acetylene produced in the first reaction region unit to produce the ethylene and the aromatic compound, and the second reaction region unit is provided with a hydrogen supply tube which is coaxially disposed in the reactor and which is hollow so that hydrogen is supplied through the hydrogen supply tube in the direction of the discharge unit towards the introduction unit,
wherein the reactor for non-oxidative direct conversion of methane includes a second reaction region catalyst in a reactor inner circumferential surface or in the hydrogen supply tube of the second reaction region unit.

US Pat. No. 11,028,025

PELLETISING PROCESS USING STARCH

York Potash Ltd, London ...

1. A method for manufacturing a pelletised mineral product, the method comprising:in a first mixing step, forming a first mixture by mixing polyhalite with non-gelatinised starch under conditions that are insufficient to substantially gelatinise the starch;
in a second mixing step, forming a second mixture by mixing the first mixture under conditions that are sufficient to substantially gelatinise the starch comprised within the first mixture; and
forming the second mixture into pellets; wherein the pellets comprise greater than 75% by weight polyhalite.

US Pat. No. 11,028,024

REACTION PRODUCTS AND METHODS FOR MAKING AND USING THE SAME

Koch Agronomic Services, ...

1. An agricultural composition comprising:A) a material selected from the group consisting of urea, dicyandiamide (DCD), urea-formaldehyde polymer (UFP), ammonia, and combinations thereof;
B) at least one adduct according to the structure of Formula 4
wherein:X is O or

R1, R2, R3, and R4 are independently selected from the group consisting of:
andwherein, if X=O,
at least one of R1, R2, R3, and R4 is
andC) a urease inhibitor.

US Pat. No. 11,028,023

METHOD FOR PREPARING MESOPOROUS SOUND-ABSORBING MATERIAL PARTICLES AND MESOPOROUS SOUND-ABSORBING MATERIAL PARTICLES

GOERTEK, INC., Shandong ...

1. A method for preparing mesoporous sound-absorbing material particles, comprising:step 1: mixing sound-absorbing material powder, a templating agent, a binding agent, and water to form a sol slurry, wherein the templating agent is an organic monomer or a linear polymer, and a purity of the templating agent is greater than 95%;
step 2: dropping the sol slurry into forming oil, wherein droplets of the sol slurry are aged in the forming oil to form gel particles;
step 3: taking out the gel particles from the forming oil, and drying the gel particles to form unroasted mesoporous sound-absorbing material particles; and
step 4: roasting the unroasted mesoporous sound-absorbing material particles to form the mesoporous sound-absorbing material particles.

US Pat. No. 11,028,022

COPPER-CERAMIC BONDED BODY AND INSULATION CIRCUIT SUBSTRATE

MITSUBISHI MATERIALS CORP...

1. A copper-ceramic bonded body comprising:a copper member formed of copper or a copper alloy; and
a ceramic member formed of silicon nitride,
wherein the copper member and the ceramic member are bonded to form the copper-ceramic bonded body,
at a bonding interface of the copper member and the ceramic member, a nitride compound layer including one or more nitride forming elements selected from Ti, Nb, Hf, and Zr, and an Ag—Cu eutectic layer are formed in order from the ceramic member side,
a thickness of the nitride compound layer is 0.47 ?m or more and 0.89 ?m or less,
an intermetallic compound phase formed of an intermetallic compound that contains the nitride forming element and Si is present between the copper member and the ceramic member,
Cu and Si are present at a grain boundary of the nitride compound layer, and
wherein 90° peeling strength between the copper member and the ceramic member is 11.0 kN/m or more and 16.4 kN/m or less.

US Pat. No. 11,028,021

TERMINATION FEEDTHROUGH UNIT WITH CERAMIC INSULATOR SUITABLE FOR VACUUM AND CORROSIVE APPLICATIONS

Watlow Electric Manufactu...

1. A method for making an insulated electrical feedthrough or electrical termination unit, said method comprising the steps of:putting aluminum into a hole in a ceramic piece, said ceramic piece having a first end and a second end, said hole providing an opening in said ceramic piece at the first end;
brazing the aluminum to create an aluminum rod within said ceramic piece joined with a hermetic joint between the aluminum and an inner surface of said hole in said ceramic piece;
removing a center of the aluminum rod to create an aluminum tube within said ceramic piece; and
removing a first portion of said ceramic piece at said first end of said ceramic piece to expose a portion of an outer surface of the aluminum tube, thereby resulting in the aluminum tube with a second portion of the aluminum tube hermetically joined along the outer surface of said aluminum tube to an interior of said hole within said ceramic piece within the center of an annular of said ceramic piece at the first end.

US Pat. No. 11,028,020

CERAMIC COMPOSITION AND METHOD OF MAKING THE COMPOSITION

THE BOEING COMPANY, Chic...

1. A method of making a ceramic composite, the method comprising:forming a wet ceramic composition comprising a plurality of discrete ceramic components and a fluxing agent dissolved in a solvent;
removing at least a portion of the solvent from the wet ceramic composition to form a dried ceramic composition comprising the plurality of discrete ceramic components coated with the fluxing agent; and
sintering the dried ceramic composition to form the ceramic composite, the sintering being carried out at a sinter temperature sufficient to fuse the discrete ceramic components at bridging sites formed where two or more of the discrete ceramic components coated with fluxing agent are in physical contact,
wherein the number of bridging sites per unit volume of the ceramic composite is greater than for a ceramic second composite, if the ceramic second composite were to be made using a similar process with the same ingredients in the same amounts by weight as the ceramic composite, except that the only fluxing agent employed in the ceramic second composite was a non-soluble fluxing agent.

US Pat. No. 11,028,017

FAST-DRYING SCREED AND SCREED MIXTURE FOR PRODUCING THE SCREED

KNAUF GIPS KG, Iphofen (...

1. A screed mixture, comprising an inorganic binder, processing additives for improving processability of the screed, and drying additives, wherein the drying additives are selected from hydrophobing agents, or wherein the drying additives are selected from a mixture of hydrophobing agents and pore forming agents, or a mixture of hydrophobing agents and porous additives, or a mixture of hydrophobing agents, pore forming agents and porous additives, wherein the hydrophobing agent is contained in a quantity of 0.03 to 0.15 wt. % related to the total mass of the screed mixture, or wherein the drying additives are selected from a mixture of pore forming agents and porous additives, wherein the pore forming agent and the porous additive are each contained in a quantity of 0.001 to 10 wt. % related to the total mass of the screed mixture.

US Pat. No. 11,028,016

METHOD OF MANUFACTURE OF COPPER-DOPED GLASSES

The Government of the Uni...

1. A method of making a copper-doped glass comprising the steps of:placing a target glass in a container;
surrounding the target glass with a powder mixture comprised of fused silica (SiO2) powder and copper sulfide (Cu2S) powder, such that both the target glass and the surrounding powder are contained in the container;
wherein the powder mixture is comprised of a SiO2 powder and Cu2S powder mixed according to the formula (SiO2)(1-x)(Cu2S)x, where 0.01 heating the container and the target glass and the surrounding powder mixture to a temperature of between 800° C. and 1150° C.

US Pat. No. 11,028,014

COATED GLASS-BASED ARTICLES WITH ENGINEERED STRESS PROFILES

Corning Incorporated, Co...

1. A coated glass-based article comprising:a glass-based substrate comprising a substrate Young's modulus value and a first surface and a second surface opposing the first surface defining a substrate thickness (t) in a range of 0.1 millimeters to 3 millimeters;
a coating on at least one of the first surface or the second surface of the glass-based substrate, the coating comprising a coating Young's modulus value equal to or greater than the substrate Young's modulus value and comprising a coating thickness (tc) from 80 nanometers to 10 micrometers; and
the glass-based substrate comprising a compressive region, the compressive region comprising a compressive stress (CS) of from 750 MPa to 1200 MPa at a surface of the glass-based article, the CS decreasing to zero at a depth of compression (DOC), the compressive region comprising a stress profile comprising a first portion and a second portion, the first portion extending from the first surface to a first depth, the second portion extending from the first depth to the DOC, points in the first portion comprise a tangent with a slope that is less than ?15 MPa/micrometers and greater than ?45 MPa/micrometers, and points in the second portion comprise a tangent with a slope that is less than or equal to ?1 MPa/micrometers and greater than ?12 MPa/micrometers, and the first depth is from about 20 microns to about 30 microns.

US Pat. No. 11,028,013

CHEMICALLY STRENGTHENED GLASS AND METHOD FOR PRODUCING THE SAME

AGC Inc., Chiyoda-ku (JP...

1. A chemically strengthened glass having a compressive stress layer formed in a glass surface layer by ion exchange, whereinthe compressive stress layer includes at least two types of stress patterns of a stress pattern A close to a glass surface and a stress pattern B on an inner side of the glass,
in the stress pattern A, compressive stress increases as going inward from the glass surface,
in the stress pattern B, compressive stress decreases as going inward from the glass surface,
depth of compressive stress layer in the stress pattern B is 90 ?m or more from the glass surface, and
compressive stress ? MPa of the glass surface in the stress pattern A and compressive stress ? MPa at a point where the stress pattern A and the stress pattern B cross each other satisfy a relation of ?>?, and wherein the compressive stress layer further includes a stress pattern C on an inner side of the glass from the stress pattern B, and when the stress pattern C is approximated as a linear function, a slope i MPa/?m of compressive stress thereof satisfies ?8?i<0.

US Pat. No. 11,028,012

LOW SOLAR HEAT GAIN COATINGS, LAMINATED GLASS ASSEMBLIES, AND METHODS OF PRODUCING SAME

CARDINAL CG COMPANY, Ede...

1. A coated glass pane having a surface that bears a low solar heat gain coating, the low solar heat gain coating comprising, in sequence moving outwardly from the surface, a first indium tin oxide film, a first nickel compound film, a second indium tin oxide film, a second nickel compound film, and an overcoat layer, the first indium tin oxide film having a thickness of between 480 ? and 725 ?, the first nickel compound film having a thickness of between 80 ? and 120 ?, the second indium tin oxide film having a thickness of between 580 ? and 870 ?, and the second nickel compound film having a thickness of between 65 ? and 100 ?, wherein the first nickel compound film is in contact with both the first and second indium tin oxide films.

US Pat. No. 11,028,011

HIGH INFRARED REFLECTION COATINGS, THIN FILM COATING DEPOSITION METHODS AND ASSOCIATED TECHNOLOGIES

CARDINAL CG COMPANY, Ede...

1. A first pane having opposed first and second major surfaces, the first pane being part of a multiple-pane insulating glazing unit that includes a second pane, wherein the multiple-pane insulating glazing unit has at least one between-pane space, the multiple-pane insulating glazing unit being mounted such that the first major surface of the first pane is exposed to an outdoor environment, wherein the second major surface of the first pane has a coated interior surface that is exposed to a between-pane space of the multiple-pane insulating glazing unit, said coated interior surface bearing a low-emissivity coating that includes, from said interior surface outward:a) a first transparent dielectric film region;
b) a first infrared-reflection film region;
c) a second transparent dielectric film region;
d) a second infrared-reflection film region;
e) a third transparent dielectric film region;
f) a third infrared-reflection film region; and
g) a fourth transparent dielectric film region;
the first, second, and third transparent dielectric film regions each being a single layer of a single transparent dielectric material;
the first, second, and third infrared-reflection film regions each consisting of silver combined with no more than about 5% of another metal selected from the group consisting of gold, platinum, and palladium;
the low-emissivity coating comprising one or more nitride or oxynitride films; and
the low-emissivity coating having a sheet resistance of less than 1.4 ohms/square.

US Pat. No. 11,028,010

MACHINING OF FUSION-DRAWN GLASS LAMINATE STRUCTURES CONTAINING A PHOTOMACHINABLE LAYER

CORNING INCORPORATED, Co...

19. A glass structure comprising:a first cladding layer formed from a first-clad glass composition having a first-clad photosensitivity;
a second cladding layer formed from a second-clad glass composition having a second-clad photosensitivity; and
a core layer interposed between the first cladding layer and the second cladding layer and formed from a core glass composition having a core photosensitivity, wherein:
the first cladding layer and the second cladding layer are photomachinable;
the first cladding layer is fused to a first surface of the core layer with a diffusive layer formed between the first cladding layer and the core layer;
the second cladding layer is fused to a second surface of the core layer with a diffusive layer formed between the second cladding layer and the core layer;
the core photosensitivity is less than at least one of the first-clad photosensitivity or the second-clad photosensitivity;
the first cladding layer and the second cladding layer each comprises a hole structure;
the core layer comprises a crystallized region connecting the hole structure of the first cladding layer and the hole structure of the second cladding layer; and
the crystallized region is narrower than the hole structure of the first cladding layer and the hole structure of the second cladding layer.

US Pat. No. 11,028,009

COEFFICIENT OF THERMAL EXPANSION FILLER FOR VANADIUM-BASED FRIT MATERIALS AND/OR METHODS OF MAKING AND/OR USING THE SAME

Guardian Glass, LLC, Aub...

1. A method of making a vacuum insulated glass (VIG) unit, the method comprising:providing first and second glass substrates, spaced apart from each other, a gap being defined between the first and second glass substrates;
having an edge sealing material proximate to the first and/or second glass substrates; and
applying energy to the edge sealing material so as to melt the edge sealing material;
wherein the edge sealing material comprises vanadium oxide, barium oxide, and zinc oxide as the three largest components, and further comprises niobium oxide.

US Pat. No. 11,028,008

FUSION-FORMABLE AUTOMOTIVE GLASS COMPOSITIONS, ARTICLES, AND LAMINATES

CORNING INCORPORATED, Co...

1. A glass article comprising a glass composition, the glass composition comprising:SiO2 in an amount in a range from about 66 mol % to about 80 mol %;
Al2O3 in an amount in a range from about 2 mol % to about 16 mol %;
B2O3 in an amount in a range from about 0.9 mol % to about 15 mol %;
P2O5 in an amount from about 1 mol % to about 6 mol %;
Li2O in an amount from about 1 mol % to about 12 mol %; and
Na2O in an amount from about 6 mol % to about 15 mol %.

US Pat. No. 11,028,006

ULTRALOW EXPANSION TITANIA-SILICA GLASS

Corning Incorporated, Co...

1. A method of annealing glass comprising:heating a modified titania-silica glass to a first temperature, said modified titania-silica glass including a non-uniform concentration of a modifier, said first temperature exceeding 850° C.;
cooling said modified titania-silica glass at a first cooling rate from said first temperature to a second temperature, said second temperature being in the range from 650° C. to 800° C.;
cooling said modified titania-silica glass at a second cooling rate from said second temperature to a third temperature, said third temperature being no more than 10° C. less than said second temperature, said second cooling rate being less than 1° C./hr, said cooling at said second cooling rate occurring for at least 10 hours; and
heating said modified titania-silica glass from said third temperature to a fourth temperature, said fourth temperature being in the range from 5° C. to 25° C. greater than said third temperature.

US Pat. No. 11,028,005

GLASS FOR SEMICONDUCTOR PROCESSING

AGC INC., Tokyo (JP)

1. A glass comprising, in mol % based on oxides:SiO2 of 30.0 to 50.0%;
B2O3 of 10.0 to 30.0%;
Al2O3 of 10.0 to 30.0%;
Y2O3 of 3.0 to 17.0%; and
Gd2O3 of 3.5 to 17.0%, wherein:
(Gd2O3+Y2O3) is from 16.0 to 22.0%;
(Gd2O3/Y2O3) is from 0.15 to 7.0;
the glass has a modulus of equal to or larger than 110 GPa; and
the glass has a devitrification viscosity log ? of equal to or larger than 1.95.

US Pat. No. 11,028,004

TWISTED GLASS CANES FOR ARTISTS

ANATOLY GLASS, LLC, Nort...

1. A method of manufacturing twisted glass cane, comprising:filling a glass tube with a combination of colored and clear glass structures forming a cross-sectional pattern within the glass tube, to form a preform;
attaching the preform to a draw machine and connecting an open end of the preform with a vacuum source; and
operating the draw machine to draw the preform to a reduced-diameter glass cane having a visually perceptible twisted pattern of colored glasses for incorporation into a piece of artwork, by passing the preform through a hot zone while pulling the preform or the reduced-diameter glass cane and rotating the preform or the reduced-diameter glass cane and while operating the vacuum source.

US Pat. No. 11,028,003

METHOD AND DEVICE FOR LASER-BASED MACHINING OF FLAT SUBSTRATES

CORNING LASER TECHNOLOGIE...

1. A system comprising:a substrate; and
a device for laser-based machining that is configured to separate the substrate into a plurality of pieces, the device comprising:
a laser providing a laser beam for machining the substrate when directed at the substrate, the wavelength ? of the laser beam being such that a material of the substrate is transparent to the wavelength ?; and
an optical arrangement positioned in a beam path of the laser, wherein:
the optical arrangement comprises a first optical element and a second optical element;
the second optical element is disposed on the beam output side of the first optical element, at a distance z1 from the first optical element; and
the first optical element and the second optical element are positioned and directed such that the laser beam strikes the second optical element in a ring shape, and a laser beam focal line extending along the direction of the laser beam is generated on the beam output side of the second optical element at a spacing z2 from the second optical element; wherein:
the substrate is positioned relative to the laser beam focal line so that in the material of the substrate, an induced absorption takes place along a segment of the laser beam focal line that is extended as viewed in the direction of the beam along a single continuous cracking zone, wherein an induced crack formation is produced in the material of the substrate along the said extended segment.

US Pat. No. 11,028,002

APPARATUS AND METHOD FOR THERMALLY TREATING AN ANNULAR REGION OF AN INNER SURFACE OF A GLASS CONTAINER PRODUCED FROM A BOROSILICATE GLASS TUBE

SCHOTT AG, Mainz (DE)

1. A method for thermally treating an annular region of an inner surface of a borosilicate glass container, wherein the annular region is at a tubular portion of the glass container,the method comprising the steps of:
forming a glass container bottom from a glass tube and thermally processing the glass container bottom to obtain a shape of the glass container bottom, wherein during the thermally processing of the glass container bottom a diffusion zone is formed that extends at least partially over the annular region, wherein during the thermally processing of the glass container bottom, boron accumulates in the diffusion zone, while boron simultaneously depletes in the glass container bottom;
heating only the annular region of the inner surface to a treatment temperature between 700 and 1000° C.;
maintaining the treatment temperature for a period of time so that boron diffuses out of the diffusion zone; and
cooling the glass container to room temperature;
wherein the annular region has an end facing to the glass container bottom and an end facing away from the glass container bottom, wherein the end facing to the glass container bottom has a distance LB from the inside of the glass container bottom along an axis of the glass container of 0 and 20 mm and a distance LA between the end facing to the bottom and the end facing away from the bottom is between 1 and 10 mm.

US Pat. No. 11,028,001

HIGH TEMPERATURE GLASS MELTING VESSEL

Corning Incorporated, Co...

1. A glass melt delivery system vessel comprising:at least one sidewall and floor, wherein the at least one sidewall and floor comprise a refractory material;
at least one electrode extending through the refractory material;
wherein the at least one electrode is configured to heat a glass melt in contact with the refractory material at an average temperature of at least about 1600° C. without exceeding a breakdown condition of the refractory material in contact with the glass melt;
wherein the melting vessel has a length and a width and the ratio of the length to the width ranges from about 2.4:1 to about 3.6:1 and wherein the melting vessel is configured to accept a glass melt having a depth of at least about 50% of the width of the melting vessel.

US Pat. No. 11,027,999

ENHANCED PROCESS FOR SELECTIVE SALT RECOVERY FROM WASTEWATER, WASTE SALTS, AND BRINES

Veolia Water Technologies...

1. A method of treating a waste brine that contains sodium, sulfate and chloride and producing sulfate and chloride salt crystals comprising:directing the waste brine to a nanofiltration device and filtering the waste brine to produce a permeate stream and a reject stream;
directing the reject stream to a first concentration unit and concentrating the reject stream;
directing the concentrated reject stream to a Mirabilite crystallizer and producing via cooling crystallization hydrated sulfate salt crystals;
melting the hydrated sulfate salt crystals to form an aqueous sulfate solution or a slurry;
directing the aqueous sulfate solution or slurry to a sodium sulfate crystallizer and crystallizing anhydrous sulfate salts from the aqueous sulfate solution or slurry to form the sodium sulfate salt crystals;
directing the permeate stream from the nanofiltration device to a second concentration unit and concentrating the permeate stream; and
directing the concentrated permeate stream to a sodium chloride crystallizer and producing the sodium chloride salt crystals.

US Pat. No. 11,027,998

SCALE CONTROL IN PHOSPHORIC ACID PRODUCTION AND HANDLING PLANTS

Ecolab USA Inc., St. Pau...

1. A method comprising:adding to a first phosphatic composition an aqueous scale-mitigating composition comprising
5% to 15% by weight of a polyamino polyether methylene tetraphosphonate,
1% to 50% by weight of a copolymer of acrylic acid and 2-acrylamido-2-methylpropane sulfonic acid,
2% to 15% by weight of a copolymer of acrylic acid and a hydroxypolyethoxy allyl ether, and water,to form a second phosphatic composition,wherein the first phosphatic composition comprises phosphoric acid and calcium sulfate.

US Pat. No. 11,027,997

ANIMAL WASTE FILTER

Brian Moore, Martinez, C...

1. A filter device for filtering animal waste, the filter device comprising:a tank unit;
a filter unit;
a first opening positioned on a top surface of the tank unit;
a second opening positioned on a bottom surface of the tank unit; and
at least one hole at a bottom surface of the filter unit;
wherein the tank unit comprises: a tank cavity and a first vertical separating wall, wherein the first vertical separating wall separates a first section from the rest of the tank cavity, and the second opening is located at a bottom of the rest of the tank cavity,
the tank unit is placed over the filter unit;
the filter device further comprises a horizontal separating wall to separate the tank unit and the filter unit, and the horizontal separating wall is perpendicular to the first vertical separating wall of the tank unit;
the tank unit receives animal waste through the first opening, and step-wise filtration of the animal waste is performed when a liquid level in the first section goes above the first vertical separating wall and spills over into the rest of the tank cavity and goes through the second opening, and
the filter unit has a filter cavity wherein the filter cavity is filled with a first filter material for filtering liquid entering into the filter unit from the rest of the tank cavity through the second opening;
the tank unit further comprises a decomposing catalyst, and the decomposing catalyst is a septic pack.

US Pat. No. 11,027,996

CROWN ETHER FUNCTIONALIZED SUBSTRATES

The United States of Amer...

1. A method for making crown ether functionalized substrates, comprising:modifying crown ether-based molecules, wherein carboxylic acid functionalized hydrocarbon chains are reacted with crown ether-based molecules, thereby forming modified crown ether-based molecules; and
attaching the modified crown ether-based molecules to substrates, thereby forming crown ether functionalized substrates.

US Pat. No. 11,027,995

TREATMENT OF TAILINGS STREAMS WITH ONE OR MORE DOSAGES OF LIME, AND ASSOCIATED SYSTEMS AND METHODS

Graymont Western Canada I...

1. A method for treating a tailings stream from oil sands, the method comprising:obtaining an oil sands tailings stream comprising clay;
adding a first dosage of lime additive to tailings stream to produce a first mixture having a first pH of from about 9.0 to about 12.0 and a first soluble calcium level less than about 100 mg/L;
after adding the first dosage, adding a second dosage of lime additive to the first mixture having the first pH to produce a second mixture having a second pH greater than 11.8 and a second soluble calcium level of at least about 93 mg/L, such that the clay from the tailings stream in the second mixture is chemically modified via pozzolanic reactions with calcium cations; and
dewatering the second mixture to produce a cake including at least 40% solids by total weight.

US Pat. No. 11,027,994

SYSTEM AND METHOD FOR ADVANCED OXIDATION OF TREATED SEWAGE EFFLUENT

QATAR FOUNDATION FOR EDUC...

1. A method for post-treatment of treated sewage effluent, consisting of the steps of:exposing treated sewage effluent to ozone and hydrogen peroxide to oxidize contaminants therein to provide a first decontaminated treated sewage effluent;
removing suspended particles from the first decontaminated treated sewage effluent, wherein the removal of particles consists of the steps of:
coagulating remaining waste in the treated sewage effluent,
flocculating the coagulated treated sewage effluent,
holding the flocculated treated sewage effluent in a settling tank for sedimentation to occur, wherein the sedimentation occurs for at least 30 minutes,
removing coarse suspended particles from the flocculated treated sewage effluent by a first filtration after sedimentation to provide a first filtered sewage effluent; and
removing fine suspended particles from the first filtered treated sewage effluent by a ceramic or polymer ultrafiltration to provide a second filtered treated sewage effluent.

US Pat. No. 11,027,993

OIL SANDS TAILINGS TREATMENT

EXTRAKT PROCESS SOLUTIONS...

1. A process of consolidating oil sands tailings which include greater than 2 wt % of fines in process water, the process comprising:treating the oil sands tailings, which result from extraction of bitumen from oil sands, with at least one highly water soluble salt, at least one polymer flocculant and sand to form a treated tailings including a consolidated material including fines from the process water; and
separating the process water from the consolidated material, which includes the at least one highly water soluble salt dissolved therein,
wherein the treated tailings has a salt-tailings concentration of the at least one highly water soluble salt of at least 0.5 wt %, and
wherein the at least one highly water soluble salt is an alkali halide salt.

US Pat. No. 11,027,991

ELECTROLYTIC BIOCIDE GENERATING SYSTEM FOR USE ON-BOARD A WATERCRAFT

ElectroSea, LLC, Wayzata...

1. A biocide generating system for inhibiting bio-fouling within a water system of a watercraft, the water system being configured to draw water from a body of water on which the watercraft is supported, the biocide generating system comprising:an electrode arrangement adapted to be incorporated as part of an electrolytic cell through which the water of the water system flows; and
a control system that interfaces with the electrode arrangement, the control system including an electrical power circuit for establishing a flow of electrical current between first and second electrodes of the electrode arrangement to generate a biocide in the water within the electrolytic cell, the control system including a switching arrangement operable in a first switch configuration in which the first electrode is an anode and the second electrode is a cathode, the switching arrangement also being operable in a second switch configuration in which the first electrode is a cathode and the second electrode is an anode, and the switching arrangement being operable in a third switch configuration in which electrical power is terminated to the first and second electrodes and the first and second electrodes are electrically connected to one another by a circuit path that by-passes the water in the electrolytic cell and provides a short circuit between the first and second electrodes.

US Pat. No. 11,027,990

PLASMA-BASED METHODS AND SYSTEMS FOR TREATING WATERS WITH HIGH ELECTRICAL CONDUCTIVITY AND/OR LOW SURFACE TENSION

Clarkson University, Pot...

1. An electrical discharge plasma reactor system for treating a liquid, the reactor system comprising:a reactor chamber configured to hold the liquid and a gas;
a discharge electrode disposed within the reactor chamber, wherein the discharge electrode is disposed within the gas;
an opposing electrode disposed within the gas within the reactor chamber;
one or more gas diffusers disposed within the liquid, wherein the one or more gas diffusers is configured to induce the generation of a layer of foam on a surface of the liquid in a plasma-contact region;
wherein the one or more gas diffusers are connected to the reactor chamber beneath the liquid, which is between the one or more gas diffusers and the gas; and
a power supply connected to the discharge electrode and/or the opposing electrode, the power supply configured to induce the discharge electrode and the opposing electrode to generate plasma in the plasma-contact region.

US Pat. No. 11,027,989

MEMBRANE FILTRATION SYSTEM WITH CONCENTRATE STAGING AND CONCENTRATE RECIRCULATION, SWITCHABLE STAGES, OR BOTH

BL TECHNOLOGIES, INC., M...

1. A process of treating a feed water comprising the steps of:flowing the feed water through a plurality of stages of membrane filtration with concentrate staging between the stages and concentrate recirculation in the last stage,
wherein the concentrate recirculation in the last stage comprises recirculating concentrate from the last stage back to the last stage.

US Pat. No. 11,027,988

SUSTAINABLE SYSTEM AND METHOD FOR REMOVING AND CONCENTRATING PER- AND POLYFLUOROALKYL SUBSTANCES (PFAS) FROM WATER

Emerging Compounds Treatm...

22. A method for concentrating per- and polyfluoroalkyl substances (PFAS), the method comprising:introducing a regenerant solution to anion exchange resin to remove PFAS from the anion exchange resin thereby regenerating the anion exchange resin and generating a spent regenerant solution comprising removed PFAS and the regenerant solution;
separating and concentrating the removed PEAS to produce a concentrated PFAS solution;
subjecting the concentrated PEAS solution to a super-loading recovery process to separate and further concentrate the removed PFAS by adsorbing concentrated PFAS onto an adsorptive media to produce a PFAS waste product and a solution substantially without PFAS.

US Pat. No. 11,027,987

BALLAST WATER, BILGE WATER, SLOP WATER, OR OILY WATER TREATMENT SYSTEM

1. A ship or sea-worthy vessel 1000 with a system for cleaning oily water, where the system comprises:a receiving station that comprises a spill containment pan, wherein the receiving station is connected via pipe or hose to a centrifugal pump so that movement of an amount of oily water is accomplished through the receiving station after the centrifugal pump has been connected to an onboard or offboard source of the oily water;
a water meter wherein the water meter measures the amount of oily water;
a bag filter 1100 coupled to said receiving station so that debris is filtered from said amount of oily water, wherein said large debris are selected from the group of consisting of garbage, rag, rock;
a primary storage tank 1150 wherein said amount of oily water is either (a) settled into an oil stream and a water stream or (b) provided through an oil/water separator to create the oil stream and the water stream;
an oil storage tank 1250 coupled to the primary storage tank 1150, wherein the oil storage tank 1250 collects and retains the oil stream after said oil stream has either been (a) removed from the primary storage tank by at least one oil skimmer/drum or (b) separated from the water stream by the oil/water separator;
a water tank 1200 coupled to the primary storage tank 1150, wherein the water tank 1200 receives the water stream from the primary storage tank 1150 after said oil stream has either been (a) removed from the primary storage tank by at least one oil skimmer/drum or (b) separated from the water stream by the oil/water separator;
a submersible pump that transfers a water layer from tank 1150 to at least three primary treatment tanks 1300 wherein
(a) the water stream is received from the water tank 1150, through water tank 1200, and pumped through a FLOC blender in a first primary treatment tank 1300 where FLOC agents, coagulation agents, and metal particles are injected into the water stream,
(b) the water stream, FLOC agents, coagulation agents, and metal particles are provided to the second primary treatment tank 1300 to settle into a water layer and a layer of agglomeration and particulate wastes, and
(c) where the water layer from the second primary treatment tank 1300 is provided to a third primary treatment tank while agglomeration and particulate waste are provided as sludge to a filter press 1320, wherein the filter press 1320 de-waters the sludge to create pressed water and pressed sludge, wherein the pressed sludge is provided to a bin 1400 for disposal or destruction, and wherein the pressed water is provided to a flush storage tank 1350 and recirculated into the primary storage tank 1150 to become a part of the water stream disposed in the primary storage tank 1150;
a sand filter 1450, wherein the water layer from the third primary treatment tank is passed through the sand filter 1450 to create a first and a second portion of sand filtered water, wherein the first portion of the sand filtered water is provided to a flush storage tank 1350 and recirculated into the primary storage tank 1150 to become a part of the water stream disposed in the primary storage tank 1150;
a diatomaceous earth (DE) filter 1500, where the second portion of the sand filtered water from the sand filter 1450 is passed through the DE filter to create a first and a second portion of DE filtered water wherein the first portion of the DE filtered water is provided to a flush storage tank 1350 and recirculated into the primary storage tank 1150 to become a part of the water stream disposed in the primary storage tank 1150;
a media tank 1550, where the media tank 1550 receives the second portion of DE filtered water wherein the DE filtered water is exposed to a polymer bond media mixture to create a treated water;
an ultraviolet light (“UV”) treatment system 1600 wherein the treated water is provided to the UV treatment system where the treated water is exposed to UV light to create sterilized water,
at least one storage tank 1650 for collecting the sterilized water from the UV treatment system; and,
a submersible pump located in the at least one storage tank 1650 that discharges the sterilized water directly into a water body or ocean from the ship or sea-worthy vessel 1000.

US Pat. No. 11,027,986

ENVIRONMENTAL WASTE WATER FILTERING SYSTEM

1. An environmental waste water filtering system, comprising:a bucket having a wall with an inside surface and an outside surface, a top opening and a bottom opening, said inside surface defining a fluid debris chamber;
a funnel in said bucket, said funnel having an input in communication with said fluid debris chamber, said funnel having a neck and an exit tube, said exit tube in communication with said neck, said exit tube extending from said neck, said exit tube extending below said bottom opening, said exit tube insertable into a drain in a floor on which said bucket can be set; and
a strainer in said neck;
wherein fluid, said fluid containing a fluid portion and particulate matter, can be introduced through said top opening into said fluid debris chamber, said fluid can flow from said fluid debris chamber through said input and through said funnel to said strainer in said neck, wherein said strainer retains said particulate matter and allows said fluid portion to pass through said strainer to said exit tube, wherein said fluid portion passes through said exit tube into said drain.

US Pat. No. 11,027,985

BMW-BASED HIGH FREQUENCY DIELECTRIC CERAMIC MATERIAL AND METHOD FOR MANUFACTURING SAME

Chang Yong Oh

1. A BMW-type high frequency dielectric ceramic material being configured of a (Ba1-a-bMaaMbb)(Mg0.5-cMccW0.5)O3 composition, wherein Ma and Mb respectively represent an alkali metal and an alkaline earth metal, wherein Mc represents a metal of a +3 oxidation state, wherein each of a and c is within a range of 0.01 to 0.1, and wherein b is within a range of 0.09 to 0.25.

US Pat. No. 11,027,984

UREA PROCESS WITH CONTROLLED EXCESS OF CO2 AND/OR NH3

1. A process for producing urea, said process comprising the steps of:optionally purifying a hydrocarbon feed gas to remove sulfur and/or chloride components if present,
reforming the hydrocarbon feed gas in a reforming step with a steam/carbon molar ratio of 2-0.2, thereby obtaining a synthesis gas comprising CH4, CO, CO2, H2 and H2O,
optionally adding H2O to the synthesis gas from the reforming step to maintain an overall steam/carbon molar ratio less than 2,
shifting the synthesis gas in a shift section comprising one or more shift steps in series utilizing a zinc-aluminum oxide based catalyst, and operating the shift section at a steam/carbon molar ratio of less than 2.6,
optionally cooling and/or adding H2O to the synthesis gas between the shift steps,
optionally washing the synthesis gas leaving the shift section with water,
removing CO2 from the synthesis gas from the shift section in a CO2 removal step to obtain a synthesis gas with less than 20 ppm CO2 and a CO2 product gas,
removing residual H2O and/or CO2 from the synthesis gas in an absorbent step,
removing CH4, CO, Ar and/or He from the synthesis gas in a nitrogen wash unit and adding stoichiometric nitrogen to the synthesis gas to produce NH3 synthesis gas,
synthesizing NH3 from the NH3 synthesis gas to obtain a NH3 product,
adding at least part of the product CO2 and at least part of the NH3 product to a urea synthesis step to make a urea product,
wherein the amount of excess CO2 and/or NH3 is controlled by adjusting the steam/carbon molar ratio in the reforming step and/or adjusting H2O addition upstream and/or in between the shift steps and/or adjusting the inlet temperature to at least one of the one or more shift steps.

US Pat. No. 11,027,983

CHABAZITE ZEOLITE SYNTHESIS WITH ORGANIC TEMPLATES

PQ Corporation, Malvern,...

1. An as-synthesized microporous material having a CHA structure and comprising a first organic structure directing agent (OSDA) that has a general structure of the quaternary ammonium cation as follows:
where R1 is a C1-C5 derivatized or underivatized alkyl chain, and
R2 is a C2-C5 derivatized or underivatized alkyl chain,
where X is H (hydrogen) or a C1-C3 alkyl substituent group or groups, derivatized or underivatized, attached to at least one carbon atom constituting the hexahydro-1H-azepinium ring.

US Pat. No. 11,027,982

MICA-MADE MEMBER, ELECTROCHEMICAL REACTION UNIT, AND ELECTROCHEMICAL REACTION CELL STACK

MORIMURA SOFC TECHNOLOGY ...

1. An electrochemical reaction cell stack comprising a plurality of electrochemical reaction units arrayed in a first direction,wherein at least one of the electrochemical reaction units is an electrochemical reaction unit,
the electrochemical reaction unit includes:
a unit cell including an electrolyte layer, and a cathode and an anode that face each other in a first direction with the electrolyte layer intervening therebetween; and
a structural member that faces a cathode chamber facing the cathode or an anode chamber facing the anode,
wherein the structural member is formed of a mica-made member that has been subjected to a heat treatment of 1,000° C. or higher for four or more hours so as to exhibit an intensity peak of KMg3(Si3Al)O10(OH)2 and an intensity peak of Mg2SiO4 in X-ray diffractometry (XRD), prior to assembling the structural member into the electrochemical reaction unit.

US Pat. No. 11,027,979

PROCESS FOR HYDROGENATING SILICON TETRACHLORIDE

WACKER CHEMIE AG, Munich...

1. A method for hydrogenating silicon tetrachloride in a reactor, comprising:supplying a feed gas comprising hydrogen and silicon tetrachloride to a reactor and heating the feed gas to a temperature in the range from 850° C. to 1600° C. by employing at least one heating element comprising a graphite surface, the at least one heating element located within the reactor and in direct contact with the feed gas, the temperature of the heating element being in the range 850° C. to 1600° C., wherein nitrogen is added to the reactor in a molar proportion of from 0.1 to 10% based on hydrogen in the feed gas.

US Pat. No. 11,027,978

SILICON NANOPARTICLE-CONTAINING HYDROGEN POLYSILSESQUIOXANE, CALCINED PRODUCT THEREOF, PRODUCTION METHOD THEREFOR, ACTIVE MATERIAL, NEGATIVE ELECTRODE, AND LITHIUM ION BATTERY

JNC CORPORATION, Tokyo (...

1. A silicon nanoparticle-containing hydrogen polysilsesquioxane calcined product, represented by general formula SiOx2Hy2 (0.3 having a chemical bond between a surface of the silicon nanoparticles and a silicon oxide structure derived from hydrogen polysilsesquioxane,
having a Si—H bond, and
substantially containing no carbon.

US Pat. No. 11,027,977

METHOD OF MANUFACTURING TANTALUM CARBIDE MATERIAL

SHOWA DENKO K.K., Tokyo ...

1. A method of manufacturing a tantalum carbide material in which a tantalum material interposed between a pair of graphite guide members is heated under a carbon source-containing gas atmosphere at 1,500° C. or higher for 0.5 hours or longer to make tantalum carbide from all the tantalum material.

US Pat. No. 11,027,976

FERROELASTIC CERAMIC COMPOSITIONS, APPLICATIONS THEREOF, AND RELATED METHODS

Colorado School of Mines,...

1. A ferroelastic ceramic composition comprising:at least one compound having a relative chemical formula of A(1-X-Y)BxCYD wherein:
an element A, an element B, and an element C are independently selected from different members of the group consisting of yttrium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, and lutetium;
an element D is selected from the group consisting of a phosphate, a niobate, and a tungstate, wherein the phosphate is PO4, the niobate is NbO3, and the tungstate is WO4;
X is equal to or greater than zero and less than one; and
Y is equal to or greater than zero and less than one;
wherein X and Y are collectively less than one;
wherein the ferroelastic ceramic composition is a single crystal.

US Pat. No. 11,027,974

REMOVAL OF MOISTURE FROM HYDRAZINE

Matheson Tri-Gas, Inc., ...

1. A process for removing moisture from hydrazine in either in a vaporous or aqueous state, comprising:contacting hydrazine containing moisture with a scavenger wherein the scavenger comprises a support having associated therewith an active scavenging moiety selected from one of more members of the group consisting of: alkali metal compounds, alkaline earth metal compounds, metal oxide or hydroxide compounds and silica-based material wherein after contacting said hydrazine containing moisture with said scavenger the moisture in said hydrazine is removed to a level of less than 2440 ppm.

US Pat. No. 11,027,973

CHEMICAL LOOPING SYNGAS PRODUCTION FROM CARBONACEOUS FUELS

OHIO STATE INNOVATION FOU...

1. A system for converting a fuel, the system comprising:a first moving bed reactor comprising a metal oxide particles having a primary component and a secondary component, wherein fuel, CO2 and steam are added to the first moving bed reactor in a co-current flow pattern relative to the metal oxide particles, wherein the first moving bed reactor is configured to reduce at least a portion of the metal oxide particles with the fuel to produce a first reduced metal oxide, and is further configured to produce a first syngas stream comprising H2, CO, CO2 and steam;
a second moving bed reactor, operating in parallel with the first moving bed reactor and comprising metal oxide particles having a primary component and a secondary component, wherein fuel, CO2 and steam are added to the second moving bed reactor in a co-current flow pattern relative to the metal oxide particles, wherein the second moving bed reactor is configured to reduce at least a portion of the metal oxide particles with the fuel to produce a second reduced metal oxide, and is further configured to produce a second syngas stream comprising H2, CO, CO2 and steam;
a separation unit, in communication with the first moving bed reactor and the second moving bed reactor, and configured to remove the CO2 from the first syngas stream and the second syngas stream, wherein the H2/CO ratios of the first and second syngas streams are controlled by recycling substantially all of the CO2 from the separation unit to the first moving bed reactor and the second moving bed reactor; and
a third co-current fluidized bed reactor in communication with the first moving bed reactor and the second moving bed reactor and configured to oxidize the first reduced metal oxide and the second reduced metal oxide with an oxidizing agent to produce oxidized metal oxide particles and recycle the oxidized metal oxide particles to the first moving bed reactor and the second moving bed reactor for subsequent reduction reactions.

US Pat. No. 11,027,972

PROCESS COMPRISING EXOTHERMAL CATALYTIC REACTION OF A SYNTHESIS GAS AND RELATED PLANT

CASALE SA, Lugano (CH)

1. A synthesis process, comprising:steam reforming a gaseous hydrocarbon feedstock, thereby obtaining a synthesis gas;
exothermically reacting said synthesis gas in the presence of a catalyst, thereby obtaining a synthesis product;
removing heat from said exothermal reaction by producing steam, wherein at least part of said steam provides a heat input to the reforming of said hydrocarbon feedstock;
wherein the steam reforming of the hydrocarbon feedstock includes:
a) forming a mixture containing steam and hydrocarbons by at least a step of adding a first stream of water to the hydrocarbon feedstock in a saturating tower, said stream of water being pre-heated by indirect heat exchange, prior to admission into said tower, with at least a portion of the steam produced by removing heat from the exothermal synthesis reaction;
b) heating said mixture by indirect heat exchange with at least part of said synthesis gas; and
c) reforming said mixture after said heating step b).

US Pat. No. 11,027,971

METHOD FOR PRODUCING HYDROGEN

NIIGATA UNIVERSITY, Niig...

1. A method for producing hydrogen, comprising: thermally reducing a reaction medium in which CeO2 is doped with a metal other than Ce; andbringing the thermally reduced reaction medium into contact with a gas containing water vapor and nitrogen gas to oxidize the reaction medium and to generate the hydrogen,
when a reaction temperature in the thermally reducing the reaction medium is defined as T1 [° C.] and a reaction temperature in the bringing the thermally reduced reaction medium into contact with the gas is defined as T2 [° C.], the following relation is satisfied; T1?T2?150 [° C.],
wherein the reaction temperature T2 is 1160° C. or more and 1300° C. or less,
wherein the metal constituting the reaction medium is Mn and/or Co, and
wherein a series of processes including the thermally reducing the reaction medium and the bringing the thermally reduced reaction medium in to contact with gas is successively repeated in a same reaction container, and
wherein in the bringing the thermally reduced reaction medium into contact with the gas, when a water vapor partial pressure in the gas to be supplied into the reaction container is defined as P1 [Pa] and a partial pressure of the nitrogen gas in the gas to be supplied into the reaction container is defined as P2 [Pa], the following relation is satisfied: 0.2?P1/P2?3/7.

US Pat. No. 11,027,970

METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

Kokusai Electric Corporat...

1. A method of manufacturing a semiconductor device comprising:(a) placing a substrate with a sacrificial film comprising a silicon dioxide film and containing impurities on a substrate support in a process chamber, wherein the sacrificial film is formed so as to cover a control electrode, a pedestal and a counter electrode formed on the substrate;
(b) heating the substrate and establishing a framework of the sacrificial film by increasing a degree of binding of silicon and silicon (Si—Si) or a degree of binding of silicon and oxygen (Si—O) while the impurities are contained therein; and
(c) modifying the sacrificial film into a modified sacrificial film by supplying an oxygen-containing gas in a plasma state to the substrate to desorb the impurities from the sacrificial film after (b) in a state where the framework of the sacrificial film is established.

US Pat. No. 11,027,969

MICRO-DEVICE HAVING A METAL-SEMICONDUCTOR COMPOUND LAYER PROTECTED AGAINST HF ETCHING AND METHOD FOR MAKING THE SAME

9. A method for making a micro-device, during which at least one first element of the micro-device is made, the method comprising:making, on a substrate, a stack of a first layer and of two second layers such that the first layer is arranged between the two second layers, that the first layer includes at least one metal, that one of the two second layers comprises at least one first material able to withstand an HF etching, that the other of the two second layers comprises at least one second material able to withstand the HF etching, and that at least one of the first and second materials able to withstand HF etching includes a semi-conductor;
heat treating, such that a part of the semi-conductor reacts with the metal to form a layer of material consisting of a compound of the semi-conductor and the metal, and such that at least one remaining part of each of the two second layers form first and second protective layers each directly contacting two opposite faces of said layer of material and such that the first and second protective layers are not in direct contact with each other at all points above the substrate;
and further comprising implementing a step of HF etching during which said layer of material is protected from HF by the first and second protective layers.

US Pat. No. 11,027,968

SEMICONDUCTOR DEVICE WITH DISCHARGE PATH, AND METHOD FOR PRODUCING THE SAME

DENSO CORPORATION, Kariy...

1. A semiconductor device comprising:a first substrate having a first surface;
a second substrate having a second surface, the second substrate being bonded to the first substrate such that the second surface faces the first surface of the first substrate and a hermetically sealed chamber is provided between the first substrate and the second substrate, the second substrate having a through hole that penetrates the second substrate in a stacking direction of the first substrate and the second substrate and exposes the first surface of the first substrate;
an insulating film disposed between the first surface of the first substrate and the second surface of the second substrate;
a sensing part disposed in the hermetically sealed chamber, the sensing part including a vibrator;
a penetrating electrode disposed on a wall surface of the through hole of the second substrate, the penetrating electrode being electrically connected to the sensing part; and
a discharge path defining a space, at a position located between the hermetically sealed chamber and the through hole.

US Pat. No. 11,027,967

DEFORMABLE MEMBRANE AND A COMPENSATING STRUCTURE THEREOF

InvenSense, Inc., San Jo...

1. A sensor comprising:a substrate;
an oxide layer disposed on the substrate;
a deformable membrane disposed on the oxide layer, wherein the deformable membrane, the oxide layer, and the substrate forms an enclosed cavity therein, wherein the deformable membrane deforms responsive to stimuli, and wherein the oxide layer forms side walls of the enclosed cavity;
an electrode positioned at a bottom of the cavity; and
a compensation structure connected to the deformable membrane, wherein the compensation structure creates a compensation force that is opposite to a bending force of the deformable membrane responsive to temperature changes and thermal coefficient mismatch.

US Pat. No. 11,027,966

FLUID DISPENSING UNIT HAVING A CIRCULATION SYSTEM AND A METHOD FOR CIRCULATING A FLUID IN A FLUID DISPENSING UNIT

DOVER FUELING SOLUTIONS U...

1. A hose and nozzle assembly for use with a fuel dispenser, comprising:an elongate tube having first and second pathways extending therethrough between first and second ends thereof, the first end of the elongate tube being configured to couple to a pump for receiving fluid from a fluid reservoir;
a nozzle coupled to the second end of the elongate tube and configured to deliver fluid to a vehicle; and
a valve having
an open state in which fluid flowing through the first pathway can flow through and exit the nozzle to be delivered to a vehicle, and
a closed state in which fluid flowing through the first pathway is prevented from exiting the nozzle; wherein:
in response to the valve moving to the closed state, the fluid is directed through the second pathway to flow back toward the first end of the elongate tube;
with the valve in the open state and with the valve in the closed state, the fluid flows from a first open end of the first pathway and toward a second open end of the first pathway;
first and second open ends of the first pathway are each on a downstream side of the pump and a downstream side of the fluid reservoir;
with the valve in the closed state, the fluid flows out of the second open end of the first pathway and into a first end of the second pathway and in the second pathway toward a second open end of the second pathway; and
the first open end of the second pathway is on the downstream side of the pump and the downstream side of the fluid reservoir, and the second open end of the second pathway is on an upstream, suction side of the pump and the downstream side of the fluid reservoir.

US Pat. No. 11,027,965

CAP ROTATION DEVICE

Marketech International C...

1. A cap rotation device, comprising:a cap rotator;
a liquid transferring device disposed near the cap rotator;
an optical detecting device disposed between the cap rotator and the liquid transferring device, wherein the optical detecting device detects a position of a sealing cap of a chemical drum to guide the cap rotator aligning with the sealing cap, the cap rotator opens the sealing cap and the liquid transferring device transfers a chemical liquid;
a fixing plate;
two vertical moving devices respectively connected between the fixing plate and the cap rotator, and the fixing plate and the liquid transferring device to vertically move the cap rotator and the liquid transferring device respectively; and
two horizontal moving devices connected to the fixing plate to horizontally move the fixing plate.

US Pat. No. 11,027,964

SYSTEM FOR PREPARING A PERSONALIZED COMPOSITION USING PRESSURE

LinkedTech, Paris (FR)

1. A preparation and dispensing system for preparing and dispensing a personalized composition from N reserves (501-508) of active compounds (A1-A2), N being an integer greater than or equal to 1, each of the reserves having a hydraulic resistance (Rh2) and each of the reserves comprising a fluid inlet (511-518), a fluid outlet (521-528) and a body (530) comprising at least one active compound, the system comprising a pneumatic-pressure generator (200, 201-202) connected to a pressure distributor (300) comprising N pressure changeover switches (301-306), each N pressure changeover switch having at least one inlet (I1) connected to the pneumatic-pressure generator, one inlet (I2) connected to atmospheric pressure and an outlet (311-316) connected to the fluid inlet of one of the reserves of active compounds (A1-A2), such that each reserve (501-508) of active compound (A1-A2) can be placed in communication either with atmospheric pressure, or with pressure generated by the pneumatic-pressure generator, and in that each of the reserves of active compound comprises, at the fluid outlet of each of the reserves, an ejection nozzle (500), a hydraulic resistance (Rh1) of which is higher than the hydraulic resistance (Rh2) of each of the reserves of active compound, wherein each of the reserves of active compound is made up of an interchangeable multi-dose cartridge (501-508) and of a cartridge support (400) designed to keep, in use, hermetically and independently, each inlet of each interchangeable multi-dose cartridge with each outlet of each of the pressure changeover switches.

US Pat. No. 11,027,963

METHOD AND APPARATUS FOR DISPENSING FLUIDS FROM CONTAINERS

1. An apparatus for dispensing hair shampoo or other hair product from a container having a base, a contents label and an outlet comprising:a) a support assembly, wherein said support assembly further comprises:
i) a container support member configured to receive a portion of said container, wherein a contents label on said container is at least partially exposed;
ii) a fluid pump support member adapted to support a fluid pump;
b) a manual fluid hand pump having an inlet and an outlet, wherein said fluid pump is at least partially disposed within said fluid pump support member;
c) a flexible hose having a first end and a second end, wherein said flexible hose is configured to directly connect said container to said fluid pump, and wherein said first end is operationally attached to said outlet of said container and said second end is operationally attached to said inlet of said fluid pump; and
d) a tool having a point configured to puncture a vent hole in said base of said container.

US Pat. No. 11,027,962

BEVERAGE SUPPLY APPARATUS AND CONTROL METHOD THEREFOR

LG ELECTRONICS INC., Seo...

1. An apparatus for supplying beverage, the apparatus comprising:a sensing unit;
a microphone;
an artificial intelligence unit, and
a controller capable of:
activating the microphone when an object detected,
recognizing a first sound data of a user when the first sound data is sensed through the activated microphone,
obtaining information of the user based on the first sound data,
storing the obtained information of the user,
determining a menu corresponding to the object based on the user's information and the first sound data, and controlling a water supply unit to supply the determined menu to the object,
wherein the artificial intelligence unit is further configured to:
store the user's information and information on the menu by learning the first sound data,
when both a linguistic expression and a non-linguistic expression are included in the first sound data, determine the user's information by considering both of the linguistic expression and the non-linguistic expression, and
store the user's information and the information on the menu,
wherein the non-linguistic expression includes a yawning sound.

US Pat. No. 11,027,961

APPARATUS, SYSTEMS AND METHODS FOR DISPENSING DRINKS, FOOD, AND OTHER LIQUIDS

1. A system for filling a beverage bag with free-flowing contents from an external device, the system comprising a container and an attachable filler assembly removably associated with the container, the beverage bag being disposed within the container, the container comprising:a top and a bottom;
a plurality of vertical walls extending between the bottom and the top;
at least one ice portal disposed in the top, the at least one ice portal having a removable cap for filling an ice chamber within the container with ice;
a removable container cap, the removable container cap forming a central part of the top;
a tube vertically disposed in the container cap, the tube extending between the beverage bag and a gate valve shaft above the container cap;
an air hose disposed in the container cap parallel with the tube;
an air bag attached to a bottom end of the air hose within the container, the air bag being adjacent to an outer surface of the beverage bag, such that a volume between the air bag, the beverage bag and an interior of the plurality of vertical walls forms the ice chamber; and
a beverage flow portal protruding longitudinally from a first side of the gate valve shaft;the attachable filler assembly being adapted to attach to a mouth of the beverage flow portal, such that the beverage bag is filled with the free-flowing contents from the external device through the mouth.

US Pat. No. 11,027,960

APPARATUS, SYSTEMS, AND METHODS RELATING TO TRANSFER OF LIQUIDS TO/FROM CONTAINERS AND/OR STORAGE OF LIQUIDS IN CONTAINERS

1. An apparatus comprising:a collapsible container including an opening;
a valve positioned relative to the opening and configured to inhibit flow out of the collapsible container through the opening; and
a conduit configured to be positioned in the opening to engage and open the valve to thereby provide an open passage to and/or from the collapsible container through which fluid is transferrable both for dispensing fluid from within the collapsible container and for filling the collapsible container with fluid, whereby a seal is defined between the conduit and a surface defining the opening;
wherein at least one of the conduit and the surface defining the opening is configured such that the seal is formed between an outer surface of the conduit and the surface defining the opening before the conduit opens the valve.

US Pat. No. 11,027,959

FLUIDIZED POWDER VALVE SYSTEM

MATSYS INC., Sterling, V...

1. A device configured for the delivery and metering of powders or granular materials, comprising:an extension or container configured for holding the powders or granular materials to be dispensed,
a fluidization funnel assembly, wherein the extension or container is operatively connected to the fluidization funnel assembly;
a fluidization stop valve assembly which is surrounded by an aperture or gap separating the fluidization funnel assembly and the fluidization stop valve assembly; and
a gas port,
wherein in a dispensing operation, the fluidization funnel assembly is configured to receive the powders or granular materials from the extension or container and lead the received powder or granular materials to the fluidization stop valve assembly,
wherein the dispensing operation is performed without any mechanical movement of parts,
wherein the fluidization stop valve assembly comprises a porous top plate and hollow section configured to allow the transport of gas from one or more supply lines, via the gas port, to a porous section of the fluidization stop valve assembly, the porous top plate being disposed between the fluidization funnel assembly and both the hollow section and the gas port, and the porous top plate opposes a bottom opening of the fluidization funnel assembly, and the porous top plate and hollow section are disposed along a center axis of the fluidization stop valve assembly such that the hollow section is surrounded by a powder outlet region through which the powders or granular materials are dispensed during the dispensing operation,
wherein the aperture or gap separating the fluidization funnel assembly and fluidization stop valve assembly, is annular and the device includes micrometer adjusters configured to adjust the gap for the dispensing of powders and granular materials of varying flow characteristics,
wherein the fluidization funnel assembly and fluidization stop valve assembly are configured to be operated at pressures below 5 psi, and
wherein the fluidization funnel assembly and fluidization stop valve assembly comprise a sub-micrometer porous material.

US Pat. No. 11,027,958

LIQUID DISTRIBUTION SYSTEM

1. A liquid distribution system, comprising:a hollow-bodied portion having an open top, a bottom, and one or more side walls running vertical from the top to the bottom;
a plurality of bowl-shaped channels extending from the bottom of the hollow-bodied portion;
a plurality of spouts, each disposed on distal ends of respective bowl-shaped channels;
a liquid container corralling structure capable of bundling a plurality of liquid-holding containers, the bundled liquid containers arranged such that openings of the liquid-holding containers are each matched with respective ones of the spouts; and
a flow regulator situated in the approximate center of the bottom of the hollow-bodied portion, the flow regulator having a star-shaped topside and a plurality of sloping sides extending from the topside, each directing an approximately equal amount of poured-in liquid to one of the bowl-shaped channels;
wherein liquid poured into the open top of the hollow-bodied portion pours out from the spouts;
wherein the hollow bodied portion is disposed above the liquid container corralling structure; and.

US Pat. No. 11,027,957

DRINK FILLING SYSTEM

Dai Nippon Printing Co., ...

1. A drink filling system comprising:a molding section that molds a bottle from a heated preform by a blow-molding treatment;
a sterilizing section that contacts a sterilizer to the molded bottle:
a rinsing section that rinses the bottle discharged from the sterilizing section;
a filling section that fills the bottle rinsed in the rinsing section with a drink and then seals the bottle filled up with the drink;
a bottle conveying path that continuously conveys the bottle from the molding section to the filling section through the sterilizing section and the rinsing section,
a chamber that covers a portion extending from the molding section to the filling section;
an air supply section chamber disposed on an upstream side of the sterilizing section chamber; and
an exhaust blower in the sterilizing section for exhausting out of the sterilizing section and maintaining a pressure inside the sterilizing section lower than the atmospheric pressure,
wherein the exhaust blower exhausts an air-flow from the air supply section chamber disposed on the upstream side of the sterilizing section chamber and an air-flow from the rinsing section chamber.

US Pat. No. 11,027,956

DRINK FILLING SYSTEM

Dai Nippon Printing Co., ...

1. A drink filling system comprising:a molding section that molds a bottle from a heated preform by a blow-molding treatment;
a sterilizing section that contacts a sterilizer to the molded bottle:
a rinsing section that rinses the bottle discharged from the sterilizing section;
a filling section that fills the bottle rinsed in the rinsing section with a drink and then seals the bottle filled up with the drink;
a bottle conveying path that continuously conveys the bottle from the molding section to the filling section through the sterilizing section and the rinsing section,
a chamber that covers a portion extending from the molding section to the filling section;
an atmosphere shut-off chamber that shuts off an atmosphere between the sterilizing section chamber and the rinsing section chamber;
an exhaust blower that exhausts out at least one of the atmosphere shut-off chamber and the sterilizing section chamber;
an exhaust duct that is connected to the exhaust blower;
a conveyor for discharging the bottle near a side of an exhaust port of the filling section chamber, the conveyor for discharging the bottle extending from a discharge wheel toward the exhaust port of the filling section chamber;
a sterilizing tank for sterilization of the conveyor by dipping; and
a duct connected to the exhaust duct for exhausting a sterilizer evaporated from the sterilizing tank by the exhaust blower.

US Pat. No. 11,027,955

APPARATUS FOR THE TRANSFER AND PRESERVATION OF JUICES

1. An apparatus for the transfer and preservation of liquids comprising:a container into which liquids will be transferred, said container having an outer wall and an inner wall and a reservoir located within said inner wall to collect said liquids;
a funnel apparatus further comprising:
a bowl into which liquid can be poured said bowl having a main chamber and an overflow chamber;
a first vent;
a second vent;
a base through which liquid can base therethrough; and
a seal at said funnel base.

US Pat. No. 11,027,954

MULTIPURPOSE DEVICE

Roger Doherty, Clonmany ...

1. A device for cracking a seal formed around a manhole cover comprising: a horizontal cross bar section comprising a bottle jack holder recess for receiving a bottle jack; a guide channel, said guide channel extending on a longitudinal side of the horizontal cross bar section and oriented perpendicular to the horizontal cross bar section;two opposed leg sections extending from opposite ends of the horizontal cross bar section;
two support struts each extending between the horizontal cross bar section and one of the two leg sections;
and a jack cap section comprising two lifting eyes, each lifting eye comprising a hook and a lifting chain for attaching to a manhole lifting key detachably connected to a manhole cover, wherein the jack cap section is configured to be disposed directly on a head of the bottle jack such that at least one of said lifting chains extends downward on one side of the bottle jack and along said guide channel to the manhole lifting key and wherein said at least one of said lifting chains is biased away from said longitudinal side of the horizontal cross bar section by said guide channel.

US Pat. No. 11,027,953

METHOD FOR MONITORING THE ROAD PATH OF A TRUCK AND A FLOOR CONVEYOR

Jungheinrich Aktiengesell...

1. A method for monitoring a travel path of an industrial truck, comprising the steps of:determining a braking distance of the industrial truck using at least one operating parameter of the industrial truck;
adjusting a travel path area monitored by a monitoring device on the basis of the determined braking distance, by adjusting an alignment of the monitoring device;
decelerating the industrial truck when an obstacle enters the travel path area monitored by the monitoring device;
measuring an instantaneous swivel angle; and
comparing an instantaneous swivel angle to a target swivel angle for enhanced accuracy.

US Pat. No. 11,027,952

LIFTING SYSTEM FOR LIFTING A VEHICLE AND METHOD FOR OPERATING THE LIFTING SYSTEM

Stertil B.V., Kootsterti...

1. A lifting system for lifting a vehicle, the lifting system comprising:at least two lifting devices operable to raise and lower the vehicle;
a group controller arranged to operate the lifting devices;
a user interface unit comprising a transmitter and/or receiver configured for communication with the group controller, a processor, a display device, and input means configuring the user interface unit to receive user input, wherein the user interface unit being adapted to communicate command signals to the group controller on basis of the user input and adapted to receive and display information obtained from the group controller; and
a network interface unit comprising a network transmitter and/or network receiver configured for communication to an external network, and a connection configured for communication with the group controller,
wherein the group controller comprises a communication optimizer for determining an appropriate communication route in the lifting system,
wherein the communication optimizer is adapted to select a first communication route to send the command signals from a first lifting device to a second lifting device, and, upon receiving an indication that the first communication route is disturbed, select a second communication route to send the command signals from the first lifting device to the second lifting device, wherein the second communication route is different from the first communication route, and
wherein the indication that the first communication route is disturbed comprises an absence of a receipt confirmation within a specified period of time.

US Pat. No. 11,027,950

SYSTEM HAVING A SECONDARY CURRENT GENERATING ASSEMBLY FOR THE SECONDARY CONVERSION INTO ELECTRICITY OF EXHAUST GAS HEAT FROM A PRIMARY CURRENT GENERATING ASSEMBLY

1. A vehicle for handling freight containers having a system having a primary current generating assembly, comprising a primary thermal engine, and having a secondary current generating assembly, in the form of an electric turbo compound installation, for secondary conversion into electricity of exhaust gas heat of the primary current generating assembly, wherein the secondary current generating assembly comprises an exhaust gas turbine, disposed in an exhaust gas stream of the primary thermal engine, and the exhaust gas turbine drives a secondary electric generator, wherein, in the exhaust gas stream, an exhaust gas cooler followed by a compressor is disposed behind the exhaust gas turbine, the compressor is driven by an electric motor and the rotational speeds for the compressor and exhaust gas turbine are controlled by a process regulating system, wherein a secondary inverter is allocated to the secondary generator, a frequency converter is allocated to the electric motor of the compressor, and the secondary inverter and the frequency converter are communicatively connected via a field bus to an electronic central controller, wherein the electronic central controller permits control of the energy flows of the primary current generating assembly and of the secondary current generating assembly, and the primary current generating assembly and the secondary current generating assembly supply at least one travel drive and at least one lifting drive with energy, wherein the rotational speeds for the compressor and exhaust gas turbine are controlled by the process regulating system in such a way that ambient pressure prevails in the exhaust gas stream at the input of the exhaust gas turbine.

US Pat. No. 11,027,949

TRANSPORT VEHICLE AND TRANSPORT METHOD

Murata Machinery, Ltd., ...

1. A transport vehicle comprising:a body;
a lift platform that includes a holder to hold an article, the lift platform being ascendable and descendable with respect to the body;
a lift driver that raises or lowers the lift platform by feeding out or taking up a flexible suspension support;
a sensor provided in the lift driver and emits a detection wave having directivity toward a certain lower position;
a lateral extender that causes the lift driver to project laterally from the body while providing cantilever support for the lift driver; and
a corrector that corrects a shift in an emission direction of the detection wave that arises from bending of the lateral extender in a state in which the lift driver is caused to project laterally from the body by the lateral extender.

US Pat. No. 11,027,948

LOAD ASSEMBLY AND METHOD FOR LIFTING A LOAD INTO AN AIRCRAFT

Gulfstream Aerospace Corp...

1. A method for moving a load in an aircraft utilizing a load assembly comprising a support sub-assembly and a lifting sub-assembly, the method comprising:coupling the support sub-assembly to a structural member of the aircraft;
coupling the lifting sub-assembly to the support sub-assembly;
coupling the load to the lifting sub-assembly;
activating the lifting sub-assembly to lift the load; and
moving the lifting sub-assembly from a first interior position to a second interior position, wherein the support sub-assembly further comprises a retainer clamp that includes an adjustable clamp portion and a fixed clamp portion, and wherein coupling the support sub-assembly further comprises engaging the adjustable clamp portion and the fixed clamp portion with opposing sides of the structural member to removably couple the support sub-assembly to the structural member.

US Pat. No. 11,027,947

LOAD-FORCE-INDEPENDENT TRIGGERING DEVICE

ALFRED-WEGENER-INSTITUT, ...

1. A load-force-independent triggering device for a load exerting a force on it that is held in a CLOSED position of the triggering device and released in an OPEN position of the triggering device, comprising:a housing;
a triggering lever, which is connected to a triggering gear via a steering lever, the triggering lever being swivel-mounted on a first housing axis, the triggering gear being swivel-mounted on a second housing axis and the steering lever being swivel-mounted on a steering-lever axis on the triggering lever and on a second steering-lever axis on the triggering gear;
a spring device configured to act on the triggering lever; and
a locking device, by which the triggering device is fixed in the CLOSED position,
wherein the steering lever has an angular design, and, in the CLOSED position of the triggering device, is configured to contact a first contact surface in the housing and, in the OPEN position of the triggering device, is configured to contact a second contact surface in the housing,
wherein the two steering-lever axes are positioned at the first contact surface immediately before a self-locking dead-center position towards the first housing axis and on the second contact surface outside of dead-center position, and
wherein the spring device comprises a tension spring, which is arranged between the triggering lever and the triggering gear and is configured to exert a force on the triggering lever in a direction of the OPEN position of the triggering device.

US Pat. No. 11,027,946

BELT-DRIVEN PEOPLE CONVEYORS

OTIS ELEVATOR COMPANY, F...

1. A conveyance element for a belt-driven people conveyor comprising:a first belt connection structure arranged to connect a drive belt to the conveyance element; and
a second belt connection structure arranged to connect the drive belt to the conveyance element;
wherein the first and second belt connection structures are arranged such that, when connected, the drive belt passes adjacent to and between the first and second belt connection structures;
wherein the first belt connection structure includes a first belt connection member configured to connect the drive belt to the conveyance element;
wherein the second belt connection structure includes a second belt connection member configured to connect the drive belt to the conveyance element;
wherein the first belt connection member and the second belt connection member are separate elements.

US Pat. No. 11,027,945

WALL SECURING ASSEMBLY FOR SECURING AN ELEVATOR COMPONENT

INVENTIO AG, Hergiswil N...

1. A wall securing assembly for securing an elevator component to an elevator shaft wall in an elevator shaft, the wall securing assembly comprising:a first concrete region of the elevator shaft wall that is strengthened by reinforcements;
a second concrete region of the elevator shaft wall that is not strengthened by reinforcements, covers the first concrete region and includes a surface that is exposed to surroundings in the elevator shaft;
an elongated profile that is C-shaped in cross-section; and
wherein the profile is embedded solely into the second concrete region and is oriented in a main extension direction of the elevator shaft, wherein the C-shaped profile extends vertically in the elevator shaft wall over substantially an entire height of the elevator shaft.

US Pat. No. 11,027,944

CLIMBING ELEVATOR TRANSFER SYSTEM AND METHODS

Otis Elevator Company, F...

1. An elevator system comprising:a plurality of hoistways, each having at least one rail;
at least one car moveable along and between the plurality of hoistways and each car of the at least one car having:
a drive assembly including:
two or more wheels engageable to opposing surfaces of the rail of a hoistway of the plurality of hoistways along which the car may move, the drive assembly configured to apply an engagement force to the rail to both support the car at the rail and drive the car along the rail; and
for at least a first wheel and a second wheel of said two or more wheels, a wheel hub motor, each said wheel hub motor comprising:
a rotor connected to a rim of the respective first wheel and second wheel; and
a stator nonrotatably connected to a shaft; and
at least one shuttle moveable transverse to the plurality of hoistways for transferring the at least one car between the hoistways,wherein:said at least one shuttle comprises at least one rail positionable in registry with the rail of one of the hoistways to receive a car from or transfer a car to that hoistway and to suspend said car for movement between that hoistway and another of the hoistways.